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Abstract
Modern-day management of infectious diseases is critically linked to the use of
mathematical models to understand and predict dynamics at many levels, from the
mechanisms of pathogenesis to the patterns of population-wide transmission and evolution.
This thesis describes the development and application of mathematical techniques for HIV
infection and dynamics on social networks. Treatment of HIV infection has improved
dramatically in the past few decades but is still limited by the development of drug
resistance and the inability of current therapies to completely eradicate the virus from an
individual. We begin with a synthesis of the important evolutionary principles governing
the HIV epidemic, emphasizing the role of modeling. We then describe a modeling
framework to study the emergence of drug-resistant HIV within a patient. Our model
integrates laboratory data and patient behavior, with the goal of predicting outcomes of
clinical trials. Current results demonstrate how pharmacologic properties of antiretroviral
drugs aﬀect selection for drug resistance, and can explain drug-class-speciﬁc resistance
risks. Thirdly, we describe models for a new class of drugs that aim to eliminate cells with
latent viral infection. We provide estimates for the required eﬃcacy of these drugs and
describe the potential challenges of future clinical trials. Finally, models and mechanisms
for understanding viral dynamics are increasingly ﬁnding applications outside traditional
virology. They can be used to study the dynamics of behaviors, to help predict and
intervene in their spread. We describe techniques for applying infectious disease models to
social contagion, drawing on techniques for network epidemiology. We use this framework
to interpret data on the interpersonal spread of health-related behaviors.
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Introduction
Eﬀective public health systems require the ability to make rapid and reliable predictions
about future trends in disease incidence and the beneﬁt of potential interventions. In the
absence of prior experience or the ability to do exhaustive randomized trials, models
become necessary. In biomedical research and clinical medicine we search for mechanistic
explanations to unify diverse observations. Quantitative theories can guide experimental
design and interpretation. When the system of interest involves dynamic processes and
interactions between many entities, mathematical models are needed to describe the
behavior. This becomes readily apparent in the study of infectious diseases, where a
parasite invades a host population that may respond with its own defense mechanisms.
Mathematical models of infection dynamics are a well-established tool integrated into all
levels of scientiﬁc understanding in this ﬁeld, from the seasonal patterns of inﬂuenza spread
to the origin of genetic variation in the human population.
In this thesis, we describe a sequence of studies modeling infection dynamics. We focus
mainly on HIV treatment, with both traditional antiretroviral therapy and investigational
latency reversing agents, and also consider the dynamics of social contagion. Each chapter
is self-contained, and includes an introduction to and discussion of the particular study.
1Here, we give a brief background to the topics considered.
1.1 Basic modeling framework
The common thread linking the chapters of this thesis, and a large body of work in this
ﬁeld, is the basic mathematical framework for modeling the dynamics of an infectious
disease[10, 247]. We consider a population of hosts, where individuals may be infected with
a parasite. Uninfected hosts, whose abundance is described with the state variable     ,
have a death rate    and are maintained by an inﬂux rate   (which could be birth or
migration, for example). Infected hosts are tracked with the variable     . They have an
increased death rate   . Contact between infected and uninfected hosts occurs at a rate
proportional to both their prevalences, and with some probability leads to the uninfected
host becoming infected. The overall infection rate is described by the transmissibility,  .
This system can be described by the system of ﬁrst-order ordinary diﬀerential equations:
  
  
               
  
  
           
(1.1)
Despite its simplicity, this model captures the most important properties of infectious
diseases dynamics. This system of equations yields two regimes of qualitatively diﬀerent
behavior. If the disease transmissibility is high enough, if it is not too deadly, and if the
host population is large enough, an epidemic will occur. Starting with a small number of
infected hosts, the prevalence of the infection will rapidly increase, following a
characteristic epidemic curve. A substantial fraction of the population will eventually be
infected. However, if these conditions are not met, the disease will quickly die out before
many more hosts are infected. The quantity that determines which regime the system is in
is called the basic reproductive ratio[10]. It describes the average number of new infections
2caused by a single infected individual introduced into a population of uninfected hosts.
Mathematically, the basic reproductive ratio for this model is
    
  
    
(1.2)
which can be justiﬁed as follows. The average lifetime of an infected host is     .
During this lifetime, the rate at which an individual contacts and infects others is    ,
where    is the abundance of uninfected hosts before the epidemic, which is      (we
assume a large population, this is roughly unchanged by the presence of a single infected
individual).    is a critical concept for infectious diseases because it quantitatively deﬁnes
the goal of all treatment and control strategies - to alter the parameters of the disease such
that        , so as to prevent or stop an epidemic. Mathematically,    corresponds to a
transcritical bifurcation between two uniquely stable equilibria.
This model is but one simple example of an entire class of models used to study
infectious processes. Hosts may represent individual organisms, such as humans[222],
animals[109], or crop plants, and the infection may be caused by any type of
microorganism. Many models include the possibility for hosts to recover or become
immune, and often more ﬁnely divide hosts into clinical stages of infection. The common
SIS or SIR models of epidemiology are examples [10]. Alternatively, the host population
could represent cells in the body that are infected with a virus. Model extensions may
explicitly track virus levels, allow for infection of diﬀerent cell types, or describe an
immune response mounted against the infection. Such scenarios often fall under the
umbrella of viral dynamics models [247]. More broadly considered, a modeled ‘infection’
could describe the state of knowing a particular piece of information, displaying a
particular behavior, or possessing any other quality that is transmitted between individuals
by any number of processes[95, 117]. The model may track multiple infectious agents, if
there are competing infections in a single host population[313], or if the infectious agent
may evolve over the course of the infection [295]. While diﬀerential equations are a popular
3tool for infectious disease modeling, in some situations it is more appropriate to use a
stochastic process to track the infection[51].
1.2 Applications to HIV
The human immunodeﬁciency virus (HIV) is the infectious agent that causes acquired
immune deﬁciency syndrome (AIDS), and currently infects an estimated 34 individuals
worldwide[255]. Since the identiﬁcation of the syndrome in the 1980’s, over 25 have died
from the disease [234]. The virus infects cells of the immune system and is dominantly
found in CD4 T lymphocytes. During early infection with HIV, individuals may
experience the nonspeciﬁc symptoms of acute viremia, but then often remain symptom-free
for years before the onset of disease. AIDS occurs when the virus has degraded the immune
system to the extent that it is unable to fend oﬀ infections from virulent opportunistic
parasites. HIV generates enormous diversity both within an individual[317] and on the
global scale[150], due to large population sizes of the virus and error-prone viral
replication[212]. This aﬀords the virus nearly unlimited potential to rapidly evolve to avoid
immunological responses and treatment eﬀorts[144].
Mathematical models of infection dynamics have complimented experimental and
clinical work on HIV since the early stages of the virus’s discovery (reviewed in [247]). At
the within-host level, models have helped explain the virus’s escape from the immune
system and the progression to AIDS [248], the immunological mechanisms of viral control
[185], the rate of cell turnover [364], the properties of long-lived infected cells [269], the
viral tropism switch [285], and the eﬀects of drug treatment [47] At the population level,
infection dynamics models have lead to advances such as evaluations of treatments
[43, 126] and preventative measures [237, 342], forecasts for the history and course of the
epidemic [335], an understanding of the role of contact patterns [157], and predictions of
the evolutionary optimal virulence [323]. We begin this report, in Chapter 2, wtih a
synthesis of the important evolutionary factors governing the HIV epidemic, and include
4the contributions of mathematical modeling and population genetics to the understanding
of the disease.
The life-expectancy of patients with HIV, and the course of the epidemic in many parts
of the world, has been dramatically improved by the introduction of antiretroviral drugs
used in combination therapy[259]. These drugs can stop viral replication, leading to
restored immune function, and preventing both progression to AIDS and disease
transmission. There are currently 8 million individuals worldwide receiving antiretroviral
treatment [254]. However, the virus’s capacity for adaptation can also lead to the
development of drug resistant strains that compromise treatment. When single
antiretroviral agents were used, resistant virus appeared within weeks of treatment, and
while combinations of drugs from diﬀerent classes can reduce and delay the emergence of
resistance, it is still a common occurrence[158]. While not yet at the same crisis levels as
the problem of antibiotic resistance, antiretroviral resistance is an important clinical
concern and is likely to increase in prevalence as treatment scale-up programs continue
around the globe[42].
Another limitation of current antiretroviral drugs is their inability to cure an infected
individual[326]. Drugs must be taken continuously for a lifetime, which exacerbates the
logistic issues of supplying expensive drugs reliably in the developing world, and further
increases the opportunity for drug resistance to develop[132]. This limitation arises from
the ability of HIV to establish a type of ‘latent’ infection[110]. After the virus enters host
CD4 T-cells, its genetic material integrates into the host cell genome. As a natural part of
their life-cycle, a small fraction CD4 T-cells revert to a long-lived resting state, where they
form the basis of immunological memory. If a cell with integrated HIV DNA reverts, the
virus remains archived in the cell despite anitretroviral treatment, and can restart infection
whenever the cell reactivates, which may be months to years later[89, 298]. This virus
population is called the latent reservoir. A large research eﬀort is currently dedicated to
understanding the details of latency and identifying compounds that can prematurely
5reactivate latent HIV from memory cells[98]. The hope is for these compounds to be given
along with current antiretroviral drugs, to ﬂush out the latent reservoir and eradicate the
infection from the treated individual, allowing drugs to be discontinued without risk of a
resurgence of the infection.
In this report we present research ﬁndings related to these two shortcomings of current
HIV treatment. The development of drug resistance follows distinct patterns among
diﬀerent classes of antiretroviral drugs, and the relationship between a patient’s adherence
to treatment and the probability of resistance is often non-intuitive. In Chapters 3 and 4
we develop a mathematical viral dynamics model that integrates laboratory data and
patient behavior, and culminates in attempting to realistically simulate clinical trials. Our
current results demonstrate how pharmacodynamics and pharmacokinetics of antiretroviral
drugs aﬀect the generation and selection of resistance mutations. We can explain
class-speciﬁc resistance-adherence relationships, and the puzzling ﬁnding that patients may
fail treatment with the protease-inhibitor drug class without developing resistance.
Our second focus concerns the new class of drugs called latency reversing agents that
are being investigated to eliminate the reservoir of latent virus. While it is generally
accepted to be infeasible for a drug to clear every single cell from this reservoir, an
acceptably safe number for the post-treatment cell count is unknown and of great
importance to the ﬁeld. In Chapters 5 and 6 we compile clinical and laboratory data and
derive estimates for the size, composition, and dynamics of the HIV latent reservoir,
allowing us to compare the stochastic rates of cell death, reactivation, and viral replication.
We use these measurements in a viral dynamics model to calculate likelihood and timing of
virologic rebound following treatment interruption, for a given drug-induced reduction in
the number of latently infected cells. Our results suggest that LRA may need to reduce the
reservoir by 99.9-99.999% to prevent relapse in most patients, and that patients may
rebound without warning even after many years of treatment cessation. We suggest that
large interpatient variability and particular unknown parameters will complicate the
6interpretation of clinical trials.
1.3 Applications to social dynamics
Health depends not only on biological processes but on the interplay of human behavior.
People often choose what preventative measures or treatments they use, and may be
inﬂuenced in these decisions by others. Just as a physical contact networks determine the
transmission patterns of a microbial infection, social networks - formed from direct
interpersonal interactions or a form of media - can direct the transmission of ideas and
behaviors.
Analyzing the inﬂuence of contagion in these systems and predicting future prevalence
levels have become popular research questions, and mathematical models of infection
dynamics have been adapted for these systems. These models may take the form of
traditional epidemiological equations, with additional terms for the role of behavioral
decisions (reviewed in [117]). Individuals may base decisions on globally available
information (for example, CDC warnings) or their own local experience (for example, sick
coworkers). The information content may be a direct property of the epidemic (like the
current prevalence) or relatively independent (like the decision to vaccinate). In response
to information, individuals may alter disease parameters (like decreasing transmission rate
by improved hygiene or increasing recovery rate by treatment), directly alter their state
(vaccination causes a susceptible individual to become immune), or alter the contact
network through which the disease spreads. All of these responses can later the course of an
epidemic in ways that could not be predicted by simple equations ignoring human behavior.
Beyond simply inﬂuencing the spread of microbial infections, behaviors themselves may
obey infection dynamics. Individuals may receive information from their contacts, imitate
the actions of those they observe, or be unknowingly inﬂuenced. These processes are
termed generally termed social contagion, and are well established to occur in many
systems. Drug use[69], mental health states[31, 55, 111], and health care[61, 231] are
7examples of behaviors found to spread between individuals [333]. The adoption of new
technologies and opinions about vaccination can be observed as they spread through social
networks [13, 303, 350]. Understanding these dynamics is crucially important, either to
predict how they will aﬀect health outcomes (for example, see [302]), or to devise ways to
use social contagion to actually target interventions [353].
In the ﬁnal sections of this thesis (Chapters 7 and 8) we present two closely related
papers that focus on modeling the spread of behaviors between individuals in a social
network. We designed a modeling framework based on traditional infectious disease
epidemiology to analyze and interpret ﬁndings for social contagion, and applied it to the
spread of emotions and weight levels in the Framingham Heart Study Network. We
highlight the importance of characterizing the particular dynamic of social inﬂuence for a
given system, based on the availability of longitudinal data. We present methods for
interpreting the importance of contagion and for understanding mechanisms behind
changes in incidence over time. We don’t attempt to determine the mechanisms of spread,
but rather focus on properties of the contagious process. Our analysis can be applied to
many other systems involving complex network structures and social inﬂuence.
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Evolutionary dynamics of HIV at multiple
spatial and temporal scales
2.1 Abstract
Infectious diseases remain a formidable challenge to human health, and understanding
pathogen evolution is crucial to designing eﬀective therapeutics and control strategies.
Here, we review important evolutionary aspects of HIV infection, highlighting the concept
of selection at multiple spatial and temporal scales. At the smallest scale, a single cell may
be infected by multiple virions competing for intracellular resources. Recombination and
phenotypic mixing introduce novel evolutionary dynamics. As the virus spreads between
cells in an infected individual, it continually evolves to circumvent the immune system. We
discuss evolutionary mechanisms of HIV pathogenesis and progression to AIDS. Viral
spread throughout the human population can lead to changes in virulence and the
transmission of immune-evading variation. HIV emerged as a human pathogen due to
selection occurring between diﬀerent species, adapting from related viruses of primates.
HIV also evolves resistance to antiretroviral drugs within a single infected host, and we
9explore the possibility for the spread of these strains between hosts, leading to a drug
resistant epidemic. We investigate the role of latency, drug-protected compartments and
direct cell-to-cell transmission on viral evolution. The introduction of an HIV vaccine may
select for viral variants that escape vaccine control, both within an individual and
throughout the population. Due to the strong selective pressure exerted by HIV-induced
morbidity and mortality in many parts of the world, the human population itself may be
co-evolving in response to the HIV pandemic. Throughout the paper, we focus on
trade-oﬀs between costs and beneﬁts that constrain viral evolution and accentuate how
selection pressures diﬀer at diﬀerent levels of selection.
2.2 Introduction
Over the course of the 20th century, human lifespans increased dramatically in many parts
of the world. This reduction in mortality is largely attributed to a reduced burden of
infectious diseases, due to improved nutrition and sanitation, and the introduction of both
antibiotics and vaccines. We were so conﬁdent of our domination over the microbial world
that in the mid-20th century it was common to surmise the end of infectious diseases as a
signiﬁcant health issue [107, 274, 337]. This sentiment turned out to be especially ill timed,
as the last few decades saw the emergence of many novel and extremely dangerous
pathogens, including Ebola, SARS, Lyme disease, Legionella, and drug-resistant malaria
and tuberculosis. Perhaps no disease shattered this view as much as the outbreak of the
human immunodeﬁciency virus (HIV), and the acquired immune deﬁciency syndrome
(AIDS) that it causes. Reaching 34 million currently infected worldwide[255], a prevalence
of 0.3% in the US [60], and near 100% untreated fatality rate, the HIV pandemic
exempliﬁes humanity’s continued vulnerability to pathogens and highlights how much we
have yet to learn about infectious diseases.
Evolution has been used to understand human disease processes from allergy to cancer
to cystic ﬁbrosis, reviving the ﬁeld of evolutionary medicine[340, 348]. Nowhere is the
10connection between evolution and medicine more evident than in the ﬁeld of infectious
diseases. Although we have recently added vaccines and chemotherapy to our arsenal of
defenses against microorganisms, augmenting the protection oﬀered by our innate and
adaptive immune responses, it is now accepted that the rapid rate of pathogen evolution
ensures infectious diseases will inevitably remain important health concerns. Therefore,
understanding the evolutionary processes relevant to infectious diseases is absolutely
necessary to prevent, control, treat and ultimately, minimize the damage to human health
due to pathogens.
HIV infection is a particularly well-suited example to highlight the medical relevance of
evolutionary dynamics occurring simultaneously on multiple spatial and temporal scales
(Figure 2.1), including the evolution of the virus within an individual and at the global
level, as well as the co-evolution between HIV and the human population. HIV originated
from a cross-species transmission of simian immunodeﬁciency virus (SIV), and it eventually
evolved adaptations facilitating productive infection in, and transmission between, human
hosts. At the individual level, the virus evolves in response to a dynamic, variably hostile
environment presented by the immune system and drug treatment. At the population level,
HIV likely evolves to evade immune control, optimizing virulence levels, and possibly
transmitting drug resistance. Creation of a vaccine is hindered by rapid and unpredictable
evolution of the virus, and if introduced, may further drive viral evolution, potentially
causing resistance to the vaccination. Due to the strong selective pressure exerted by
HIV-induced morbidity and mortality in many parts of the world, evolution of human
populations in response to the virus is likely.
In this review, we will summarize the range of evolutionary processes important to
HIV, and highlight how understanding them can help guide prevention, control and
treatment of AIDS. We ﬁrst summarize the natural history of the epidemic and the
host-driven selective pressures that the virus faces regardless of treatment. We then
consider the eﬀect of medical interventions on viral evolution, focusing on recent eﬀorts to
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Figure 2.1: HIV evolution occurs on multiple spatial and temporal scales. a) Multiple virions
may infect a single cell, competing for cellular resources controlling viral replication. Budding
virions may contain RNA, structural proteins and enzymes from various genetic backgrounds. b)
During infection of a single individual, HIV diversiﬁes into multiple strains that compete to in-
fect CD4 T cells and evade immune responses and drug treatment. c) As HIV spreads through
the human population it may adapt, becoming more or less virulent and accumulating mutations
selected by immune responses or even widespread drug use. d) HIV arose from a cross-species
transmission of simian immunodeﬁciency virus (SIV), known to infect many primate groups.
Primate phylogeny, from left to right: humans, chimpanzees, gorillas, orangutans, gibbons, old
world monkeys, new world monkeys, prosimians.
understand and quantify the mechanisms that can render treatment ineﬀective.
2.3 Natural history of the HIV pandemic
2.3.1 High retroviral mutation rate facilitates rapid evolution
Evolution requires the generation of variation through mutation. The capacity for HIV to
evolve exceeds that of many other pathogens, due in part to the high mutation rate of
retroviruses. At          substitutions per base per replication cycle [212] and a genome
size of 9800 base pairs, one in every three replication events is expected to create a
mutated genome. This puts the virus very near the error catastrophe threshold: at
mutation rates higher than approximately one per genome per replication cycle, it is not
possible for a genome to accumulate and maintain beneﬁcial alleles, and a lineage risks
extinction [54, 103, 150, 241](Section 3.1.8 of [150]). While the high mutation rate of
retroviruses is usually explained by the fact that their virally encoded reverse transcriptase
lacks error-correcting domains found in other organisms, it is currently unknown how much
of this mutation rate is due to HIV reverse transcriptase and how much is due to host cell
12RNA polymerase, since experiments to date cannot separate out these two steps. High
mutation rates are expected to be favored more often in heterogeneous or rapidly changing
environments than in stable ones [167], and due to the chronic nature of HIV infection and
its ability to reach many tissues, it is possible that its high mutation rate has been favored
by natural selection. Recent theoretical modeling work demonstrates that host-pathogen
co-evolution may also generate selective pressure for high pathogen mutation rates, even in
a static, homogeneous environment [167, 233]. Interestingly, mutation in HIV seems to be
strongly skewed towards adenosines, much more than is represented by the adenosine bias
in its sequence composition [3, 296]. The high mutation rate of HIV leads to tremendous
variation in a given viral population; with up to 10% sequence variation between strains
within an individual and up to 50% between diﬀerent types circulating over the globe
(Figure 7.10 Section 7.2 of [18, 150]).
Humans and other primates actually have an innate defense targeted towards the high
mutation rate of retroviruses. The APOBEC3G enzyme edits the viral cDNA during
reverse transcription, likely as part of a host defense mechanism. HIV encodes a protein
Vif that facilitates polyubiquitylation and subsequent proteasomal degradation of
APOBEC3G, but in the absence of Vif, the enzyme causes suﬃcient mutation to scramble
the viral genome, triggering an “error catastrophe” and preventing productive infection
[65, 133, 195].
In addition to mutation, the potential of the virus to recombine during replication is
high, as reverse transcriptase typically jumps templates about 10 times per genome[199]. If
two distinct viral strains infect the same cell (the likely frequency of such an event is
discussed in a later section on within-cell competition), then each one may contribute to
one of the two RNA copies in budding virus. When this virion infects a new cell,
recombination between the two parental genomes may then occur. Many strains of HIV
currently circulating the globe appear to be recombinant forms of divergent virus
strains[346].
132.3.2 The emergence of HIV
As HIV spreads between individuals in a population, selection occurs on traits that
maximize its transmission. HIV is a zoonotic disease, meaning it had its origins in a closely
related infection of animals; in this case, non-human primates. Analysis of molecular
phylogenies has traced the origin of HIV-1 (for example, see Section 7.2 in [150]), the viral
strain responsible for the largest global epidemic, to the simian immunodeﬁciency virus
infecting chimpanzees (SIVcpz) [173]. Similar cross-species jumps have happened with
other primate species: a smaller epidemic of HIV restricted mainly to western Africa is
caused by HIV-2, with origins in the virus of sooty mangabeys (SIVsmm) [305].
Adaptation of any disease to a new species proceeds through ﬁve phases (adapted from
Chapters 12 & 16 of [340]): Firstly, there must be contact between the animal reservoir
and humans that allows transfer of the pathogen. For SIV, this is hypothesized to have
occurred through hunting for and preparing primate bushmeat. The second phase of
adaptation - the ability to produce a productive infection in the new human host - is
calculated to have occurred at the turn of the 20th century near Kinshasa in the present
day Democratic Republic of Congo[376]. However, both these ﬁrst and second phases have
occurred more than once: humans in some central African regions may have antibodies to
multiple simian viruses[374] (suggesting primary transmissions may be frequent), and the
ancestry of HIV-1 subtypes implies distinct human-chimpanzees zoonoses (Section 7.2 in
[150]). SIV infection of humans is not able to generate high viral loads needed for
transmission. The third phase is for the disease to become transmittable between humans.
However, to cause an epidemic, the pathogen must be suitably adapted to the new host so
that every infected individual passes the disease on average to at least one other
individual[10, 218]. HIV has been in this fourth phase of emergence for the past three
decades. This phase may be facilitated by viral adaptations, or, by changes in the host
population that increase transmission[336], such as higher population density and increase
in behaviors that facilitate transmission. The later is believed to be an important factor for
14HIV, potentially explaining the delay between the evolution of HIV’s ability to
productively infect humans, and the beginning of the global epidemic.
Determining the origins of HIV is not just for scientiﬁc and historical interest - hopes
are that it could be key to determining how to control the disease. SIV infections are
common in many species of primates, and related CD4-tropic lentiviruses are found in
many other mammals, with current evidence pointing to a lentiviral origin over 7 million
years ago [171]. Most SIV infections in their native hosts do not lead to AIDS-like
immunodeﬁciency illness. Viral loads may be sustained at very high levels, but CD4 T cell
levels remain high. These ﬁndings have strongly suggested that HIV pathogenesis is driven
by more than direct killing of target cells by the virus [329] Chronic immune activation is
emerging as a potential mechanism for HIV pathogenesis; in natural SIV infection, immune
activation is only transient [105]. In SIV infections, there are also strong cellular immune
responses that seem to recognize highly conserved regions of the viral genome [125, 307].
The recency of successful immune control and avirulence of SIV in natural host populations
is a topic of debate. Rapid host virus-coevolution towards reduced pathogenicity would
result in a selective sweep, which would likely be detected by molecular phylogenetic
methods as a relative absence of lineages that coalesce prior to the emergence of avirulence
[149, 368]. A recent study suggests that the most recent intraspecies common ancestors of
SIV in sooty mangabeys and chimpanzees, respectively, existed just 200 and 500 years ago,
consistent with very recent evolution of an avirulent infection in both viral strains [368].
Biogeographical evidence gathered from comparisons of island and mainland viral strains in
west Central Africa, however, suggests that SIV evolution proceeds at a rate two orders of
magnitude slower than HIV evolution, implying a corresponding increase in the time since
a common ancestor [377]. Further supporting this analysis, phylogenetic reconstruction
that is unconstrained by geological or historical evidence may systematically underestimate
branch lengths when lineages are subject to strong purifying selection, as is generally the
case for RNA viruses [367].
15While viruses represent only about 15% of all human pathogens, the majority of
emerging diseases are RNA viruses, with high mutation rates (Chapter 16 of [340]).
Emerging diseases tend to have reservoirs in animals, and they tend to be adapted to a
broad range of hosts prior to arrival in humans. By examining likely patterns of
cross-species transmission in HIV/SIV and other widespread RNA viruses [149], we may
uncover clues that allow us to identify pathogens at risk for jumping the species barrier
into humans.
Frequent viral recombination presents a major obstacle to an accurate understanding of
HIV origins. Indeed, the entire scheme of classifying the main group of HIV-1 into nine
subtypes has recently been called into question by evidence that subtype G may actually
have resulted from recombination between subtypes A and J[2]. The occurrence of
recombination, which requires infection of a cell by two strains and so should grow roughly
as the square of viral load, may mirror the situation in some bacterial species, in which the
frequency of horizontal gene transfer depends on population density[85]. The recent growth
and success of “species tree” approaches in molecular systematics provides a powerful
method for disentangling the discordant evolutionary histories of multiple loci that are
brought together by recombination (reviewed in [101]). Though useful in metazoic taxa,
these approaches have not been applied to virus evolution; they require the partitioning of
the genome into discrete loci, with recombination occurring between, but not within, loci
[75, 101]. The frequency of recombination in HIV may be prohibitively high, and therefore
the “eﬀective locus size” prohibitively small, in order to import these methods wholesale to
the study of its evolutionary history.
2.3.3 Is HIV evolving to be less virulent?
The ﬁfth and ﬁnal phase of emergence of a new infectious disease is adaptation of the
pathogen to optimize transmission between hosts, and the switch from an epidemic phase
(rapidly increasing prevalence) to an endemic one. Although disease prevalence may remain
16approximately constant in this phase, the system is by no means static - both pathogen
and host populations can evolve continually to circumvent each other, in an evolutionary
arms race (also known as “Red Queen” race)[352]. The infectivity of a strain is deﬁned as
the rate of infection of susceptible individuals, and the virulence is usually deﬁned as the
increased death rate that infected individuals suﬀer due to the virus. At ﬁrst glance, it
seems that it would be optimal for a disease to evolve to both maximize its infectivity and
minimize its virulence in a host, the latter allowing the host to live longer and infect more
people. However, there are often trade-oﬀs between these two parameters that complicate
the optimization of transmission - for example, high numbers of pathogens within a host
may be necessary for infectivity but may contribute to virulence [217]. As well, there are
clear conﬂicts between the role of within-host evolution and population level evolution on
virulence-related traits. Competition within a host selects for the fastest replicating strain,
which could be more virulent, while at the population level an intermediate replication rate
that maximizes transmission may be favored [220, 246]. Even within a host there is
selection to control the death rate of infected cells to maximize transmission between cells.
Bottlenecks that occur at transmission may to some extent “reset” viral evolution between
hosts [18], with the result being that within-host selection may have little eﬀect on the
long-term, population level evolution of HIV. However, recent studies have shown that in
the case of HIV, there is heritable variation in virulence (measured by viral load) between
20-60%(reviewed in [232]). There is no clear consensus as to whether HIV is evolving at a
population level to become less virulent (summarized in [18, 323]), although a recent
meta-analysis has concluded that virulence has actually increased over the past three
decades [141]. A recent paper modeling the evolution of HIV virulence based on known
viral load-transmission rate and viral load-mortality relations concluded that HIV has
already reached the optimal virulence to maximize transmission between hosts [323].
172.3.4 Does competition within a single cell drive evolution?
In HIV infection there is potential for multiple genetically distinct virions to infect a single
cell [94]. This results in a new level of selection for the virus which we call within-cell (as
opposed to within-host and population level), which introduces novel viral dynamics.
Firstly, competition for resources related to viral replication within the cell can select for
an increased production rate of virions and hence greater cytopathicity [372]. Secondly,
when multiple virions infect the same cell, the new virions created will have a mix of
genetic material from both strains and structural proteins and enzymes (determining
“phenotype”) also from both strains. This is termed phenotypic mixing [370]. As a result,
deleterious mutations may persist at a higher frequency than expected by
mutation-selection balance, since they can be shielded by the wildtype phenotype
[240, 370]. Virions carry two strands of RNA genome, which may be from diﬀerent strains.
When this virion infects a new cell, these genomes may recombine, as reverse transcriptase
often jumps between RNA strands[199]. Recombination alters the spread of viral genotypes
maintained by mutation and changes the error catastrophe threshold [44]. Together, the
eﬀects of co-infection have been shown in models to accelerate the rate of CTL escape [230]
but may either promote or hinder the development of drug resistance, depending on
whether multiple mutations display synergistic or antagonistic epistasis [50]. Importantly, a
pre-requisite for these dynamics to aﬀect the genetic composition of the population is the
existence of a signiﬁcant number of cells co-infected with genetically distinct virions. Some
studies claim that co-infection with genetically distinct virions happens quite frequently in
the lymph tissue [166], but much lower rates (1-10%) have been found in the peripheral
blood [163] and have been estimated from eﬀective recombination rates measured from
patient sequence data [30, 235].
182.3.5 HIV pathogenesis involves immune-directed evolution
Despite three decades of research on HIV, its mechanism of pathogenesis is still not entirely
clear. Evolutionary processes are implicated to a large extent in the hypothesized
mechanisms of disease progression [247, 248, 250, 306]. It is well understood that over the
course of a single infection, HIV continually evolves to circumvent host defenses. HIV
infects CD4 T lymphocytes, also known as helper T cells, using the receptors that they
uniquely express to gain access to the cell. After initial HIV infection, patients experience
very high viral loads and occasionally the ﬂu-like symptoms of acute viremia, after which
viral load declines to a comparatively low level called the “set point”, where it may remain
for many years. This decline occurs both due to the limitation of uninfected target CD4 T
cells [272] and by the appearance of cellular immune responses against HIV [331].
Immune control of HIV is largely due to CD48 T cells [203, 359, 373](also called
“killer” T cells or cytotoxic T lymphocytes (CTLs)), though antibodies [365] and innate
immunity [62] also play a roll. Small virus-derived peptides called epitopes are presented
on the surface of infected cells by the HLA class 1 molecules, which then allows CTLs to
recognize and kill these cells. Throughout the course of chronic infection, which may last
from a few years to a decade, viral diversity and ﬁtness gradually increase [18, 49, 189].
Antigenic diversity also increases, as HIV continuously generates escape mutations in CTL
epitopes, preventing them from being presented or recognized [8, 49, 124, 250, 273]. About
2/3 of mutations acquired over the course of HIV infection have been attributed to CTL
selection pressure [7]. These mutants are subsequently selected and may grow to a high
frequency. The immune response is further weakened by the fact that HIV is infecting and
destroying cells involved in immune control.
While evolution is typically thought of as an open-ended process that may follow many
paths, certain aspects of HIV evolution are very predictable. For a given HLA allele
present in an individual, certain escape mutations in epitope regions are highly consistent
between patients [53, 57]. Another predictable evolutionary event is a switch in the virus’s
19machinery for entering its target cells (reviewed in [200, 285]). HIV enters cells by binding
to the CD4 cell surface receptor, but also requires a co-receptor. Early in infection, the
viral population seems to be composed of strains that preferentially use the CCR5
co-receptor, termed “R5” virus. Later on in infection, about 50% of patients experience a
switch in the tropism of the dominant virus population to an “X4” virus that instead uses
another co-receptor, CXCR4, for entry. The factors determining this switch are not
completely understood. It seems that R5 viruses have a selective advantage early in
infection and dominate the viral population after sexual, mother-to-child, or direct
blood-to-blood transmission, though individuals homozygous for the ∆     mutation can
be infected with X4 virus [322]. Later in infection, selection pressure seems to change to
favor X4 virus. This is hypothesized to be a result of the change in the population
composition of T cells over the course of chronic infection. The X4 virus seems to be more
susceptible to antiviral immunity but able to infect a broader range of target cells,
including resting T cells, and so as immune function declines, it may outcompete R5
viruses. The reason only 50% of patients experience this switch is unclear, though could be
a result of the chance accumulation of multiple mutations required to make the tropism
switch. Patients with X4 virus tend to experience more rapid decline in CD4 T cells, and
so this phenotype switch may be facilitated by immune deﬁciency but then lead to
accelerating deﬁciency. The co-receptor switch is less common in treated patients [197].
Mathematical models have demonstrated that the accumulation of escape mutations
can explain the clinical course of HIV infection [167, 248, 286](Figure 2.2). Viral diversity
increases as HIV progressively escapes CTL responses, resulting in higher viral load, and
due to HIV-induced damage of CD4 T cell populations, a progressively weaker immune
response. There is an asymmetry in the HIV-T cell interaction, since any strain of HIV can
infect and damage any CD4 T cell, but each CTL can only target the HIV strain it is
speciﬁc for. Eventually infection reaches a point where the immune response is unable to
control the variable strains of HIV, and viral loads rapidly increase as CD4 T cell levels
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Figure 2.2: Hypothetical evolutionary mechanism for HIV pathogenesis. Colors schematically
represent diversity of viral strains. Bottlenecks during transmission lead to acute infection grow-
ing from approximately a single viral strain. Viral loads peak and decline rapidly during acute
infection, with diversity remaining low. During asymptomatic infection, which may last from
months to decades, viral loads remain near a lower set point. Diversity gradually increases,
potentially as mutants that escape cytotoxic T cells are generated. At a certain point helper
(CD4 T cells) reach a critically low level, due to direct and indirect eﬀects of HIV, leading to
rapid rise in viral load and progression to the clinical symptoms of AIDS. Mathematical models
suggest that crossing a diversity threshold could cause progression to disease. At the ﬁnal stages
of disease, diversity begins to decrease, possibly due to reduced selection pressure from a failing
immune system. Figure adapted from [18, 174, 196, 242, 317]
21fall. This is called the “diversity threshold”, and could explain the onset of the clinical
symptoms of immune deﬁciency, called AIDS. This theory highlights that the two speciﬁc
features of HIV, which make it especially harmful to the host, are the fact that its target
cells are involved in orchestrating the immune response, and its high rate of evolution in a
single infected host.
Despite its elegance, the evolutionary model for HIV pathogenesis may not be the
whole story. Various lines of evidence suggest that CTL responses are important for viral
control, including the observation that the selective advantage of escape mutations
correlates with rate of disease progression (speciﬁcally, the portion of this rate that is
statistically associated with particular HLA alleles)[20]. However, it has been observed that
only a small fraction of CD4 T cells are infected with HIV, making it diﬃcult to explain
how either direct viral killing or CTL killing, for which death rates have been measured,
could be responsible for such a large decline in their numbers. During infection, there is a
large increase in the death rate of uninfected (termed “bystander”) CD4 T cells. Multiple,
though not mutually exclusive, mechanisms have been proposed to explain this observation,
including 1) direct cytotoxicity of free-ﬂoating HIV proteins on uninfected cells, 2) an
increase in apoptotic signals, or 3) an increase in the fraction of activated, short-lived T
cells due to HIV-induced immune activation [5, 84, 200]. While the importance of each of
these mechanisms remains to be determined, it is interesting to note that models for many
potential pathogenic processes have found that the extremely slow decline of CD4 T cells
is diﬃcult to explain by any process that does not, at some level, involve gradual evolution
and an accompanying change in the balance between the virus and host defenses [382].
However, evolution could be either viral or related to somatic evolution of T cells: an
increased turnover rate of cells could lead to the accumulation of deleterious mutations and
eventual senescence of immune cells [118]. The ability of HIV to induce immune activation
may itself be subject to selection. The direction and strength of selection depend on the
trade-oﬀ between creating more target cells and increased virulence. However, the ability
22to cause immune activation is only under selection if it preferentially changes the ﬁtness of
a particular viral genotype, that is, if it is local. The ability to cause systemic immune
activation aﬀecting all viral genotypes is a selectively neutral trait [28].
Clues to the virus’s mechanism of harm can be deduced from a rare group of patients
who become infected with HIV, but maintain lifelong low viral loads and do not seem to
progress to AIDS[92]. Existence of these “elite controllers” suggests that immune control of
the virus is possible in humans, though how this control works is still under investigation.
This sub-population of individuals is enriched for certain HLA alleles, and their CTL
responses tend to have higher HLA avidity, proliferate more, kill better, and preferentially
recognize epitopes from the HIV capsid protein Gag (reviewed in [186]). Immune activation
levels remain relatively low in elite controllers. Despite very low viral loads, they do seem
to experience ongoing viral replication, and even continual evolution, including escape
mutations [251]. How then, do they avoid increasing viral loads and decreasing immune
function? When HIV mutates to avoid immune recognition, these mutations often harm
native functions of the virus, leading to a ﬁtness cost (deﬁned as a reduction in replication
rate as compared to a wildtype virus in a laboratory environment, free of immune
response). The selective advantage of an escape mutant depends on a trade-oﬀ between the
beneﬁt attained from escaping CTL killing and the ﬁtness cost of the mutation, and it in
elite controllers the cost of escape may be so great and the advantage so low that viral
loads remain approximately constant [226, 227, 251, 378]. The “diversity threshold” model
of HIV pathogenesis mentioned earlier does include speciﬁc parameter regimes where
indeﬁnite control of the virus occurs[244], but it has yet to be determined if these
parameter regimes are quantitatively consistent with elite controllers.
The ability of HIV to rapidly escape from immune control has important implications
for vaccine development. There are currently eﬀective vaccines for many diseases, including
measles, smallpox and polio. For each of these diseases, a single natural infection provides
lasting immunity. Vaccine-induced immunity is similarly eﬀective. In contrast, individuals
23infected with HIV can be superinfected with other strains and eﬀective immune control is
rarely achieved. Designing an HIV vaccine requires ﬁrst determining the unknown
correlates of immune control. Such a vaccine will have to elicit immune responses to an
extremely diverse viral population. All currently used protective vaccines elicit antibodies,
which until recently were believed to be generally ineﬀective in controlling HIV, leading to
much focus on CTL-based vaccines [261]. However, recent years have seen advances in the
characterization of “elite neutralizers,” individuals capable of naturally controlling HIV
infection with potent broadly neutralizing antibody responses, which has renewed
conﬁdence in the future of antibody-based vaccines (reviewed in [184]). This strategy is
complicated by the ﬁnding that elite neutralizers can produce these antibodies only after
extensive somatic mutation of B cells, suggesting that a vaccine may have to elicit the
“ancestral” antibodies and then direct evolution through particular aﬃnity maturation
pathways. Studying the mechanisms of immune control in elite controllers and elite
neutralizers will likely continue to be an important step in research towards a vaccine [39].
HIV’s ability to evade immune responses also emphasizes the importance of trade-oﬀs
in evolution [160]. Overall, HIV and other lentiviruses have evolved an infection strategy
that evades many defenses of the immune response, allowing the virus to persist and
establish a chronic infection lasting many years. One of the particular adaptations enabling
this strategy is the arrangement of the cell-binding proteins in the viral envelope. These
proteins are placed so that conserved regions are inaccessible to antibody recognition,
explaining the scarcity of broadly neutralizing antibodies against HIV. However, as a
result, HIV’s ability to infect cells is compromised. In immune-free cell culture, strains
quickly evolve which have higher replication rates but are more susceptible to antibodies.
Other viruses infecting humans take a diﬀerent strategy; replicating very quickly and
relying on most transmission to occur before the host mounts an immune response, which
will then likely clear the infection. This trade-oﬀ between the “acute infector” and
“persistor” viral lifecycle strategies is reminiscent of life history theory [338, 339], which
24posits that trade-oﬀs constrain fertility and that organisms respond to dynamic
environments with a variety of reproductive strategies, e.g., producing few oﬀspring and
investing heavily in each, or producing many oﬀspring each with a low chance of survival.
2.3.6 Is HIV evolving at the population level response to human immune
control?
There is evidence that HIV may be evolving at the population level, evading immune
responses characteristic of speciﬁc human sub-populations. Escape mutations prevent the
virus from being recognized by a certain individual host’s immune response, and when the
virus is transmitted to another host, they may revert back to wildtype [198] or be
maintained [124]. Studies have shown that in various populations, the prevalence of escape
mutations in particular epitopes was highly correlated with the prevalence of the HLA
allele presenting that epitope, even when only individuals without the allele were
considered. Particular escape mutants also appeared to be increasing in prevalence over
time [114, 172]. It has been suggested that in populations where there are HLA alleles
common to many individuals, CTL escape mutations may be retained upon transmission
and contribute to increasing virulence of the epidemic, while in populations with high HLA
diversity (many African populations), it is more likely for virulence to decrease [18].
2.3.7 Host-pathogen co-evolution: Are humans evolving in response to HIV?
We have so far discussed evolution of HIV in response to selection pressure imposed by
host immune defenses and by potential vaccines. It is however also possible that the human
population may be evolving in responding to the virus. Given the high prevalence of HIV
in certain regions, and the severe decrease in reproductive success incurred by untreated
HIV-positive individuals, a strong selective pressure for protective alleles is expected and
changes in allele frequency should be apparent in several generations. Since severe disease
burdens have only existed for 1-2 generations so far, these changes may not yet be
25detectable.
Studies have identiﬁed various sources of natural genetic variation to HIV infection in
humans [108, 139, 228]. Heterozygosity at the HLA loci, and certain HLA alleles, especially
at the HLA-B locus, are strongly related to slower disease progression. Two cellular
proteins involved in innate antiviral immunity show strong signatures of positive selection
in human populations, and polymorphisms have been implicated in diﬀerential
susceptibility to HIV infection. TRIM5  interferes with the uncoating of the viral capsid
upon entry into a host cell, and APOBEC3G, as discussed earlier, can edit viral cDNA
during reverse transcription, leading to hypermutation of viral genomes. Variation in
cytokine loci are also implicated in HIV control. About 1% of the European population is
homozygous for a 32 base pair deletion in the CCR5 gene (∆    ), rendering them resistant
to infection by HIV, which requires the CCR5 protein as a co-receptor during initial
infection. To the extent that these polymorphisms are prevalent in regions with a high
burden of HIV-induced mortality, their frequency may change in response to the epidemic.
2.4 HIV evolution in response to medical interventions
2.4.1 How might an HIV vaccine drive population level virulence?
Attempts to make a vaccine against HIV have so far been unsuccessful, largely due to the
enormous genetic variation of HIV, both within an individual, starting early in infection,
and worldwide. Due to the fact that HIV is only rarely controlled by antibodies, which are
induced by most vaccines to date, and that the virus quickly establishes long-lived
reservoirs in latently infected cells, it has been suggested that a potential vaccine may not
be able to prevent infection, but may instead only lead to a reduced viral load set-point
[26]. Theory suggests that vaccines that completely prevent infection could lead to reduced
virulence, either by directly targeting virulence factors (as is the case with the diphtheria
vaccines), or, by reducing co-infection and hence the strength of within-host competition,
26which often selects for high replication rates and high virulence[119, 246]. The latter eﬀect
is likely to be relevant in certain high-risk populations where infection with multiple strains
is common, though in general multiple infections are a rare occurrence [355]. However,
“leaky” vaccines that allow some infection but reduce host death rate, like that proposed
for HIV, can alter the virulence-infectivity trade-oﬀ, making increased virulence less costly
(less chance of host death) and more beneﬁcial (to achieve high transmission in face of
reduced pathogen titers), and therefore lead to evolution of increased virulence [119]. Virus
may also escape vaccine control, similar to escape to naturally occurring immune
responses, with unknown consequences for virulence.
2.4.2 HIV evolves resistance to antiretroviral drugs
In the developed world, deaths from AIDS have decreased dramatically since the
introduction of highly active antiretroviral therapy (HAART) in the late 1990’s [259]. By
targeting multiple HIV proteins with drug combinations at high doses, HAART minimizes
the likelihood of developing resistance. However, these drugs remain prohibitively
expensive and inaccessible to most HIV infected individuals, and suboptimal adherence
and drug resistance remain a problem worldwide. At ﬁrst we consider the case of resistance
evolving de novo, in an individual initially infected with drug-sensitive HIV; later we
consider the less frequent case where resistance is transmitted.
Like the host immune response, antiretroviral drug treatment provides a strong
selective pressure on the virus, and over the course of a single individual’s infection, HIV
can evolve drug resistance. Unlike the immune response in a typical individual, drug
treatment easily results in a negative growth rate for the virus, limiting ongoing viral
replication and slowing the rate of evolution. Resistance mutations can arise from one of
three sources [296]. Firstly, if treatment does not completely suppress all viral replication,
new mutations may arise during treatment from the residual viral replication. This
likelihood of generating resistance depends on the strength of the drug, measured by the
27fraction of viral replication events prevented by the drug at a given concentration.
Secondly, viral loads are generally quite high when treatment starts, and mutations may
pre-exist in the viral population with some low frequency termed mutation-selection
balance [47, 288], which is determined by the mutation rate and the ﬁtness cost of the
mutation in the absence of treatment. Thirdly, occasionally HIV-infected CD4 T cells
revert to a resting state, bringing with them integrated HIV in their genome. These cells
comprise the latent reservoir and may remain in a resting state for many years, unaﬀected
by drug treatment, which only inhibits active viral replication. Cells in the latent reservoir
harbor a representative sample of viral genomes that have existed in the plasma over the
course of infection. Mutation frequencies in the reservoir are likewise determined by
mutation-selection balance, and resting cells may re-activate randomly at any point during
drug treatment, reseeding the infection with both wildtype and mutant viruses.
In order for clinical drug resistance to emerge, resistant viral strains must be selected
for. Viral ﬁtness is determined by drug concentration, and typically follows a sigmoidal
dose-response curve with a variable      and slope [319]. Mutant viruses have altered
dose-response curves and beneﬁt from having a higher      or lower slope. Resistant
mutants also tend to carry a ﬁtness cost, meaning that in the absence of the drug, their
ﬁtness is lower than the wildtype virus [304]. As a result there is only a certain range of
intermediate drug concentrations, termed the mutant selection window (MSW), where any
particular mutant is selected over the wildtype (Figure 2.3a). At lower concentrations, the
wildtype is favored, and at higher concentrations, even mutant ﬁtness is so low that the
growth rate is negative. No HIV mutants have been characterized that lack susceptibility
to any drug concentration, though many may only be controlled with concentrations that
are not clinically achievable due to toxicity [304]. Even when concentrations fall within the
MSW, the favored mutant may still be lost to random drift, with a probability depending
on the population dynamics of the infection. Heterogeneity and ﬂuctuations in the host
environment during treatment generally increase drift, making a favored mutant less likely
28to establish a persistent lineage (see Box 1).
Drug concentrations within the MSW may inhibit wildtype growth but select for
resistance. Drug concentrations are not constant in a given individual, but ﬂuctuate due to
the dose taken, the drug bioavailability and half-life, and the patient’s adherence to
medication (Figure 2.3b). Consequently, selection pressures also ﬂuctuate (Figure 2.3c).
Drug concentrations that are high, yet still within the MSW, may slow the rate of
emergence of resistance, since ongoing viral replication is greatly reduced and resistant
mutants can only arise if they are pre-existing (either in the actively infected cells or in the
latent reservoir).
Keeping drug levels above the MSW is required to guarantee the resistant mutant
won’t be selected for. If these concentrations are clinically possible, then this particular
mutant alone is not an insurmountable threat, since if it arose, it could be eradicated by
ensuring that drug concentrations exceed the MSW for suﬃcient time. However, clinically
relevant resistance may require more than a single mutation. If a single resistance mutation
arises, it may facilitate the emergence of stronger, untreatable strains with multiple
mutations (Fig 2.3g), or with compensatory mutations, which reduce the ﬁtness cost of the
ﬁrst mutation. It is possible that these strains will then be untreatable at maximum
clinical drug concentrations, in which case they will lead to treatment failure.
Most current ﬁrst-line antiretroviral regimens include a drug that can reduce viral
replication by at least ﬁve orders of magnitude, even at minimum clinical plasma
concentrations [319, 320], and so it is likely that multiple factors acting in concert are
typically required to provoke treatment failure. Three main environmental factors can
conspire to enable viral replication despite ongoing treatment. First, drug concentrations
may temporarily drop, either when the concentration reaches a minimum prior to a
scheduled dose or when the patient fails to adhere to the regimen. Certain drugs, notably
the protease inhibitors, have very sharp dose-response curves, meaning that despite having
the beneﬁt of requiring lower concentrations to achieve the same inhibition, have the
29Figure 2.3 (following page): Drug-dependent ﬁtness landscape for the antiretroviral drug
efavirenz derived using measured pharamacodynamic and pharmacokinetic parameters for wild-
type and the K103N drug resistant strain. Viral growth rate is positive only when      1 (above
grey dotted line) a) Fitness of wildtype and resistant strains follow dose-response curves, result-
ing in a mutant selection window where resistant strains are selected. We compare a single mu-
tant (K103N) to two hypothetical double mutants by adding either a second equivalent resis-
tant mutation (further increases      and decreases slope) or a compensatory mutation (changes
ﬁtness cost only). b) Drug concentrations decay over time according to drug half-life. c) Rela-
tive ﬁtnesses of wildtype and resistant strains consequently change over time as drug decays d)
In the CSF, reduced drug penetration results in concentrations reduced to 0.5%, allowing viral
replication at higher systemic drug levels. e) Assuming about 10% of cells are susceptible to di-
rect cell-to-cell transmission, which typically occurs with around 100 virions and is sustainable
with a single virion. f) Combining the eﬀects of (d) and (e). g) At the maximum clinical drug
concentration (immediately following a dose), only the doubly resistant mutant can grow. h)
At intermediate concentrations, the single resistant mutant can grow, facilitating evolution of
the compensated mutation or the untreatable doubly resistant mutant. i) Without treatment,
the wildtype is favored. While the doubly resistant mutant can step-wise revert to wildtype, the
compensated mutant is less likely to do so due to the presence of a ﬁtness valley at either of the
intermediate single mutants. See Appendix (§2.5) for methods.
30Figure 2.3: (continued)
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31disadvantage that a small decline in drug concentration can lead to a large drop in viral
suppression [319]. Secondly, replication rates are increased in tissues such as lymph nodes
that are densely populated with target cells. In particular, multiple infections per cell (for
example, by local spread of virus or direct cell-to-cell transmission via virological synapses)
may occur in such tissues[127, 162], although the evidence for a high multiplicity of
infection in vivo is limited [163, 166]. The presence of even a small collection of cells
vulnerable to this mode of transmission may suﬃce to dampen a drug regimen’s inhibitory
eﬀect by an order of magnitude [324] (Figure 2.3e,f).
Finally, drug concentrations in certain anatomical compartments may be a small
fraction of plasma levels. The concentration of efavirenz in the CNS, for instance, is
typically only 0.5% of the plasma level [36] (Figure 2.3d, f). Infected monocytes may
introduce the virus to the CNS or other drug refuge, thereby initiating a locally blooming
infection, despite successful viral suppression elsewhere in the host [36, 38, 83]. For
example, on the basis of a simple calculation using dose-response curves measured in vitro,
we estimate that wildtype (drug-susceptible) virus can generate a self-sustaining infection
in the CNS if target cells are also capable of direct cell-to-cell transmission [324], in the
presence of efavirenz therapy just below the clinical minimum drug concentration (Figure
2.3d). A single missed or delayed dose would allow concentrations to dip below this
minimum level, allowing the infection to grow locally. If a resistance mutation occurs every
104 replication events, then a transient growth in viral load to detectable levels (  50
copies/ml, or 25 virions/ml) conﬁned to the CNS (  200 ml), experiencing daily turnover
[214], should generate a resistant mutant every other day. This explains why resistant
strains may evolve in vulnerable anatomical compartments even while plasma viral load is
suppressed, potentially leading to therapy failure[102, 332]. Equations and parameters for
generating Figure 2.3 are given in the Appendix (§2.5).
Drugs that inhibit binding of HIV to host cells (entry or fusion inhibitors) are currently
in various stages of development. Like antiretrovirals that act at other phases of the viral
32lifecycle, these drugs come with a risk for the development of resistance; but they may also
have other consequences for disease progression. Models have shown that drugs that inhibit
the CCR5 co-receptor (for example, FDA-approved Maraviroc) could facilitate the switch
to more pathogenic X4 variants, while anti-CXCR4 drugs may have the added beneﬁt of
decreasing selection pressure for X4 strains [285, 366].
The risk of resistance can be reduced with higher drug concentrations and by ensuring
that drugs penetrate all tissue compartments; combination therapy plays a crucial role.
When multiple drugs with diﬀerent sites of action are used, the virus may need mutations
that reduce susceptibility to all drugs in order for treatment failure to occur. Since
multiple independent mutation events are relatively unlikely to occur on the same viral
genome, it is generally more diﬃcult for the virus to become fully resistant to combination
therapy than to single therapy.
Predicting drug resistance should be an important consideration when designing dosing
regimes for antiretroviral drugs, and would ideally be done as a part of the drug design
process. Laboratory assays can characterize costs and beneﬁts of mutant strains in the
presence of drugs[304]; however, mutations are typically chosen for study only after they
are observed in patients failing therapy. Bioinformatic techniques are needed to predict
sites where resistance-conferring mutations may occur and how multiple mutations
interact[33, 34, 193]. High-throughput implementations of known techniques for creating
and testing mutant strains could help prevent the emergence of resistance and aid in design
of “resistance-proof” drug regimens.
There are a few novel ideas for drug treatments that act in a very diﬀerent way from
current antiretrovirals, which reduce viral infectivity; instead, they aim to alter HIV’s
intrinsic mutation rate. Drugs have been proposed which increase the mutation rate
beyond the error catastrophe discussed previously, besetting the viral genome with
unsustainable levels of deleterious mutational load (reviewed in Section 4.3 of [150]). An
example is inhibitors of the viral protein Vif, which prevents the cellular APOBEC3G
33enzyme from hypermutating HIV cDNA during reverse transcription. A mutagenic drug
(ribavirin) that acts with a diﬀerent mechanism already exists for the hepatitis C, foot and
mouth disease, and respiratory syncytial virus [82]. It is also possible that drugs that
decrease the mutation rate may be useful, since much of HIV’s proposed pathogenesis is
due to its high mutation rate. It has also been hypothesized that drugs could be used in
concert with natural immune control to create an evolutionary trap for HIV: if drugs are
designed such that any potential resistance mutations are potent CTL-eliciting epitopes,
than the virus would be unable to escape both methods of control simultaneously [385].
2.4.3 Could HIV become a drug-resistant epidemic?
It is generally assumed that individuals are infected with drug-sensitive virus, and that
suboptimal treatment (i.e. monotherapy) or poor adherence leads to the de novo
generation and selection of resistant mutants within that individual, as described earlier.
Recent data, however, suggests a signiﬁcant minority of cases where individuals are
infected with a resistant strain. Worldwide, the detection of transmitted drug resistance in
treatment-naive individuals is becoming increasingly worrisome. Between 10-25% of
individuals in high-risk groups in the US and Europe are infected with virus harboring
mutations associated with resistance to one or more antiretroviral drug [275, 354].
Surprisingly, drug resistance is transmitted not only from treated individuals, but may be
transmitted directly between untreated individuals[153]. Transmitted drug resistance
occurs much more frequently in regions where antiretroviral use is more prevalent. As
drugs become more readily available globally, will the HIV epidemic become untreatable?
Widespread transmission of drug resistance requires both the generation of resistance
within infected individuals, as well as the maintenance of these mutations upon
transmission to uninfected individuals. Traditionally, it was believed that the ﬁtness cost of
resistance mutations, resulting in them having a lower ﬁtness that wildtype strains in
untreated individuals, made persistence of resistance unlikely (Fig 2.3a/i). Often, reversion
34of resistance mutations is observed when studying transmission pairs. However, reversion
to wildtype is observed to occur much more slowly than the initial take-over by a resistant
mutant [206], sometimes taking years due to smaller relative diﬀerence in ﬁtness in the
absence of drugs that in their presence (see Figure 2.3g-i). In other cases, resistance may
persist. This occurs when the ﬁtness of resistance mutations is oﬀset by the accumulation
of compensatory mutations, which have been identiﬁed for many resistance mutations.
Even if these compensatory mutations are unable to fully oﬀset the cost, reversion may be
very unlikely to occur if intermediate mutational steps leading back to the wildtype are less
ﬁt than the original (multi-step) mutant[131, 275, 310](Fig 2.3i). When this occurs,
resistance is no longer reversible, and persistence of resistant strains in untreated
individuals will occur, compromising their likelihood of treatment success when they begin
antiretroviral therapy.
Transmitted drug resistance is just beginning to be studied in the context of HIV. The
ﬁnding that overall, lower viral loads are not observed with transmitted drug resistance
[134] suggests that the mutations are not costly, and it was also shown that transmitted
resistance impairs treatment responses [371]. A recent modeling study for the spread of
drug resistance in San Francisco, where prevalence of transmitted resistance is among the
highest in the world, suggested that the most important determinants of spread are the
relative ﬁtnesses of the wildtype and resistant strain, especially during the asymptomatic
(i.e. early, untreated) stage of infection [335].
Many other diseases have already established widespread, costly, and often deadly
drug-resistant epidemics: examining them may help assess the threat of spread of drug
resistant HIV (reviewed in [340, 384](Chapter 10 of [340]). Antibiotic resistant bacterial
epidemics, such as methicillin resistant Staphylococcus aureus (MRSA) and vancomycin
resistant Enterococcus (VRE), are facilitated in hospital settings by widespread antibiotic
use and easy transfer between high densities of often immunocompromised patients.
Bacteria may acquire drug resistant genes on plasmids through horizontal gene transfer
35with unrelated bacterial species. Since many antibiotics were derived from naturally
occurring compounds, resistance genes may pre-exist in certain environmental bacteria[6].
Widespread use of antibiotics in livestock exacerbates this problem. Multiple factors
contribute to the persistence of resistance genes even when bacteria infect untreated
individuals. When carried on small plasmids or linked (on plasmids) to beneﬁcial genes,
there may be little ﬁtness cost incurred for carrying the resistance gene. Plasmids may
potentially carry resistance genes to multiple drugs. Drug resistant infections may be more
or less virulent than susceptible ones, due to either linked virulence factors or ﬁtness costs
to resistance, and studies have found that both scenarios occur[78]. The multidrug
resistant tuberculosis (MDR-TB) epidemic in the developed world ﬁrst emerged in
immunocompromised individuals, particularly AIDS patients[100], and has been
suggested-though not consistently demonstrated-to be less virulent and transmissible [79].
It is clear that persistence of HIV drug resistance is not inﬂuenced by many of these factors
facilitating antibiotic resistance.
Examining the potential for transmitted drug resistance from an evolutionary point of
view suggests that it will likely be easier to prevent such an epidemic from occurring, than
to control it once it emerges. Worldwide, there have been multiple population level
attempts to reduce the prevalence of drug resistant infections by lowering sub-therapeutic
use of antibiotics (for example, in agriculture, or in mild infections of humans): they have
shown very little success. Predicting resistance during drug development will be an
important step. Improving patient adherence to drugs is extremely important. Most
currently HAART regimes involve drug combinations that suppress viral replication to
such an extent that clinical resistance is extremely unlikely, and the strongest predictor of
resistance is patient adherence, which currently averages around 70% [24]. While using
antiretroviral treatment as a preventative measure against HIV infection in high risk
groups (called pre-exposure prophylaxis, or PrEP) may reduce the number of new
infections, in some cases it could increase the percent of infections that are drug resistant
36[342]. A similar eﬀect could potentially occur for “test-and-treat” strategies, which aim
scale-up diagnostic tests in underserved areas and to start antiretroviral treatment as soon
as individuals are diagnosed with HIV [42].
2.4.4 Box 1: Population size and emergence of drug-resistant mutation
from the latent reservoir
Several studies have estimated the eﬀective population size (denoted   ) of the HIV
infection at various stages of the infection. This quantity is used to describe the strength of
random genetic drift [135], and so it is important for understanding the likelihood that a
favored drug resistance mutation will by lost by chance [188, 268]. Since eﬀective
population size is an abstract concept deﬁned in the context of particular mathematical
models, the appropriate deﬁnition to use depends on the particular biological question
being asked. To demonstrate this point, we explore a general mathematical description of
emergence of drug resistance from the latent reservoir. Though simple, this framework can
be used to understand clinical data on the frequency of treatment failure due to drug
resistance [268].
While a patient is on suppressive HAART, the rate at which a drug-resistant mutation
from the latent reservoir becomes active and generates a persistent resistant strain is
                        (2.1)
where   is the rate at which infected cells exit the latent reservoir,         is the
probability that a randomly selected latently infected cell carries a resistance mutation,
and          is the probability that a resistance mutation, once in the actively replicating
population, survives drift and establishes a persistent lineage during drug treatment.
A patient on fully suppressive HAART still has approximately 3000 cells in the actively
infected population [93, 147, 296], all of which come from the latent reservoir. Since these
cells have a lifespan of approximately one day [214],   can be estimated to be 3000 cells per
37day.
If the latent reservoir is seeded by a pre-treatment population that has reached
mutation-selection balance, then         can be estimated as    , where   is the rate at
which a resistance mutation occurs during replication, and   is the selective disadvantage
(ﬁtness cost) of the mutation in the absence of treatment. The value of   for a
single-nucleotide replacement varies from        to       , with a genome-wide average
of          [3, 296]. The value of   also varies widely, from 0.05 to 0.9 [296, 304]. Note
that, while     represents an average value, stochastic eﬀects can cause         to vary
over time and among patients, even taking zero values for many patients. In particular, a
smaller pre-treatment eﬀective population size would lead to a more dispersed        
distribution.
The probability          depends on the population dynamics during treatment.
Assuming that the wildtype (drug-susceptible) virus cannot replicate during treatment,
only the description of mutant replication matters for calculating         . The viral ﬁtness,
deﬁned as the basic reproductive ratio   , is the expected number of oﬀspring cells
generated by a single mutant-infected cell during its lifetime[247]. For this simple model,
we assume that    is constant (that is, ﬂuctuations in drug concentration are negligible). If
this value is not too much greater than 1, then a second-order approximation can be used
to estimate survival probability [106, 268]:
          
         
   (2.2)
where    is the variance in expected number of oﬀspring for the drug-resistant mutant
during treatment. This parameter is higher for “winner-take-all” types of infection
dynamics. In the limit that       ,          approaches either 0 or 1, and this
approximation does not hold. To see more concretely how    relates to a possible scenario
involving reproductive skew: if a single infected cell may either die or give rise to   many
oﬀspring cells in a single timestep, then                .
38Combining the three factors, the rate at which drug-resistance emerges is
      
           
      (2.3)
Note that this rate does not depend upon the infection population size, except insofar
as the parameter   depends on the size of the latent reservoir. Estimates of the
pre-treatment    [52, 297] are not relevant to understanding the expected value of     ,
though they can explain inter-patient variation in this rate.
The composite quantity      may be thought of as an ersatz “eﬀective reservoir exit
rate” analogous to an eﬀective population size. It is, roughly, the number of cells activating
from the latent reservoir each day that are relevant to the future infection dynamics during
treatment. Using resistance data from a 3-year clinical study to parameterize the expression
for      [213], a study estimated      to be only 5 cells per day [268], which (using   =
3000) implies an enormous variance        600. This result could be achieved, e.g., with
       and reproductive skew (as deﬁned above) of        . In that case, the vast
majority of resistant mutants do not reproduce, but 0.7% give rise to 300 or more oﬀspring.
This extreme state of aﬀairs is plausible if the host environment is heterogeneous, and in
addition to being resistant, an infected cell must ﬁnd itself in a replication-permissive
locale in order to have any oﬀspring at all. Three important sources of this heterogeneity
are discussed in the main text: temporal variation in drug concentrations, spatial variation
in drug concentrations, and spatial variation in target cell density.
2.5 Appendix
2.5.1 Deriving viral fitness values for Figure 2.3
Wildtype viral ﬁtness (described by the basic reproductive ratio,   ) varies with drug
concentration according to a dose-response curve, with                              .
Drug resistant virus sustains a ﬁtness cost   and obeys an altered dose response curve with
39altered      and slope given by
      
         
   
(
 
   50
)       (2.4)
After a single dose of drug is taken, drug concentration falls exponentially over time
with a rate determined by the half-life  :                . In the CSF, if drug levels are
only a fraction   of the plasma level, then viral ﬁtness here is given by
                . If a fraction   of infectable cells are susceptible to a direct cell-to-cell
(or other high multiplicity-of-infection) process, in which MOI infectious units enter a cell
at once when the drug is absent, then viral ﬁtness is given by:
                               
          0     0   
          (2.5)
If direct cell-to-cell transmission can occur in the CSF, then viral ﬁtness is then given
by                       .
Parameters were used for the drug efavirenz (an NNRTI) and the K103N mutation:
          ,                , slope( ) = 1.69,              , half-life ( ) = 35.8
hours,   = 85,   = -0.17,   = 0.3 [296, 304, 319] . For the hypothetical double mutant,
      ,                    and                   . For the hypothetical compensatory
mutation alone,   = 0.45 and   = 1 and   = 0. For the compensatory mutation along with
K103N,   = 0.15,   = 85 and   = - 0.17. We assumed that in the CSF, the drug
concentration was reduced to a fraction   = 0.5% of plasma values [36] and that  = 10%
of cells were susceptible to direct cell-to-cell infection with an     = 100 [324].
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Antretroviral dynamics determines HIV
evolution and predicts treatment outcomes
3.1 Abstract
Despite the high inhibition of viral replication achieved by current anti-HIV drugs, many
patients fail treatment, often with emergence of drug-resistant virus. Clinical observations
show that the relationship between adherence and likelihood of resistance diﬀers
dramatically among drug classes. We developed a mathematical model that explains these
observations and predicts treatment outcomes. Our model incorporates drug properties,
ﬁtness diﬀerences between susceptible and resistant strains, mutations and adherence. We
show that antiviral activity falls quickly for drugs with sharp dose-response curves and
short half-lives, such as boosted protease inhibitors, limiting the time during which
resistance can be selected for. We ﬁnd that poor adherence to such drugs causes treatment
failure via growth of susceptible virus, explaining puzzling clinical observations.
Furthermore, our model predicts that certain single-pill combination therapies can prevent
resistance regardless of patient adherence. Our approach represents a ﬁrst step for
42simulating clinical trials of untested anti-HIV regimens and may help in the selection of
new drug regimens for investigation.
3.2 Introduction
The prognosis of HIV infection has dramatically improved since the introduction of highly
active antiretroviral therapy (HAART), which, when successful, can bring viral loads below
the detection limit, improve immune function and prevent progression to AIDS[260].
Although a complete understanding of how virologic, pharmacologic and host factors
interact to determine therapeutic outcome is still lacking, it is clear that a major obstacle
to successful treatment is suboptimal drug adherence. Non-adherence can lead to virologic
failure and the emergence of drug resistance[121, 132, 210, 357].
Because of their high antiviral activity, protease inhibitors are crucial in HIV-1
treatment and are used in three of the ﬁve recommended initial regimens and many salvage
regimens[253]. Clinical trials have shown that for many drug combinations involving
protease inhibitors, treatment failure occurs without resistance mutations in the viral gene
encoding protease[19, 137, 278, 343], though mutations conferring resistance to other drugs
in the regimen are often found. It is generally believed that combination therapy works
because it is unlikely that multiple mutations conferring resistance to all drugs in the
combination will appear in the same viral genome. Thus, failure without protease inhibitor
resistance is puzzling, because it seems to contradict this fundamental explanation for the
success of HAART. It is commonly believed that protease inhibitors have a higher ‘barrier
to resistance’ than other drugs, meaning that clinically signiﬁcant protease inhibitor
resistance requires the accumulation of multiple mutations in the protease gene[80].
Protease inhibitor resistance also typically occurs at a narrower range of adherence levels
than resistance to other drug classes[121, 177]. Although these concepts are suggestive, no
theory has been developed to explain why patients fail protease inhibitor-based regimens
without protease inhibitor resistance.
43A resistance mutation may exist before treatment in the latent or active viral
populations or may arise during treatment[239]. Drug resistance develops clinically if the
mutant strain is selected for over the wild-type strain. Selection depends on the ﬁtness
costs and beneﬁts of the mutation, as well as on drug levels, which vary with the dosing
interval, the drug half-life and the patient’s adherence. Here we use a modeling approach
to integrate these factors, enabling us to determine when a resistance mutation will be
selected and to predict the outcome of therapy with diﬀerent drugs. Our results explain
the unique adherence-resistance relationship for protease inhibitors and show why patients
fail protease inhibitor-based therapy without protease inhibitor resistance.
3.3 Results
3.3.1 Defining the mutant selection window
Antiretroviral drugs reduce viral ﬁtness in a dose-dependent manner (Fig. 3.1a). Viral
ﬁtness can be summarized as a single parameter, the basic reproductive ratio   , which
encompasses all phases of the viral life-cycle [247] (Supplementary Methods, §4.1). The
Hill dose-response curve describes the relationship between drug concentration and   :
    
   
   
(
 
  50
)  (3.1)
Here   is drug concentration,      is the concentration at which 50% inhibition
occurs, and   is a parameter determining steepness of the curve [66, 319]. The numerator
    is baseline ﬁtness in the absence of treatment.
A drug-resistant mutant is any viral variant that is less inhibited than the wild type for
some drug concentration, described by the altered dose-response curve that determines
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Figure 3.1: Drug concentrations determine the relative ﬁtness of the wild-type virus and a re-
sistant mutant. (a) The ﬁtness of the wild-type virus (  , blue line) decreases with increasing
drug concentration (here shown normalized by wild-type     ), following equation (1). A drug-
resistant strain ( ′
 , red line) is less ﬁt than the wild type at low concentrations but more ﬁt at
higher concentrations, owing to an increased      or a reduced slope. The MSW is the range of
concentrations where a resistant mutant, if present, will grow faster than the wild type and still
has  ′
    1. The WGW is the range of low concentrations where the wild type has      1,
leading to treatment failure without the need for resistance. For drug concentrations in the over-
lapping range of these windows, virologic failure can occur even without resistance but will be
hastened by the appearance of a faster-growing mutant. (b) As drug concentrations decay after
the last dose is taken, the viral ﬁtness passes through four diﬀerent selection ranges. Depending
on the drug, dose level and mutation, not all of these ranges may exist. The time spent in each
selection window is also determined by the drug half-life. WT, wild type.
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Mutations have a ﬁtness cost, meaning that the drug-free ﬁtness of the mutant virus is
reduced by a fraction   (         ). In the presence of the drug, the mutation confers a
beneﬁt, multiplying the      by a factor   (the fold change in     ,      ). Many
mutations also reduce the slope ( ) of the dose-response curve by a fraction       [304].
Virologic failure occurs when treatment fails to prevent the growth of virus to high
levels. A viral strain grows when       . The strain with highest    outcompetes
others[247]. The range of drug concentrations where a resistant mutant can cause virologic
failure is called the mutant selection window (MSW)[96, 97]. Above the MSW, even
replication of the mutant is suppressed ( ′
        ), although toxicity may prevent these
drug concentrations from being achieved clinically. We here deﬁne the wild-type growth
window (WGW), where drug concentrations are so low that wild-type virus is not
adequately suppressed and failure can occur even without resistance (         ).
3.3.2 The MSW explains therapy outcome patterns
To predict how well each drug suppresses growth of resistant and susceptible strains, we
computed the time during a treatment interruption that a patient spends in the MSW and
WGW. During treatment interruption, both    and  ′
  increase. Up to four selection
ranges can be identiﬁed (Fig. 3.1b). Using pharmacokinetic and pharmacodynamic
data[304, 319](Suppl. Table 4.1), we determined the time spent in these ranges for 66
drug-mutation pairs (Fig. 3.2a) on the basis of their speciﬁc dose-response curves (Fig.
3.2b-e). For each pair, we determined how soon after the most recent dose the mutant or
wild-type virus starts to grow. This quantity is shorter than the expected time until
virologic failure, which requires plasma HIV RNA to reach detectable levels and may also
46depend on the time until mutant virus appears. We examined here only single-point
mutations that are fully characterized by their eﬀect on the dose-response curve (Eq. (3.2),
Supplementary Tables 2-3). For this reason, we caution that our results may be
over-optimistic, as virus with multiple resistance mutations often appears during infection.
Use of our results for clinical recommendations is therefore premature. Below, we discuss
extending the model to multiple mutations.
Successful treatment must both minimize the time spent in the MSW and delay entry
into the WGW. These two goals are in tension, as shortening the time spent in the MSW
(for example, by decreasing drug half-life) can also hasten entry into the WGW (Fig.
3.1b). Results from our model (Fig. 3.2a) suggest that non-nucleoside reverse-transcriptase
inhibitors (NNRTIs) are protected against failure via wild-type virus due to their long
half-lives but are vulnerable to mutation due to the time spent in the MSW. Protease
inhibitors are at the opposite end of the spectrum, with little time spent in the MSW but
rapid entry into the WGW. This behavior is caused by high slope parameters (extreme
sensitivity to changes in concentration) and short half-lives. These results explain the
unique trade-oﬀ presented by protease inhibitor therapy: greater protection against the
evolution of resistance but vulnerability to wild-type-based virologic failure after short
treatment interruptions. This feature is depicted schematically by plotting the drugs along
a single axis, which measures the relative risk of mutant growth versus wild-type growth,
independent of the overall risk of virologic failure (Fig. 3.2f and Suppl. Methods 4.1).
3.3.3 Simulation of clinical outcomes
Whereas the MSW and WGW concepts describe instantaneous growth of mutant and
wild-type virus for a given drug concentration, virologic failure depends on sustained
growth and, therefore, drug concentrations over time. To explain clinical observations
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Figure 3.2: Selection windows can be calculated for particular drug-mutation pairs. (a) The
distance to the right along each horizontal bar is the time since the last dose, and the color cor-
responds to the selection window during that time interval (described in Fig. 3.1b). (b-e) Exam-
ples of dose-response curves (showing drug concentration normalized by wild-type     ) for drug-
mutation combinations indicated in a. Shading indicates the MSW. If the cost of a mutation is
too high or its beneﬁt (  or  ) too low, it is possible that the MSW does not exist. (f) Rank of
each drug for relative risk of wild-type versus mutant virus growth, independent of the overall
risk of therapy failure. For each drug, we show a ‘synthetic’, worst-case, single-nucleotide muta-
tion (Suppl. Methods,§4.1, and Suppl. Fig. 4.12). PI, protease inhibitors; FI, fusion inhibitors;
II, integrase inhibitors; ABC, abacavir; FTC, emtricitabine; ATV, atazanavir; TPV, tipranavir;
EVG, elvitegravir; ENF, enfuvirtide. Protease inhibitors are often boosted (co-formulated) with
ritonovir (/r), which interferes with breakdown in the liver and increases half-life.
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Figure 3.3: Schematic of algorithm for simulating viral dynamics in a patient undergoing treat-
ment. (a) A single simulated patient takes a particular drug (or drug combination) with a des-
ignated adherence level, starting with an initial viral load (VL). Over a 48-week clinical trial,
drug levels ﬂuctuate and viral load levels are simulated according to a viral dynamics model.
(b) Drug levels ﬂuctuate according to patient￿s dosing pattern and pharmacokinetics (dose size,
half-life, bioavailability); gaps show missed doses (ﬁgure shows single drug). (c) Wild-type viral
ﬁtness (  ) ﬂuctuates in response to drug concentration depending on the dose-response curve.
(d) Fitness of drug-resistant strain ( ′
 ) depends on an altered dose-response curve; at high drug
concentrations, mutant ﬁtness exceeds that of the wild type. (e) Wild-type viral load depends on
viral dynamics equations, which account for active replication, exit from the latent reservoir and
competition between strains. (f) A mutant virus may appear (red star) but be below the thresh-
old for detection (dotted red line) before eventually leading to virologic failure.
across drug classes and adherence levels, we developed a stochastic model of viral evolution
(Fig. 3.3 and Methods). Our model builds on the large body of previous work modeling
HIV therapy [247, 294, 334, 358, 379] by integrating new data on class-speciﬁc drug
properties[319] and realistic costs and beneﬁts of mutations[304]. We also modiﬁed past
approaches by allowing drug concentrations, and hence   , to ﬂuctuate, rather than taking
time-averages.
We ﬁrst simulated 48-week trials of single agents in a cohort of patients. The results
are presented in two ways: as outcome versus patient adherence at the trial endpoint (Fig.
3.4a) and as outcome versus time for a distribution of patient adherence levels (Fig. 3.4b,c).
Consistent with a previous meta-analysis of combination therapy clinical trials[23], our
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Figure 3.4: Outcomes for simulated patients in a clinical trial. (a-c) The height of the area
shaded indicates probability of the corresponding outcome at a given adherence level (a) or time
point (b,c). (a) Adherence is deﬁned as the fraction of scheduled doses taken. These are mainte-
nance trials (see Methods). (b,c) Measurements are taken every 2 weeks for simulated patients
with a distribution of adherence levels (Suppl. Methods 4.1 and Suppl. Fig. 4.13b). (b) Suppres-
sion trials (see Methods). (c) Maintenance trials. (1) 3TC therapy (pattern includes AZT, ABC,
d4T, ENF, EVG, FTC, NVP, RAL, TDF). (2) EFV and ETV therapy. (3) NFV therapy (pat-
tern includes ddI). (4) DRV/r and ATV/r therapy (pattern includes ATV, TPV/r; variation on
this pattern described in the Results includes LPV/r, SQV, SQV/r IDV, IDV/r).
50model predicts that the level of adherence necessary for mutant virologic failure diﬀers by
drug class (Fig. 3.5). Speciﬁcally, for the NNRTIs efavirenz (EFV) and etravirine (ETV),
the risk of mutant virologic failure is greatest at low adherence levels; for unboosted
protease inhibitors, the risk peaks at a higher adherence level and remains substantial up
to 100% adherence; for boosted protease inhibitors (paired with ritonavir to increase
half-life), resistance occurs infrequently and at intermediate adherence levels. Researchers
have previously argued that drug half-life and ﬁtness costs of mutations are key factors
explaining these general trends[121, 177]. By incorporating these factors as parameters, our
model formalizes this argument.
In examining simulations of each drug individually (Suppl. Figs. 4.1-4.6), we found
four qualitative patterns of outcome, which correspond closely-but not exactly-to drug
class (Fig. 3.4).
For most nucleoside reverse-transcriptase inhibitors (NRTIs), the integrase inhibitors,
the fusion inhibitor, and the NNRTI nevirapine (NVP), even perfect adherence led to
mutant virologic failure in all simulated patients. As adherence declined, some wild-type
virologic failure occurred. Virologic failure and resistance occurred soon after the trials
started. These results are consistent with the notion that monotherapy often leads to rapid
evolution of resistance.
For most protease inhibitors and the NNRTIs EFV and ETV, however, perfect
adherence resulted in treatment success in simulations. Control of viral replication has
been observed in a substantial fraction of patients in protease inhibitor monotherapy
trials[270], but similar trials with EFV and ETV have not been carried out. In simulations,
declining adherence aﬀected performance of these two drug classes diﬀerently.
For the NNRTIs EFV and ETV, there was a large range of low-to-intermediate
adherence for which mutant virologic failure was likely. Below this range, wild-type
virologic failure became increasingly likely, whereas above this range the simulated patients
succeeded. The size of this range is explained by the low ﬁtness costs of drug-resistant
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Figure 3.5: Our calculated adherence-resistance relations are in agreement with those observed
in clinical trials. (a) Adherence versus simulated probability of resistance in a 48-week sup-
pression trial for a protease inhibitor, a boosted protease inhibitor and an NNRTI. The inset
shows a qualitative summary of results from a meta-analysis of clinical trials[23], which agrees
with our simulations. (b) Adherence versus fraction of time spent in the MSW for the same
drugs. Adherence-resistance trends demonstrate that time in MSW is a good proxy for the risk
of mutant-based virologic failure. For both plots, curves were generated by averaging over all
boosted protease inhibitors, all unboosted protease inhibitors, and the NNRTIs EFV and ETV.
Protease inhibitor curves in a were ﬁtted to skewed-T distributions to smooth step-like behavior.
NVP, which was excluded from this ﬁgure, shows a diﬀerent pattern from the other two NNR-
TIs; speciﬁcally, mutant virologic failure can occur even for perfect adherence (Suppl. Figs. 4.1
and 4.2).
mutations and long half-lives of NNRTIs, which allowed the patient to remain within the
MSW for a substantial duration (suggested in [25]).
The protease inhibitor nelﬁnavir (NFV) and the NRTI didanosine (ddI) showed a large
range of intermediate adherence leading to mutant virologic failure. Near-perfect adherence
was required for treatment success. Under most clinical settings (adherence < 95%), our
model predicts that these drugs perform similarly to monotherapy with other NRTIs,
typically leading to mutant virologic failure.
For many protease inhibitors, a decline from perfect adherence led abruptly from
success to wild-type virologic failure, with little or no intermediate range for mutant
virologic failure. This result explains the outcomes of clinical studies, which have shown
that virologic failure in many boosted protease inhibitor-based regimens (including
52monotherapy) does not require the evolution of resistance[19, 137, 343]. Variations on this
pattern exist for some protease inhibitors: simulations of lopinavir (LPV/r), saquinavir
(SQV, SQV/r), and indinavir (IDV, IDV/r) showed mutant virologic failure at low and
moderate adherence levels, mainly for trials where initial viral load was high. Still, like all
the protease inhibitors simulated except NFV, as adherence declined from the successful
range, the ﬁrst failing outcome observed was wild-type virologic failure (Suppl. Figs. 4.1
and 4.2).
We also examined the sensitivity of our results to changes in the baseline viral ﬁtness,
    (Suppl. Figs. 4.8 and 4.9). As the intracellular half-lives of several NRTIs are not
deﬁnitively established, we tested a range of half-lives for lamivudine (3TC),
azidothymidine (AZT), stavudine (d4T), ddI and tenofovir disoproxil fumarate (TDF)
(Supplementary Fig. 10). Against a strain with higher    , higher adherence levels were
required for treatment success, and there was a wider range of adherence levels for which
mutant virologic failure occurred. The eﬀect of increasing half-life was drug-dependent, but
for most NRTIs simulated, it increased the likelihood of mutant virologic failure.
3.3.4 Explaining outcomes of combination therapy
Equipped with a model of drug interaction, we were able to extend the simulations to
combination therapy (Suppl. Methods,§4.1 and Suppl. Fig. 4.11). For proof of concept, we
use a two-drug combination of the boosted protease inhibitor darunavir (DRV/r) with the
integrase inhibitor raltegravir (RAL). The combined eﬀect of these two drugs is given by a
Bliss-independent[41] interaction pattern[159], which describes drugs acting on diﬀerent
targets, therefore reducing viral replication multiplicatively. In a recent DRV/r-RAL
clinical trial[343], patients experiencing virologic failure had their plasma viral population
genotyped. Although 17% of patients tested positive for RAL-resistance mutations in the
gene encoding integrase, no patients tested positive for DRV resistance in the gene
encoding protease[343]. Our simulation is consistent with this study: treatment failure
53occurred without DRV resistance (Fig. 3.6a).
RAL-resistant mutants were selected for only when the concentration of DRV/r was
low and the concentration of RAL was moderate to high (Suppl. Fig. 4.11). This state of
￿eﬀective monotherapy￿ ([25]) can occur if the drugs are administered as separate pills. If,
however, dual therapy were administered as a combination pill, then the two
concentrations would rise and fall roughly together, reducing the chance that they reach
the discordant levels that select for resistance. Simulation of dual therapy as a single
combination pill veriﬁed this hypothesis. However, this protection from resistance came at
a cost: higher adherence was required to prevent wild-type virologic failure. For example,
to ensure a 95% chance of success in the simulation, a patient taking separate pills must be
25% adherent to each pill (Fig. 3.6b), but 35% adherent to a combination pill (Fig. 3.6c).
We expect this trend to apply to other drug combinations.
3.4 Discussion
Recent eﬀorts to quantify pharmacodynamics [304, 319, 321], combined with insights into
patients￿ drug-taking behavior[24], have enabled us to develop what is to our knowledge the
ﬁrst explanatory model of virologic failure in agreement with clinical trials. All parameters
in our model have direct physical interpretations, and their values were taken directly, or
derived from, previous literature. The model was not ﬁt or trained to match clinical data.
Despite our model￿s simplicity, it can explain the clinically observed drug-class-speciﬁc
relationship between adherence and outcome[23] (Fig. 3.5). Even without full viral
dynamic simulations, a straightforward analysis of the mutant selection window can
explain why certain drugs are more likely to select for resistance (Figs. 3.2f and 3.5b).
In addition, we address a long-standing mystery of antiretroviral therapy. Even when
failure of protease inhibitor-based regimens is documented, mutations that confer
resistance to the protease inhibitor appear infrequently[19, 137, 278, 343]. Although it is
possible that mutations may occur outside the protease-encoding gene[87, 130, 238, 265]
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Figure 3.6: Outcomes of DRV/r plus RAL dual suppression therapy simulations, considering re-
sistant mutants for both drugs. (a) Each drug is taken independently, and adherence may diﬀer
between them. The brightness of each color at a particular point indicates the probability of the
corresponding outcome, with the black contours showing where each outcome occurs 95% of the
time. Success depends largely on adherence to DRV/r (success is almost certain if adherence is
 50%), whereas the type of failure is determined by adherence to RAL (resistance is almost cer-
tain if adherence is  30%). All failure via resistance is due to RAL mutant-based virologic fail-
ure. DRV mutant-based virologic failure (virologic failure) never occurs in the simulations. (b,c)
Drugs are taken with equal average adherence. The height of the area shaded indicates probabil-
ity of the corresponding outcome at that adherence level. (b) Drugs are taken as separate pills.
Average adherence is the same, but pills are taken independently. (c) Drugs are packaged as a
combination pill and are always taken together. Mutant virologic failure occurs only when the
two drugs are given in separate pills; combination pills eliminate mutant virologic failure but in-
crease the adherence required for near-certain success.
55and escape routine detection, our model provides a more straightforward explanation: due
to the sharp slope of protease inhibitor dose-response curves[319], even relatively strong
protease inhibitor resistance mutations are selected only in a narrow range of drug
concentrations. Moreover, as protease inhibitor concentrations decay rapidly compared to
other drugs, they traverse this narrow range quickly, leaving little time for a resistant
strain to grow before wild-type-based virologic failure. We predict that patients who fail
protease inhibitor therapy with wild-type virus should be able to re-suppress the virus if
the same drug is taken with improved adherence. A previous study[177] observed this
outcome in patients who failed LPV/r without detectable resistance. Even with protease
inhibitors that are more susceptible to resistance, only wild-type virus is detectable when
adherence dips below the level guaranteeing success, providing an antiresistance ‘buﬀer’
that may warn clinicians of resistance risk. NFV is the sole exception to this pattern,
owing to its having the lowest slope and second-highest      of the protease inhibitors and
consistent with its documented vulnerability to resistance[177].
The tradeoﬀ between protection from resistant and susceptible strains occurs not only
between drug classes but also between diﬀerent formulations of the same drugs. We predict
that a new combination pill containing DRV/r and RAL would not lead to resistance, even
though the current separate-pill formulation does. This result suggests that some
combination pills may be ‘resistance proof’, but their known beneﬁt of increasing patient
adherence must be weighed against the fact that they require higher adherence to prevent
wild-type-based virologic failure. This tradeoﬀ results from the possibility that a patient
who is prescribed multiple pills may at times take only some of them[120], providing
partial protection from the virus but allowing entry into a ‘zone of monotherapy’[25] that
can select for resistance.
We can extend our model to a broader range of combination therapies once interactions
between drugs[159] are characterized; these interactions aﬀect the evolution of
resistance[223]. Our monotherapy results are a ﬁrst step for examining how
56pharmacokinetics and pharmacodynamics determine treatment outcomes. These results
can inform innovations in lower-cost maintenance therapy among highly adherent patients,
for whom monotherapy shows promise but also poses resistance risks[270]. Speciﬁcally, on
the basis of our simulations, we propose that EFV and ETV monotherapy may be
promising avenues for further study, despite the disheartening performance of monotherapy
with the ﬁrst approved NNRTI, NVP[64], and the ambiguous performance of ETV-based
HAART for patients with resistance to the NRTI backbone[300].
Simulations that start with a high viral load (suppression phase) and simulations that
start with an undetectable viral load (maintenance phase) generally showed similar
outcomes; however, for several drugs, failure with resistance was more likely during the
suppression phase. Such diﬀerences are often attributed to the presence of preexisting
mutants when viral load is high[47, 165, 262, 330]. However, in our model, frequent
reactivation from the latent reservoir provides a suﬃcient source of mutants during both
phases (Suppl. Tables 4.4 and 4.5), and ongoing replication is an additional common cause
of resistance (Suppl. Figs. 4.6 and 4.7). The key diﬀerence between the two phases is in
how virologic failure is deﬁned. As patients remained in suppression simulations until the
predeﬁned endpoint, wild-type growth sometimes preceded (and contributed to) growth of
the mutant. More frequent measurement of viral load in maintenance simulations improved
the chance that virologic failure was diagnosed before resistance reached detectable levels,
consistent with clinical meta-analysis[129]. Also consistent with clinical observations[148],
continuation of maintenance trials after rebound allowed the possibility of re-suppression,
but it sometimes led to emergence of resistance (Suppl. Fig. 4.5).
It is diﬃcult to quantitatively compare our simulations to clinical trials, as adherence is
rarely precisely known. We suspect that our results are biased toward success for several
reasons. First, we considered only single-point mutations, but strains with multiple
mutations may lead to failure at higher adherence levels. Second, we considered neither
correlations between consecutive missed doses nor variations in the time of day when a
57dose is taken, both factors that lead to longer treatment interruptions and increase the
chance of virologic failure [170, 207, 263, 264, 358]. Third, as is common in models of viral
dynamics, we assumed that the virus population is homogeneous and well mixed. Actual
infections may include subpopulations that grow faster (higher   , for example, owing to
cell-to-cell transmission[324]) or that reside in tissues that drugs do not fully
penetrate[178, 308, 356]. For example, the concentration of EFV in the cerebrospinal ﬂuid
is only 0.5% of plasma concentrations[36]. As our predictions rely on plasma drug
concentrations, they may be optimistic in the case of EFV (see [144] for further discussion).
In the absence of strong evidence for these eﬀects, suboptimal adherence is the most likely
cause of treatment failure. Given the above limitations, our modeling results should not be
taken as clinical recommendations at this stage.
Patients experiencing virologic failure may not respond to a similar regimen in the
future[145, 204, 263], but the precise reasons for this are not clear. The simplest
explanation is that growth of a resistant strain during prior treatment makes it more likely
this strain will exist in the future[46]. This explanation assumes that, in the absence of
prior growth, most resistant mutants are relatively rare. If the diversity (eﬀective
population size) of the latent reservoir is not severely depleted over time, then our
calculations contradict this assumption for single mutations: even in the absence of prior
treatment, a majority of mutations exit the reservoir every few weeks. Resistance is then
available to be selected regardless of prior growth. The occurrence of multiple mutations
within the same viral genome is unlikely, however, without prior growth. To explain
generally how prior virologic failure undermines future treatment, we need to model the
long-term accumulation of multistep mutations in the viral population[249, 317]. To build
such models, it will be important to understand interactions between mutations (including
compensatory mutations[144]) and account for recombination[235].
We have emphasized here the variable nature of anti-HIV drug resistance. Common
practice classiﬁes a genotype as resistant if it is associated with virologic failure in a
58meta-analysis of clinical outcomes; otherwise it is sensitive. This categorization is
misleading: a mutation’s ability to promote viral growth depends on all of the drugs in a
regimen, adherence and the other mutations present. As standards of care evolve and
study populations change, a mutation may gain or lose resistant status as a result of shifts
in these confounding variables. Our model provides a rigorous alternative for evaluating
resistance, by using mechanistic parameters to predict clinical outcomes. Our framework
can help researchers prioritize drugs for clinical trials and select regimens for personalized
HIV treatment.
3.5 Methods
3.5.1 Pharmacokinetics, pharmacodynamics and the mutant selection win-
dow
Viral ﬁtness followed equation (3.1) with parameters    ,      and  . Fitness of resistant
mutants followed equation (3.2) with parameters  ,   and  . (Suppl. Tables 4.1-4.3).
Relative wild-type and mutant viral ﬁtness values           and  ′
         were
measured using in vitro assays and were ﬁt to Hill curves to determine the parameters
    ,  ,  ,   and  ; these values were reported previously[304, 319]. We estimated absolute
in vivo viral ﬁtness in the absence of drugs (   ) using measurements from previous studies
(Suppl. Methods, §4.1). We modeled drug concentration as instantaneously increasing
after a dose to the steady-state peak concentration (    ) and then decaying exponentially
(with half-life     ) to the trough concentration (    ) before the subsequent dose. When
doses were missed (representing suboptimal adherence), the concentration continued to
decay, and a subsequent dose increased the concentration by ∆               .
We determined the bounds of the MSW by solving for   in          ′
     and
 ′
        . We determined the upper bound of the WGW by solving       = 1. We
computed the time after a single dose when a particular concentration   was reached by
59solving for   in              1 2.
The MSW concept as applied here to antiretroviral therapy was adapted from the
extensive literature on antibiotic resistance. Both in vitro and in vivo, drug concentrations
that ﬂuctuate within the MSW lead to the development of resistance, but those outside it
do not (reviewed in [97]). Although some studies of antibiotic-resistant Escherichia coli
have found no upper limit to the MSW[383], no such results are known for antiretroviral
resistance. The deﬁnition of the MSW most commonly used in antibiotic work is slightly
diﬀerent from the one we use, with the lower limit deﬁned as           because of
experimental constraints[96]. We have chosen to modify this deﬁnition, as selection for the
mutant can occur even at lower drug concentrations where           [128]. The MSW and
WGW can be described for each drug during combination therapy (Suppl. Methods, §4.1).
3.5.2 Simulation of the viral dynamics model.
Our model for HIV dynamics during antiretroviral drug treatment uses equations common
in the literature[247]. These equations track the number of uninfected CD4 cells, amount
of free virus and number of infected CD4 cells. A constant number of uninfected cells are
produced each day, and they die at a constant rate. Cells are infected at a rate
proportional to the number of uninfected cells, the amount of virus, and the viral ﬁtness.
Virion production from infected cells is described by the burst rate, and virions are cleared
at a constant rate. Infected cells have a higher death rate than uninfected cells.
Additionally, we include a population of long-lived infected cells in the latent reservoir,
which activate at a constant daily rate regardless of viral ﬁtness. Because we are interested
only in viral dynamics during treatment and at the initial stages of failure, we have ignored
the eﬀects of the immune response. Viral ﬁtness, and hence the rate of infection of new
CD4 cells, is determined by the baseline    and the drug concentration. All equations and
parameters are given in the Supplementary Methods (§4.1) and Supplementary Table 4.6.
In the Supplementary Methods, we also derive a simpliﬁed form of HIV dynamics that
60requires fewer parameters and only one state variable per viral strain; we used this
simpliﬁed model to design our simulations. More detailed models that explicitly track
multiple stages of the viral life cycle may more accurately reﬂect some short-term
dynamics, such as lags in viral growth during acute infection or lags in viral decay during
the early days of treatment[289, 312]. Summarizing viral ﬁtness by a single parameter (  )
smoothes out these dynamics.
There may be multiple strains of virus (wild-type and mutants) and consequently
multiple types of infected cells. Even in the absence of drug, mutations will arise due to
random errors in replication, though they will be selected against due to their ﬁtness cost
( ). Each mutation appears at a rate   that depends on the particular nucleotide changes
required to eﬀect the desired amino acid substitution (Supplementary Tables 4.2, 4.3, 4.7).
The balance between these two processes results in all mutations being present in the
population at an expected low level    , called mutation-selection equilibrium[247, 288].
We assume that the plasma virus population reaches this equilibrium in each patient before
treatment (that is, that suﬃcient time has passed between initial infection and treatment
initiation and that no prior treatment has selected for resistance to the particular drug
being studied) and that the population in the latent reservoir is representative of the
plasma population (Supplementary Tables 4.4 and 4.5). De novo mutations occur with a
probability   during replication.
We used stochastic simulations to study the dynamics of the system described. Many
mutations have been characterized for each drug, and to model a realistic worst-case
scenario we considered a single synthetic mutant deﬁned as having the highest beneﬁts ( ,
negative  ), lowest cost ( ), highest mutation rate and highest equilibrium frequency (due
to mutation-selection balance) of all the single-nucleotide mutants known for that drug.
Each monotherapy simulation therefore tracked only two strains, wild-type and mutant.
For dual therapy, we considered three strains: wild-type, resistant to drug 1, and resistant
to drug 2. Simulations modeled 48-week trials, using discrete time-steps of ∆  = 30 min.
61All simulations were done in Matlab R2010b. The full details of the algorithm for
simulating a single patient are given in the Supplementary Methods(§4.1).
In maintenance trials, patients began with full viral suppression (2 RNA copies per ml,
c ml  ) and underwent monotherapy for 48 weeks or until virologic failure, whichever
occurs ﬁrst. Virologic failure is deﬁned as ‘conﬁrmed rebound’: two consecutive weekly
measurements (starting at week 5) with viral load above 200 c ml  . In suppression trials,
patients began with a realistic distribution of treatment-naive viral loads (between 3,000
and     c ml  ) (Supplementary Fig. 4.13a) and underwent monotherapy for a full 48
weeks. We tracked measurements every 2 weeks. Virologic failure is deﬁned as a viral load
above 50 c ml  at week 48. In both types of trials, virologic failure is classiﬁed as ￿with
resistance￿ if at least 20% of the viral population at the time of detection is mutant.
We simulated imperfect adherence by allowing each dose to be missed with a constant
probability given by the expected adherence level parameter. In reporting outcomes versus
time, we simulated patients with a distribution of adherence levels taken from a study
using unannounced pill counts[24]. For simulations with two drugs, the value of adherence
may be diﬀerent for each drug, allowing for ￿diﬀerential adherence, which has been
observed in many studies[120]. Even when adherence to the two drugs has the same
average value, the drugs can be simulated as two separate pills (allowing each pill to be
taken or forgotten independently) or as a single combination pill (causing the two drug
concentrations to rise and fall in lockstep).
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Supplementary Information: Antiretroviral
dynamics determines HIV evolution and
predicts therapy outcome
4.1 Supplementary Methods
4.1.1 Viral dynamics model
The following system of equations models the dynamics of multiple strains                
of HIV in a patient:
         
  ∑
   
           
                        
                  
(4.1)
where state variables  ,   , and    are the number of infectable CD4 T-cells, the
64number of actively infected cells of strain  , and the number of free virus particles of strain
 , respectively. The number of latently infected cells is considered to be constant, as it
doesn’t decay signiﬁcantly over the course of a clinical trial, and so latently infected cells of
strain   activate at a constant rate   . Active cells produce virus at rate    and die at rate
  , and virus is cleared at rate   . The infectivity parameter    determines the rate at
which virus of strain   infects susceptible host cells. Host cell dynamics are determined by
production rate   and death rate   .
When        for a strain  , this model reduces to the traditional viral dynamics
model[247]. For that model we can describe the basic reproductive ratio, which is deﬁned as
the number of new infections generated by a lone infected cell before it dies. Strain   will
only have a positive growth rate and be capable of sustaining an infection if its basic
reproductive ratio,                      , is greater than 1. In the model we present here
the latent reservoir provides a constant source of virus (  ), which removes the threshold
criteria for   , although this value still describes viral ﬁtness and the amount of ongoing
viral replication.
For a single strain, the unique non-negative steady-state solution to our model is
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  (4.2)
In our model, for        , strain   grows to a high steady state that depends on
availability of host cells and the abundance of other strains. There are several limiting
cases that can be derived from equation (4.2). In the absence of other strains (or if
    ≪   for all   ̸   ), and for small reactivation    ≪  , strain   grows to the steady state
                               . The value      is the setpoint viral load that is maintained
by replication alone, without additional contribution from the latent reservoir. The
residual active infection maintained by the latent reservoir in complete absence of viral
65replication (       ) is               . For positive        , strain   reaches a low steady
state                             . Since anti-HIV drugs act by decreasing    and   , the value
of     is understood to depend on the current drug concentration(s).
To eliminate some of the model parameters and smooth the high-frequency ﬂuctuations
that may have little clinical impact over the course of a drug trial, we study a simpliﬁed
version of the model in equation (4.1). We assume that    and   are at equilibrium relative
to   . This allows us to derive a reduced  -dimensional model:
                
[
    
   
∑ 
           
   
]
(4.3)
When the total infection is small, the summation term vanishes, and
                          . For     ≪  , nearly all of strain   is produced by exit from the
reservoir;    therefore approaches a value near      . As the total infection grows (assuming
        for one or more  ), the fractional term approaches  , describing saturation of the
limiting resource, at which point new infection events are balanced precisely by death of
infected cells and    approaches a value near     . This reduced model has identical steady
state values of virus and CD4 cells as the full model, but smooths out ﬂuctuations in
infection size caused by the dynamics of total CD4 cells. Because we focus on initial
virologic failure, which occurs at relatively low viral loads, the ﬂuctuations in CD4 cell
levels are minor, and the approximation captures the full dynamics (equation (4.1)) well.
We can account for mutation by including the mutation rate matrix  , where    
describes the probability that an infected cell of type   gives rise to one of type  :
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∑ 
           
       (4.4)
664.1.2 Model parameters
The value of     at each point in time depends on the baseline basic reproductive ratio
(        , see below), the current drug concentration(s), and parameters describing
resistance of the strain, as described by equations 1 and 2 in the main text. The death rate
of actively infected cells,   , is 1 per day [214]. Supplementary Table 4.6 summarizes the
parameters used in the model.
4.1.2.1 Basic reproductive ratio
The basic reproductive ratio (  ) combines various components of viral ﬁtness into a single
number.        is required for the virus to have a positive growth rate and sustain an
infection. The baseline   , which we denote    , is deﬁned in the absence of drug and has
been estimated in past studies by measuring the increase in viral load during the early days
of acute infection or during planned treatment interruption. During the acute phase, before
the CTL response develops, typical values for     are 10-20[205, 289]. After this initial
phase,     declines to 2-5, with some outliers as high as 6-11 [89, 116, 154, 190, 279]. Based
on these ﬁndings, we chose a value of    =10 to present our results. We also checked
sensitivity to this parameter by using larger and smaller     values (Figures 4.8 -4.9).
We can also double-check that our value of     from the literature is consistent with an
independent set of measurements. The growth rate of a mutant strain in the absence of
drug is               (see equation 1 in the main text), where   is the reduction in the
replication capacity of the mutant virus. If                  , then a mutant strain will
expand in the absence of drug. If this condition fails, then the mutant strain would never
be detected at high abundance (ignoring secondary or compensatory mutations). Since all
the resistance mutations that we study do occur clinically, we expect that                
should almost always hold. 95% of the mutations studied have        , for which the
positive growth condition is satisﬁed for the value         .
To maintain consistency with the chosen value         , we capped the cost of
67mutations used in the viral dynamics simulation at        , guaranteeing that no mutant’s
baseline    would be less than 1. Values of   that are negative are also inappropriate for
our model, as they imply that the resistant mutant is more ﬁt than the wild type even in
the absence of the drug, causing the mutant to be prevalent at baseline. Measurements of  
that were close to 0 or negative were assumed to be caused by experimental error, and so
we set these values to          to represent a small cost to these mutations.
4.1.2.2 Latent reservoir exit rate
Based on the following argument, we estimate the total reservoir exit rate
∑
     to be 3000
cells per day. The exit rate for a particular mutant strain is determined by multiplying by
the equilibrium frequency of pre-existing mutants,    . (Our simulation treats each exit as
an independent event; use of this modeling approach implicitly assumes that the reservoir
was seeded by a large, diverse population, and that its diversity, or eﬀective population
size, is maintained over time.) Viral loads of around 2 RNA copies per mL are maintained
in patients on maximally suppressive HAART [93]. The rate of exit from the reservoir
must be enough to account for this residual viral load, since ongoing replication is
negligible. This viral load corresponds to           plasma virions (for a 70 kg person with
3L plasma). It has been shown, for a wide range of viral loads, that the total number of
infected cells in a patient is roughly equal to the number of plasma virions [147]. The
infection size
∑
      
∑
       is therefore        , implying a total reservoir exit rate of
3000 cells per day.
Alternately, we can estimate the number of infected cells by noting that total viral
production (burst from infected cells) must balance total viral clearance (breakdown of free
virus in lymphatic tissue). Using parameters previously established[91], free virus in lymph
tissues is 100 times as abundant as virus in the extracellular ﬂuid, and so would be about
          virions (based on 15L ECF) for this example. This paper also determined that
the ratio of viral burst size to viral clearance rate is typically 500 virions per cell (e.g.,     
6810,000 virions per day per cell;      20 per day). These ﬁgures again imply an infection
size of 3000 cells.
Our calculations also agree with the results of a model which examined the many
years-long decay of the latent reservoir in HAART patients [311]. Although this model
used diﬀerent sources for parameter values, it is consistent with an exit rate of 3000 cells
per day, as long as the reservoir is not signiﬁcantly depleted.
4.1.2.3 Host cell production rate
For a single wild-type strain in the absence of drug, the model (equation (4.3)) provides
                       , where     is the total number of infected cells at infection setpoint.
As established above, this value is approximately equal to the number of plasma virions at
setpoint. We considered setpoint viral loads from      to     RNA copies per ml plasma,
or           to           total plasma virions. These values give a range of         to
          cells per day for  .
4.1.2.4 Resistance mutation rates
The mutation rate matrix entry     describes the probability that strain   reproduces to
create strain  . We include only single step mutations from the wild type (     ) to
another strain   (at rate   ) and ignore back-mutation. Therefore          for      ,
          
∑ 
      ,         for       and         for all other entries.
The overall mutation rate for HIV is          per base per replication cycle [212], and
recent work has shown that the rate varies considerably depending on the speciﬁc base
changes involved. The nucleotide mutation matrix used in this study was derived by
normalizing mutation accumulation data from a study of HIV replication of lacZ  reporter
sequence [3]. The normalized data was then rescaled to convert from the lacZ  base
composition to the HIV consensus sequence base composition [191]. Speciﬁcally:
1. Deﬁne the variables:
69•              is the average per-site mutation rate of HIV.
•     is the total number of single-nucleotide substitutions from base   to base  ,
combining data from both the forward and reverse orientations of lacZ  in Table
3A of Abram et al. [3].
•     is the total number of single-nucleotide substitutions from base   to any
other base.
•   is the total number of single-nucleotide substitutions overall.
•    and  ′
  are the abundance of base   in the reporter sequence and in the HIV
consensus sequence, respectively.   and  ′ are the lengths of the two sequences,
respectively.
–        ,        ,        ,        ;        
–  ′
        ,  ′
        ,  ′
        ,  ′
        ;  ′       
2. Calculate the relative mutability of each base   in the reporter sequence,
                   . A value        indicates that base   is more mutable than the
average, while        indicates the opposite.
3. The per-site mutation rates from all bases  , denoted    , are assumed to be
proportional to the relative mutabilities   . To compute the values    , scale the
relative mutabilities so that the sum  ′
       ′
       ′
       ′
     equals  ′ , the
genomic mutation rate of HIV (about 0.3 substitutions per replication). The correct
scaling factor is           ′   
∑
   ′
  .
4. To determine the individual rates    , partition each value     proportional to the
substitutions counted in the reported sequence; that is,                    .
Supplementary Table 4.7 gives the resulting per-site probability (   ) for each
nucleotide substitution in a single round of viral replication.
70Mutation rates were calculated only for those amino acid substitutions which could be
achieved via a single nucleotide change. All drugs studied had at least one such
substitution that conferred resistance. For each possible starting codon, the rate of
substitution equals the sum of all rates of nucleotide substitutions that achieve the desired
amino acid change. The mutation rate   then equals the average of rates for all possible
starting codons, weighted by the probability of ﬁnding that codon (based on the HIV
consensus sequence base composition) (used in Supplementary Tables 4.4, 4.5).
4.1.3 Simulation algorithm
We used stochastic simulations to study the dynamics of the system described in equation
(4.3) with mutation. Multiple mutations have been characterized for each drug, and to
model a realistic worst-case scenario, we considered a single “synthetic” mutant deﬁned as
having the highest beneﬁts ( , negative  ), lowest cost ( ), and highest mutation rate of all
the single-nucleotide mutants known for that drug. Each monotherapy simulation therefore
tracked only two strains, wild type    and mutant   . Simulations modeled 48-week trials,
using discrete timesteps of ∆       minutes. All simulations were done in Matlab R2010b.
The following steps describe the simulation for a single patient on monotherapy, with
expected adherence value  :
1. Draw from the viral load setpoint distribution in Figure 4.13a. This setpoint is used
to determine the value of the   parameter, assuming that the patient has 3 L plasma.
• In the suppression phase of therapy, the initial infection size is the setpoint,
rounded to the nearest integer number of cells.
• In the maintenance phase of therapy, the initial infection size is the
fully-suppressed infection size
∑
      
∑
           c.ml  (RNA copies per
ml).
712. Assign each infected cell to the mutant population (  ) with probability    ;
otherwise the cell is in the wild-type population (  ).
3. Identify all scheduled doses for the entire trial. All scheduled doses are evenly spaced,
with the ﬁrst dose occurring at the beginning of the trial. The patient takes each
scheduled dose with probability  .
• Exception: in the maintenance phase, the patient is always assumed to take the
ﬁrst scheduled dose.
4. Calculate the drug concentration every timestep, as described in §3.5.
• In the suppression phase, the initial drug concentration is zero.
• In the maintenance phase, the initial drug concentration is     .
5. Calculate the basic reproductive ratios for the wild type and the mutant every
timestep, as described in equations 1 and 2 of the main text and the §3.5.
6. For each timestep:
(a) The number of infected cells of strain   to exit the reservoir is drawn from a
Poisson distribution with mean value   ∆ .
(b) The number of newly infected cells generated by strain   is drawn from a
Poisson distribution with mean value     ∆ 
[
  0 
  
∑ 
 =1  0     
]
.
(c) Each cell newly infected by the wild type enters the mutant population with
probability  ; otherwise it remains wild type. Cells infected by the mutant do
not back-mutate.
(d) Each infected cell dies with probability            ∆  .
7. Determining outcome at 48 weeks:
72• In the suppression phase, the patient’s status is observed at the end of the
48-week trial. If viral load is below 50 c.ml  , the trial is declared successful;
otherwise virologic failure occurs.
• In the maintenance phase, the patient’s status is observed each week for 48
weeks, beginning at Week 5. If any two consecutive observations show a viral
load of at least 200 c.ml  , virologic failure occurs; otherwise the trial succeeds.
• A failed trial is considered a mutant-based failure if at least 20% of the viral
population is mutant; otherwise it is considered a wild type-based failure.
8. Determining outcome over time:
• Patient’s status was evaluated every 2 weeks, for 48 weeks.
• In the suppression phase, if viral load is below 50 c.ml   at the evaluation, the
patient is classiﬁed as having “suppressed viral load;” otherwise the patient has
“detectable viral load.”
• In the maintenance phase, the patient’s viral load is measured each week for 48
weeks, beginning at Week 5. If any two consecutive measurements at or before
the evaluation show a viral load of at least 200 c.ml  , the patient is declared to
have “detectable viral load,” and is then removed from the trial, retaining this
classiﬁcation for all future time-points. Otherwise, the patient is declared to
have “suppressed viral load.”
• In the maintenance phase allowing recovery, the patient’s viral load is measured
as in the maintenance phase above. If viral load is at least 200 c.ml   both at
the evaluation and at the immediately preceding measurement, the patient is
declared to have “detectable viral load.” Patients who were previously
“detectable” remain in the trial and may re-suppress.
• A measurement of “detectable viral load” is considered “via resistance” if at
73least 20% of the viral population is mutant; otherwise it is considered to be “via
wild type.”
By using a well-mixed population and by assuming that the processes of reservoir exit,
replication, and death are Poisson, this method implicitly sets the eﬀective population size
of the infection equal to the census size of infected cells. Population structure, selection on
linked loci, and variations in burst size among infected cells are all mechanisms that could
increase variance in viral oﬀspring number, decreasing the eﬀective population size [4, 113].
Estimating the relevant population size to use for a model of drug resistance is diﬃcult, as
most approaches deﬁne an eﬀective population size only for neutral loci. Simply “plugging
in” a population size derived from a model without selection would be misleading in this
context [187], and in lieu of a more informed value, we simply use the census size. This
approach likely overestimates probabilities of mutant emergence and underestimates
variability among patients [144, 267].
For dual therapy, we consider three strains: wild type, resistant to Drug 1, resistant to
Drug 2. The two drugs can be simulated as two separate pills (allowing each pill to be
taken or forgotten independently) or as a single combination pill (forcing the two drug
concentrations to rise and fall in lockstep). In the case of two separate pills, the value of  
may be diﬀerent for each drug, allowing for “diﬀerential adherence” – which has been
observed in some studies [120].
4.1.4 Graphing outcome versus adherence
For each monotherapy, 25,250 patients were simulated, with expected adherence   ranging
from 0 to 1 (roughly equal numbers of patients were simulated for each 1% increment,
including 50 patients with       and 50 patients with      ). The x-axis measures the ex
post adherence for patients — that is, the actual percentage of doses taken, which may
diﬀer from the expectation  . Results were plotted for overlapping 2% windows, centered
every 1% between 0 and 1, as well as for the points 0 and 1 themselves.
74Analysis of dual therapy with a combination pill was similar to that of monotherapy,
but with 126,250 patients (including 250 patients with       and 250 patients with      ).
For dual therapy with separate pills, 169,000 patients were simulated, with expected
adherences       ranging from 0 to 1 (roughly equal numbers of patients were simulated
for each 4%   4% increment, including 25,000 patients on the border of the distribution
where at least one    is equal to 0 or 1.) As with monotherapy, the axes measure ex post
adherence. Results were plotted for overlapping 4%   4% windows, centered every 2%
between 0 and 1; points plotted on the border of the distribution show patients with at
least one    exactly equal to 0 or 1.
Note that, for maintenance therapy, the axes do not include zero, as each patient is
guaranteed to take the ﬁrst dose (adherence is never zero).
4.1.5 Graphing outcome over time
Analysis was performed separately for each overlapping 2% adherence window, centered
every 1% between 0 and 1, as well as for the points 0 and 1 themselves. The resulting
graph shows a weighted average of these results, using the adherence distribution in
Figure 4.13. Measurements were taken every two weeks, and the graphs show the
proportion of the population with each outcome. As there is no censoring of data, the
analysis is equivalent to the Kaplan-Meier method [168].
4.1.6 MSW for combination therapy
For calculations involving combination therapy (limited to two drugs in this paper), viral
ﬁtness is inﬂuenced by the dose-response curves of all drugs. DRV and RAL belong to
diﬀerent classes and have been shown to reduce ﬁtness in a multiplicative
(Bliss-independent) fashion, which is often expected for drugs acting on diﬀerent targets
[41, 159]. The equation describing viral ﬁtness with two Bliss-independent drugs is given
by:
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where       are the concentrations of each drug in the relevant compartment,
              are the concentrations at which     inhibition occurs, and       are the
slope parameters. The numerator     is the baseline basic reproductive ratio in the
absence of drug treatment. Mutations that confer resistance to a given drug change the
    , slope and drug-free ﬁtness similarly to the way described in equation 2 (main text).
For a two-drug combination where we assume that a viral strain may only be resistant
to a single drug, there are now eight potential selection windows. Drug levels may be high
enough for guaranteed treatment success; in the MSW for one or both drugs; in the
overlapping region for one or both of the MSWs and the WGW, or strictly in the WGW.
Figure 4.11 shows the possible windows for the RAL+DRV/r combination.
4.1.7 Derivation of Fig. 3.2f: comparing risk of wild type-based and mutant-
based VF from selection window data
Figure 3.2f in the main text ranks drugs by the relative risk of mutant versus wild-type
failure, regardless of the total risk of failure, based on the time spent in each selection
window. The ranks are plotted along a line with values ranging from -1 (DRV/r and d4T,
highest relative risk of wild-type failure) to 1 (FTC, the highest relative risk of mutant
failure). This plot was constructed based on the data in Figure 3.2a in the main text. To
76devise this scale, we let
    time until entry into MSW (days) / time until entry into WGW (days)
  length of green bar / length of green + dark red bars,
    time spent in MSW (days)
  length of both red bars 
(4.6)
If the drug immediately enters the WGW at day 0, or if it skips the MSW completely,
then   is deﬁned to be  .
Then the scale value to be plotted,  , is calculated as
   
 
    
    (4.7)
where             days, the maximum time that a drug spends in the MSW (obtained for
FTC). Since both   and        range between   and  , the scale ranges between   
(failure via wild type only) and   (largest relative risk of resistance).
In this formula,   is a proxy for the rapidity of wild type-caused virologic failure
(“wild-type risk”) relative to mutant-caused virologic failure (“mutant risk”). When   is
small, the MSW window is reached long before the WGW, meaning that “mutant risk” is
high and “wild-type risk” is low. When   is high, the WGW is reached soon after the
MSW, or without ever entering the MSW, and so “wild-type risk” is high and “mutant
risk” is low. While   considers how quickly the infection can start to grow, it does not
consider the length of time in the MSW. Even if the MSW begins as soon as a dose is
taken (so that      ), one still needs to consider for how long the mutant strain is selected
over the wild-type to determine whether mutant-based or wild type-based virologic failure
is more likely to occur. Figure 4.12 shows a scatter plot of   versus  .
774.2 Supplementary Tables
Table 4.1: Pharmacokinetic and pharmacodynamic parameters for anti-HIV drugs used in the
study[304]
Class Drug      ( Mol) slope      ( Mol) half-life (hrs) dosing (d  )
NRTI 3TC 0.0298 1.15 15.3 10.0 2
ABC 0.0381 0.93 10.5 21.0 2
AZT 0.1823 0.85 4.5 8.5 2
d4T 0.5524 1.13 2.3 3.5 2
ddI 0.1795 1.07 39.4 18.0 1
FTC 0.0079 1.20 7.3 39.0 1
TDF 0.0561 0.97 1.1 60.0 1
NNRTI EFV 0.0035 1.69 12.9 35.8 1
ETV 0.0050 1.75 1.6 41 2
NVP 0.0490 1.49 25.2 21.5 1
PI ATV 0.0150 2.90 3.3 6.5 1
ATV/r 0.0150 2.90 6.3 8.6 1
DRV/r 0.0265 3.55 14.8 15.0 2
IDV 0.0550 4.5 10.9 1.8 3
IDV/r 0.0550 4.5 12.5 3.5 2
LPV/r 0.0380 2.1 15.6 9.9 2
NFV 0.2360 1.88 5.1 4.0 3
SQV 0.0550 3.74 3.1 4.3 3
SQV/r 0.0550 3.74 7.9 4.3 2
TPV/r 0.2500 2.55 77.6 6.0 2
II EVG 0.0280 0.94 1.7 8.6 1
RAL 0.0150 1.03 4.0 10.0 2
FI ENF 0.0349 1.60 1.1 3.8 2
78Table 4.2: Parameters for all single-point mutations considered in the study[304]
Class Mutation Cost ( )   Drug    
NRTI K65R 0.41            3TC 61 -0.19
ABC 47 0.01
ddI 20 -0.09
FTC 29 -0.04
TDF 43 0.00
M184V 0.46            3TC 963 -0.58
ABC 9.5 -0.44
AZT 0.28 -0.03
ddI 9.5 -0.21
FTC 1186 -0.49
TDF 3.0 -0.27
M41L 0.17            AZT 2.2 0.07
d4T 1.0 0.07
T215Y 0.05 * AZT 3.1 -0.34
d4T 1.08 -0.12
NNRTI G190S 0.79            EFV 70 -0.40
NVP 237 -0.34
K101P 0.7 * ETV 5.00 -0.27
K103N 0.3            EFV 85 -0.17
NVP 94 -0.15
Y181C 0.26            EFV 2.6 -0.11
ETV 11 -0.26
NVP 234 -0.40
Y181I 0.44 * ETV 100 -0.37
NVP 1309 -0.50
* Indicates mutation that requires two nucleotide changes;
mutation rate depends on prevalence of intermediate states.
79Table 4.3: Parameters for all single-point mutations considered in the study (Cont’d)[304]
Class Mutation Cost (s)   Drug    
PI D30N 0.27            NFV 2.3 -0.29
G48V 0.45            SQV 2.0 -0.23
I47A 0.9 * LPV 5.8 -0.40
I47V 0.05            LPV 1.8 -0.29
I50L 0.75            ATV 1.2 -0.34
I50V 0.93            DRV 0.68 -0.07
I54L 0.05            DRV 0.98 -0.01
I84V 0.82            ATV 0.60 -0.34
DRV 0.94 -0.01
IDV 0.73 -0.39
TPV 0.26 -0.39
L33F 0.49            TPV 1.4 0.02
L90M 0.30            NFV 1.5 0.01
SQV 1.1 -0.28
M46I 0.05            IDV 1.0 -0.29
M46L 0.05            IDV 0.76 -0.24
N88S 0.55            ATV 3.1 -0.31
V32I 0.09            LPV 0.53 -0.16
V82A 0.59            LPV 1.03 -0.33
V82F 0.79            IDV 0.89 -0.58
LPV 1.45 -0.44
V82T 0.22 * IDV 0.98 -0.34
LPV 0.87 -0.17
TPV 0.68 -0.20
II G140S 0.71            RAL 2.1 0.03
N155H 0.55            EVG 20 0.00
RAL 27 0.02
Q148H 0.73            EVG 6.8 -0.04
RAL 86 0.06
Q148K 0.76            EVG 19 0.03
RAL 128 -0.06
Q148R 0.61            EVG 68 0.06
RAL 90 0.04
Y143C 0.74            RAL 3.6 0.06
Y143H 0.55            RAL 2.7 -0.04
Y143R 0.32 * RAL 75 -0.01
FI G36D 0.12            ENF 1.7 -0.45
N42T 0.54            ENF 2.9 -0.13
N43D 0.88            ENF 13 -0.06
Q40H 0.26            ENF 12 -0.31
V38A 0.17            ENF 11 -0.32
* Indicates mutation that requires two nucleotide changes;
mutation rate depends on prevalence of intermediate states.
80Table 4.4: Parameters for pre-existing frequency of mutations and exit rate from the latent
reservoir. See §3.5 and §4.1 for explanations.
class mutation equilibrium frequency reservoir exit (days)
NRTI K65R            12
M184V            14
M41L            43
T215Y * *
NNRTI G190S            12
K101P * *
K103N            68
Y181C            8
Y181I * *
PI D30N            2
G48V            177
I47A * *
I47V            2
I50L            279
I50V            28
I54L            19
I84V            25
L33F            26
L90M            31
M46I                 
M46L            13
N88S            17
V32I            1
V82A            18
V82F            769
V82T * *
II G140S            11
N155H            349
Q148H            166
Q148K            39
Q148R            18
Y143C            22
Y143H            17
Y143R * *
FI G36D            2
N42T            342
N43D            27
Q40H            59
V38A            5
* Indicates mutation that requires two nucleotide changes;
equilibrium frequency depends on prevalence of intermediate states.
81Table 4.5: Parameters for pre-existing frequency and exit rate from the latent reservoir for best
“synthetic” mutation for each drug. See §3.5 and §4.1 for explanations.
class drug equilibrium frequency reservoir exit (days)
NRTI AZT            14
d4T            43
3TC            12
FTC            12
ABC            12
ddI            12
TDF            12
NNRTI EFV            8
NVP            8
ETV            8
PI DRV            19
NFV            2
SQV            31
LPV            1
ATV            17
IDV                 
TPV            25
II RAL            11
EVG            18
FI ENF            2
Table 4.6: Viral dynamics parameters in the absence of drug therapy
Parameter Value Units Reference
    Baseline basic reproduction
ratio
10 (unitless) See text
   Death rate of actively
infected cells
1 d   [214]
   Residual plasma viral load
maintained by activation
from latent reservoir,
absent viral replication
2 RNA copies
per ml
plasma
[93]
  Latent reservoir exit rate 3000 cells.d   Based on   , see text
82Table 4.7: Nucleotide substitution rate parameters for HIV. Each entry gives the per-site tran-
sition probability from row base to column base in one round of viral replication. For derivation
and source see Section 4.1.2.4. The extraordinary skew of this matrix (the largest entry, G-to-A
mutation, is more than 300 times the smallest, C-to-G mutation) reﬂects the base composition of
the genome, particularly the bias towards A. Values less than 10   are particularly uncertain, as
they were computed from fewer than 5 substitution observations each.
U C A G
U                                 
C                                 
A                                 
G                                 
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Figure 4.1: Simulated clinical outcomes versus adherence for all drugs. In “Suppression” tri-
als, patients begin with a realistic distribution of treatment-naive viral loads (between 3000 and
10  c.ml  ) and undergo monotherapy for a full 48 weeks. Virologic failure (VF) is deﬁned as a
viral load above 50 c.ml  at Week 48. VF is classiﬁed as “via resistance” if at least 20% of the
viral population at the time of detection is mutant. Adherence (x-axis) is measured as the frac-
tion of scheduled doses taken. The height of the area shaded indicates probability of the corre-
sponding outcome at that adherence level. 3TC, lamivudine; ABC, abacavir; AZT, zidovudine;
d4T, stavudine; ddI, didanosine, FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; EFV,
efavirenz; ETV, etravirine; NVP, nevirapine; ATV, atazanavir; DRV, darunavir; IDV, indinavir;
LPV, lopinavir; NFV, nelﬁnavir; SQV, saquinavir; TPV, tipranavir; EVG, elvitegravir; RAL, ral-
tegravir; ENF, enfuvirtide.
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Figure 4.2: Simulated clinical outcomes versus adherence for all drugs. In “Maintenance” trials,
patients begin with full viral suppression and undergo monotherapy for 48 weeks or until viro-
logic failure (VF), whichever occurs ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive
weekly measurements (starting at week 5) with viral load above 200 c.ml  . VF is classiﬁed as
“via resistance” if at least 20% of the viral population at the time of detection is mutant. Adher-
ence (x-axis) is measured as the fraction of scheduled doses taken. The height of the area shaded
indicates probability of the corresponding outcome at that adherence level.
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Figure 4.3: Simulated clinical outcomes versus time for all drugs. In “Suppression” trials, pa-
tients begin with a realistic distribution of treatment-naive viral loads (between 3000 and 10 
c.ml  ) and undergo monotherapy for a variable time (x-axis). “Detectable viral load” is deﬁned
as above 50 c.ml  and is classiﬁed as “via resistance” if at least 20% of the viral population at
the time of detection is mutant. The height of the area shaded indicates prevalence of the corre-
sponding outcome at that time. Patients have a realistic distribution of adherence levels with an
average of 70%.
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Figure 4.4: Simulated clinical outcomes versus time for all drugs. In “Maintenance” trials, pa-
tients begin the trial with full viral suppression and undergo monotherapy for a variable amount
of time (x-axis) or until “detectable viral load” is observed, whichever occurs ﬁrst. “Detectable
viral load” is deﬁned as “conﬁrmed rebound”: two consecutive weekly measurements (starting
at Week 5) above 200 c.ml  . It is classiﬁed as “via resistance” if at least 20% of the viral pop-
ulation at the time of detection is mutant. The height of the area shaded indicates prevalence of
the corresponding outcome at that time. Patients have a realistic distribution of adherence levels
with an average of 70%.
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Figure 4.5: Simulated clinical outcomes versus time for all drugs. In “Maintenance with re-
covery” trials, patients begin the trial with full viral suppression and undergo monotherapy for
a variable amount of time (x-axis). “Detectable viral load” is deﬁned as “conﬁrmed rebound”:
two consecutive weekly measurements (starting at Week 5) with viral load above 200 c.ml  . It
is classiﬁed as “via resistance” if at least 20% of the viral population at the time of detection is
mutant. We allow recovery, meaning that patients stay in the trial to see if they will re-suppress,
instead of being removed immediately like in regular “Maintenance” trials. The height of the
area shaded indicates prevalence of the corresponding outcome at that time-point. Patients have
a realistic distribution of adherence levels with an average of 70%.
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Figure 4.6: Simulated clinical outcomes versus adherence for all drugs, distinguishing pre-
existing from de novo mutations. In the “Suppression” trials shown, patients begin with a re-
alistic distribution of treatment-naive viral loads (between 3000 and 10  c.ml  ) and undergo
monotherapy for a full 48 weeks. Virologic failure (VF) is deﬁned as a viral load above 50
c.ml  at Week 48. VF is classiﬁed as “via resistance” if at least 20% of the viral population at
the time of detection is mutant. Resistance is classiﬁed as de novo if the majority of mutants at
the time of failure descended from a mutation event that occurred during replication since the
start of the trial. Otherwise, resistance is classiﬁed as “pre-existing,” which includes mutants
arising from both the pre-treatment plasma population and the latent reservoir. Adherence (x-
axis) is measured as the fraction of scheduled doses taken. The height of the area shaded indi-
cates probability of the corresponding outcome at that adherence level.
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Figure 4.7: Simulated clinical outcomes versus adherence for all drugs, distinguishing pre-
existing from de novo mutations. In the “Maintenance” trials shown, patients begin with full vi-
ral suppression and undergo monotherapy for 48 weeks or until virologic failure (VF), whichever
occurs ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measurements (start-
ing at Week 5) with viral load above 200 c.ml  . VF is classiﬁed as “via resistance” if at least
20% of the viral population at the time of detection is mutant. Resistance is classiﬁed as de novo
if the majority of mutants at the time of failure descended from a mutation event that occurred
during replication since the start of the trial. Otherwise, resistance is classiﬁed as “pre-existing,”
which includes mutants arising from both the pre-treatment plasma population and the latent
reservoir. Adherence (x-axis) is measured as the fraction of scheduled doses taken. The height of
the area shaded indicates probability of the corresponding outcome at that adherence level.
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Figure 4.8: Simulated clinical outcomes versus adherence for all drugs,    =20. Results are
shown for “Maintenance” trials only. In the “Maintenance” trials shown, patients begin with
full viral suppression and undergo monotherapy for 48 weeks or until virologic failure (VF),
whichever occurs ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measure-
ments (starting at Week 5) with viral load above 200 c.ml  . VF is classiﬁed as “via resistance”
if at least 20% of the viral population at the time of detection is mutant. Adherence (x-axis) is
measured as the fraction of scheduled doses taken. The height of the area shaded indicates prob-
ability of the corresponding outcome at that adherence level. As compared to    =10, increasing
    to 20 leads to higher adherence levels being required for treatment success, and it extends
the range of adherence levels (in both directions) for which resistant strains can cause failure.
Mutant VF becomes a possible outcome for the PIs ATV, ATV/r, IDV, IDV/r, and SQV/r, and
treatment success cannot occur at any adherence level for ddI and NFV.
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Figure 4.9: Simulated clinical outcomes versus adherence for all drugs,    =5. Results are
shown for “Maintenance” trials only. In the “Maintenance” trials shown, patients begin with
full viral suppression and undergo monotherapy for 48 weeks or until virologic failure (VF),
whichever occurs ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measure-
ments (starting at Week 5) with viral load above 200 c.ml  . VF is classiﬁed as “via resistance”
if at least 20% of the viral population at the time of detection is mutant. Adherence (x-axis) is
measured as the fraction of scheduled doses taken. The height of the area shaded indicates prob-
ability of the corresponding outcome at that adherence level. As compared to    =10, decreasing
    to 5 leads to lower adherence levels being required for treatment success, and it reduces the
range of adherence levels for which resistant strains can cause failure. A range of high adherence
levels appears where there is treatment success for ABC and AZT, and near-perfect adherence is
no longer required for ddI and NFV success. Mutant VF no longer occurs for SQV, and for AZT
and ddI, wild-type failure may be the ﬁrst outcome to occur as adherence levels decrease from
the successful range.
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Figure 4.10: Simulated clinical outcomes versus adherence for NRTIs with large inter-
experimental variation in half-life. The ranges included were {10, 16, 22} for 3TC, {4, 8.5, 11}
for AZT, {3.5, 7, 10} for d4T, {15, 18, 20} for ddI, and {60, 120, 180} for TDF. Results are
shown for “Maintenance” trials only. In the “Maintenance” trials shown, patients begin with
full viral suppression and undergo monotherapy for 48 weeks or until virologic failure (VF),
whichever occurs ﬁrst. VF is deﬁned as “conﬁrmed rebound”: two consecutive weekly measure-
ments (starting at Week 5) with viral load above 200 c.ml  . VF is classiﬁed as “via resistance”
if at least 20% of the viral population at the time of detection is mutant. Adherence (x-axis) is
measured as the fraction of scheduled doses taken. The height of the area shaded indicates prob-
ability of the corresponding outcome at that adherence level. Compared to the half-lives used
throughout the rest of the paper (see Table 4.1), the results barely change for 3TC or d4T. For
AZT, varying the half-life changes the adherence level where wild-type failure becomes more
likely than mutant failure. For ddI, the adherence level where treatment success occurs shifts.
For higher TDF half-lives, mutant VF becomes the only outcome, with the exception of rare
(  3%) wild-type failure at the lowest adherence levels for      = 120 hours.
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Figure 4.12: Relative risk of wild type- vs. mutant-caused virologic failure for anti-HIV drugs,
considering the best “synthetic” mutation deﬁned in Section 4.1.3. Two metrics can be used to
compare the risk of resistance to the likelihood of wild-type growth, shown on both axes. The
x-axis measures the time until a patient interrupting treatment reaches the MSW, divided by
the time until that patient reaches the WGW. The y-axis measures the number of days that a
patient spends in the MSW during a treatment interruption. Drugs tend to cluster near the end-
points of the x-axis: most NRTIs, the IIs, and the FI are on the left, meaning that the patient
enters the MSW immediately or soon after interruption, and most PIs are on the right, mean-
ing that the patient waits relatively long to enter the MSW. Section 4.1.7 further describes the
two metrics and explains how they were used in Figure 3.2f in the main text to rank the drugs
by relative risk of mutant-based versus wild type-based VF. Note that the symbol for DRV/r is
obscured behind the symbol for d4T at (1 0).
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www.hiv.lanl.gov/content/immunology) and b) adherence levels [24] used in simulations.
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Predicting the outcome of treatments to
eradicate the HIV-1 latent reservoir
5.1 Abstract
Highly active antiretroviral therapy (HAART) controls HIV-1 replication but cannot
eradicate the infection due to a reservoir of latent virus present in resting memory CD4 T
cells. Latency reversing agents (LRAs) that reactivate latent HIV-1, rendering the infected
cells susceptible to viral cytopathic eﬀects and host cytolytic T lymphocytes, oﬀer hope of
a cure. Here we use a stochastic model of infection dynamics to interpret measurements of
reservoir composition obtained by both PCR and co-culture experiments, and we calculate
the degree of reservoir reduction needed to prevent viral rebound during long periods of
HAART interruption. Our ﬁndings suggest that reduction of 1,000- to 20,000-fold is
required to let a majority of patients interrupt HAART for one year without rebound and
that viral rebound may occur suddenly after multiple years of successful interruption. We
predict that large variation in rebound times following LRA therapy will complicate
interpretation of clinical trials.
985.2 Introduction
The latent reservoir (LR) for HIV-1 is a population of long-lived resting memory CD4 T
cells with HIV-1 DNA integrated into their genomes [71, 72]. After the reservoir is
established during acute infection [74], it increases to           cells and then remains
stable. As only actively replicating virus is targeted by current anti-HIV drugs, latently
infected cells persist even after years of eﬀective treatment [73, 110, 327, 375]. Cellular
activation leads to virus production and, if treatment is interrupted, a rapid increase in
viremia is observed within weeks of discontinuation of therapy. This dynamic prevents cure
of HIV-1 by HAART alone and thus necessitates lifelong adherence to HAART. Drugs that
speciﬁcally target LR cells for rapid activation may reduce the size of the LR [67, 98].
Collectively called latency reversing agents (LRA), this class includes the histone
deacetylase inhibitors such as vorinostat [14, 16] and valproic acid [15, 328], the alcoholism
drug disulﬁram [380], protein kinase C activators prostratin [37] and bryostatin [221, 280],
and quinoline derivatives [381]. The hope is that following treatment with these drugs,
patients might be able to discontinue HAART with minimal risk of viral rebound. While
the discovery of LRAs is now the subject of an intense research eﬀort, it is unclear how
much the LR must be reduced to enable patients to discontinue HAART safely.
Mathematical models of treatment dynamics are urgently needed to inform clinical trial
design, interpret outcomes, and guide further drug discovery.
Mathematical models have been instrumental in understanding the dynamics of HIV-1
infection, including the LR. Multi-compartment models of HIV-1 infection have successfully
been used to describe the phases of viral decay after initiation of HAART [181, 247, 269],
the role of ongoing replication in slowing the rate of LR decay [311], and the appearance of
viral “blips” during treatment [81, 292, 293]. Recent studies have considered the role of the
LR in the development of drug resistance to HAART[296]. However, no model has been
developed to study the eﬀect of treatment with LRAs. Here we build and analyze such a
99model to predict how in vitro drug eﬃcacy translates to patient outcomes, measured as the
length of time following discontinuation of HAART before viral rebound occurs.
5.3 Methods
We consider proposed therapy protocols for latency reversing agents (LRAs) that
administer the treatment while a patient is on fully suppressive HAART [98]. It is believed
that LRA therapy will reactivate transcription at the HIV-1 LTR, leading to production of
cytotoxic viral products and cell death. While plasma HIV-1 levels may increase during
this phase, strict adherence to HAART is expected to prevent new cellular infections. After
a period of treatment with both LRAs and HAART, both therapies would be interrupted.
Here we provide a model of the viral infection immediately after this therapy ends (Fig.
5.1(A)). Our goal is to estimate the probability of cure, or, barring that best-case outcome,
to estimate the distribution of times until virologic rebound, in terms of parameters
describing the underlying infection dynamic and the LRA therapy.
The model tracks two cell types: productively infected active CD4  T cells, and
latently infected resting CD4  T cells. Cells carrying nonviable HIV-1 provirus (which may
vastly outnumber cells carrying replication-competent proviruses) are excluded from these
two quantities. The level of plasma virus is not tracked explicitly, but is assumed to be
proportional to the productively infected cells. Four types of events can occur in this
model, which is described formally as a two-type branching process (Fig. 5.1(C)). A
latently infected cell can either activate at rate  , or die at rate   . An actively infected
cell can either produce a burst of virions at rate  , resulting in the infection of   other cells,
after which it dies, or it can die without producing virions (at rate  ). The number of cells
infected after each burst event is a Poisson random variable with mean and variance  
(Fig. 5.1(D)). Details of the model are described in Suppl. Methods. §6.1.3.
The total death rate of productively infected cells (          ) has been well
characterized to be 1 day   from treatment initiation studies. The rate of reactivation of
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Figure 5.1: Schematic of LRA therapy and stochastic model of rebound following therapy. A)
Proposed treatment protocol, illustrating possible viral load and size of latent reservoir before
and after LRA therapy. When HAART is started, viral load decreases rapidly and may fall be-
low the limit of detection. The latent reservoir is established early in infection (not shown) and
decays very slowly over time. When LRA is administered (either continuously, as shown, or in
intervals), the latent reservoir declines. Depending on the eﬃcacy of LRA therapy, the infection
may be cleared, or viremia may eventually rebound. B) LRA eﬃcacy is deﬁned by the parameter
Q, the number of log  -reductions in LR size. C) Stochastic model of viral dynamics following
LRA therapy, tracking both latently (rectangles) and actively (ovals) infected cells. Each arrow
represents a type of event that occurs in the model and its rate, described in the text. D) The
expected number of “oﬀspring” for each productively infected cell is the basic reproductive ratio
   = 2. The “infectivity variance” parameter   determines variance of the oﬀspring distribution.
The oﬀspring distribution conditional on event   occurring is given by a Poisson:  ( ) =        !
101cells from the latent reservoir can be estimated based on the size and composition of the LR
(Fig. 5.2) and the level of residual plasma virus for patients on fully suppressive HAART
(  2 copies HIV-1 RNA per milliliter plasma, c ml  ). We estimate   to be          day  
and consider values in the range      to         . The death rate of latently infected cells
is estimated from studies of the rate of decay of the LR to be                 day  
(corresponding to a 44 month half-life). We also present results for two extremes: a
half-life of only 6 months, and,       . The basic reproductive ratio for this model, deﬁned
as the expected number of new infected cells that a single actively infected cell produces, is
               . The average    value is estimated from time-to-rebound in
HAART-interruption studies to be        (which is lower than the values estimated for
acute infection).    does not uniquely determine the dynamics of the stochastic model
because   and   cannot be simultaneously identiﬁed. Holding    constant, the parameter  
controls the strength of random drift in the infection: for high  , reproduction resembles a
“jackpot” event where a few infected cells give rise to many new infection events, while
many other infected cells die before infecting additional cells. Here we vary   in the range
2 – 50. Justiﬁcations for these parameter estimates are provided in Suppl. Methods. §6.1.2.
The initial conditions depend upon the number of latently infected cells that survive
LRA therapy. This quantity is deﬁned by the latent reservoir size prior to LRA therapy
and the log-eﬃcacy of LRA therapy (Fig.5.1(B)). The model aims to determine whether or
not this population of cells will escape drift and restart the infection before all the cells die.
These results are independent of the details of how the drug is administered or the
mechanism of action. As the model does not provide for any limitation of growth as the
infection becomes large, it is valid only for the initial stages of viral rebound. Since clinical
viral rebound thresholds (viral load above 50 – 200 c ml  ) are well below carrying
capacity (typical setpoint viral load of     –     c ml  ), this model suﬃces to analyze the
probability and timing of rebound following LRA therapy and HAART interruption.
1025.4 Results
We used several experimental ﬁndings to estimate the size range of the LR, which we
deﬁne as the number of resting CD4 T cells with integrated HIV that are capable of
producing infectious virus upon reactivation (Fig. 5.2). We considered three cases for the
LR size distribution among patients. Limiting dilution co-culture assays [325] are currently
the gold standard for LR size measurement. In case (i), we assume all patients have a
reservoir size equal to the average measured in these assays (           cells), and in case
(ii) we incorporate inter-patient variability in assay results [104]. PCR measurements
detect cells with HIV-1 DNA at a higher frequency than co-culture assays, but much of this
virus may be defective. Full genome clonal sequencing of provirus from cells not induced in
co-culture identiﬁes a portion with all open reading frames intact [146]. In case (iii), we
include these cells in the LR. For all cases we assume a total resting CD4 cell count of
    . The resulting distributions are shown in Fig. 5.3(A). Formal deﬁnition of each
distribution is provided in Suppl. Methods. §6.1.1.2
The best-case outcome of LRA therapy, barring complete eradication of the reservoir,
is that none of the surviving latently infected cells activate and lead to a resurgent
infection. In this case, we say that LRA has cleared the infection. We used the model to
predict the relationship between LRA log-eﬃcacy (denoted  ) and clearance probability
(Suppl. Methods §6.1.3.2.1). Fig. 5.3(B) shows results for the three possible reservoir
distributions (i) – (iii) described above.In cases (i) and (ii), where the average pretreatment
reservoir size is    , the reservoir must be reduced by three to ﬁve orders of magnitude
before half of patients clear the infection. Including inter-patient variability only causes the
clearance probability to increase more gradually with  . If co-culture does not detect all
cells in the latent reservoir (case iii), then   of four to six is required for 50% clearance. In
all three cases, the clearance probability decreases with reservoir half-life. Clearance
probability also increases with infectivity variance  , as this parameter controls the
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Figure 5.2: Experimental scheme for classifying resting CD4  T cells based on HIV-1 infection
and viral production, using data from [104, 146]. Scheme starts at the top, with puriﬁed resting
CD4  T cells, and proceeds downward through the experimental analyses listed. The   variables
represent fractions of this resting CD4 T cell pool with the characteristics listed. “PCR”: Digital
droplet PCR identiﬁed cells containing HIV-1 DNA, nearly all of which is expected to be inte-
grated. “Co-culture”: PHA was used to induce viral replication in latently infected cells. “Seq.
defect”: Non-induced cells were analyzed for genetic defects preventing production of replication-
competent virus. A fraction   of these non-induced cells had no observable defects (all open read-
ing frames intact); this fraction constitutes      of all resting CD4 T cells. Question marks in-
dicate that it was not possible to determine by this analysis what fraction of cells would produce
replication-competent virus in vivo, due to integration site eﬀects and undetectable sequence de-
fects. Even defective provirus may be able to produce defective virions that contribute to resid-
ual viremia (gray arrow). The latent reservoir (shaded box) consists of induced and replication-
capable non-induced cells. Values shown are averages and ranges of   30 patients.
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Figure 5.3: Clearance probabilities and rebound times following LRA therapy predicted from
model. A) Three cases for the population-level distribution of LR size (Suppl. Methods §6.1.1.2).
Case i) All patients have the same latent reservoir size,     = 10 , estimated from the geomet-
ric mean number of cells that are capable of producing infection in laboratory co-culture assays.
Case ii) Latent reservoir size is distributed according to variation observed in co-culture assays,
with geometric mean 10 . Case iii) The latent reservoir includes many cells that fail to be de-
tected in co-culture but have intact viral genomes. B) Probability that the reservoir is cleared
by LRA. Clearance occurs if all cells in the reservoir die before a reactivating lineage leads to
viral rebound. C) Median viral rebound times, among patients who do not clear the infection.
D) Survival curves for patients following LRA therapy. The percentage of patients who have
not yet experienced viral rebound is plotted as a function of the time after interruption of LRA
therapy and HAART. Curve color indicates the eﬃcacy of LRA in reducing the size of the LR
(  = 0 to 6, see legend). Results are shown for a half-life of 44 months; other half-lives are shown
in Fig. 6.6 Solid lines represent simulations, and open circles represent approximations from a
branching process calculation(Suppl. Methods §6.1.3.2.2),[81]). All simulations included 10   10 
patients and used parameters   = 7   10  ,   = 20 and    = 2.
105likelihood of viral lineage extinction by drift (Fig. 6.4B).
If LRA therapy fails to clear the infection, the next-best outcome is substantial
extension of the time until virologic rebound, deﬁned as a viral load of 200 c
ml  (§6.1.2.2). We computed the relationship between eﬃcacy of LRA therapy and the
median time until rebound, among the patients who do not clear the infection (Fig.
5.3(C)). For an LR size of     (case i), only modest increases in median rebound time are
predicted for up to 100-fold reductions in the size of the reservoir (     ). In this range,
the rebound time is independent of latent cell lifespan, and it is driven mainly by the
reactivation rate and the viral reproductive ratio. The curve inﬂects upward at       (on a
log scale) and reaches a ceiling as clearance of the infection becomes the dominant outcome
(Fig. 5.3(C)(i)). If cells in the reservoir are extremely long-lived, it is possible for rebound
to occur even after decades of apparent cure. If the LR size is larger (case iii), then the
median rebound time curve is shifted rightwards, requiring higher LRA eﬃcacy for the
same outcomes (Fig. 5.3(C)(iii)). In all three cases, the inﬂection point decreases in  . In
case (i), this point varies between         (for       ) and       (for      ). Accordingly,
the median rebound time increases in   (Fig. 6.4C).
The upward inﬂection observed in median rebound time results from an important
change in the forces governing viral dynamics. If the reservoir is large enough (low  ), a
surplus of cell activation occurs such that the dominant component of rebound time is the
time that it takes for virus from one of the many activated cells to grow exponentially to
rebound levels; the system is in a growth-limited regime. If the reservoir is small (high Q),
the expected waiting time until activation of the ﬁrst cell fated to establish a rebounding
lineage is the dominant component of rebound time; the system is in an activation-limited
regime. Since this waiting time is roughly exponentially distributed, times to rebound in
this regime can vary widely among patients. The “threshold  ” deﬁning the boundary of
these two regimes matches the value where upward inﬂections are observed (Fig. 6.5(A)).
The scope of predicted interpatient variability in outcomes can be seen in survival
106curves, plotting the fraction of simulated patients maintaining virologic suppression over
time (Fig. 5.3D). For small reductions in LR size (     ) patients uniformly rebound
within a few months, since rebound dynamics are not in the activation-limited regime (Fig.
5.3(D)(i)). If LRA therapy manages to decrease the reservoir size      -fold (     ), then
about 20% of patients remain rebound-free for at least a year. Higher   leads to clearance
in many patients, though rebound can still occur after a decade without viremia.
Interpatient variation in LR size makes it more likely to observe long periods without
rebound (Fig. 5.3(A)(ii)). Rebound delays of over three years are achieved for 10% of
simulated patients at      , versus only 1% in case (i). The fortunate few who completely
clear the infection started with an LR smaller than the average size of     prior to
treatment. Survival curves decline more rapidly if the average LR size is larger (case iii) or
if   is lower (Fig. 6.7), indiciating a less beneﬁcial outcome for LRA therapy.
For all three reservoir size distributions considered, rebound may occur even after long
periods of virologic suppression. Taking case (ii) for example, among the patients without
rebound at six months post-therapy, 71%, 38%, or 11% suﬀer rebound in the following six
months, for eﬃcacies      ,      , or      , respectively (Fig. 5.3(A)(ii)).
To set goals for treatment eﬃcacy, we calculate three “target values” of  , assuming a
pretreatment reservoir size of    . One month is near the upper limit of rebound times
without LRA therapy, and we ﬁrst calculate deﬁne the log-eﬃcacy for which 50  of
patients exceed this limit (Fig. 5.4(A)). This value is insensitive to the estimate for
reservoir half-life and increases logarithmically with the activation rate. For a broad range
of activation rates, a 1.5- to 3-log reduction is needed for a one-month delay. We next
calculate the target eﬃcacy for one-year delays (Fig. 5.4(B)). Using estimated parameter
values, this goal requires a 3-log reduction in reservoir size. This value is only mildly
sensitive to reservoir half-life (declining only for very short half-lives, at which reservoir
clearance is likely) and also scales logarithmically with activation rate. If activation
exceeds the estimated rate, then the target   is closer to     – a       -fold reduction.
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Figure 5.4: Eﬃcacies required for successful LRA therapy. Target LRA eﬃcacy values based
on three diﬀerent treatment goals are plotted versus reservoir half-life (
     
    ) and the reservoir
reactivation rate ( ). A) The target eﬃcacy   at which at least 50% of patients still have sup-
pressed viral load one month after treatment interruption. B) The target eﬃcacy   at which
at least 50% of patients still have suppressed viral load one year after treatment interruption.
C) The target eﬃcacy   at which at least 50% of patients have eradicated the reservoir with-
out experiencing viral rebound. Because some patients may go for a year without rebound but
then rebound later, the target   for one year oﬀ therapy is always less than that for a lifetime
oﬀ therapy. Results were calculated from the branching process description of the stochas-
tic process, which agrees with simulation (Suppl. Methods §6.1.3.2.2). All calculations used
  = 20 and varied    to ensure baseline rebound time was constant (12 days). Worst-case:
  = 3   10      = 1 43, high:   = 4 6   10      = 1 7, estimated:   = 7   10      = 2,
best-case:   = 10      = 2 21.
108Finally, since the ultimate goal of LRA therapy is to clear the reservoir completely, we
determine the log-eﬃcacy for which at least half of patients clear the infection (Fig.
5.4(C)). This value consistently exceeds the more modest one-year target and scales
logarithmically with the product of activation rate and half-life. Parameter scaling
relationships follow from a generating function analysis of the branching process, described
in the Suppl. Methods §6.1.3.2.1, §6.1.3.2.3. All target   values also scale with the
reservoir: a 1-log increase in reservoir size would necessitate a unit increase in  .
We evaluated the robustness of our conclusions to simultaneous changes in latent cell
activation and death rates, pretreatment reservoir size distributions, and infectivity
variance. For a worst-case analysis, the latent cell death rate was set to zero (such that the
reservoir decays only via activation), the pretreatment reservoir size distribution was set to
that of case (iii), and infectivity variance was set to a low value. The resulting target   for
a one-month delay increased by 2, and the clearance target   increased by 3 versus
baseline (Fig. 6.8(i) versus (iii)). For a best-case analysis, the latent cell activation rate was
set to 7 times lower than baseline and the death rate was increased to yield a reservoir
half-life of only six months, the pretreatment reservoir size distribution was set to that of
case (i), and infectivity variance was set to a high value. The results were similar to that of
the baseline case, but with   shifted upwards by 1, and with a lower ceiling rebound time
( 200 days versus over       days) (Fig. 6.8(i) versus (iii)).
Throughout our analysis, we have characterized LRA drug eﬃcacy by the log-reduction
in reservoir size following therapy, which may not be observable. Laboratory studies of
cellular models of latency may estimate  , but their relevance in vivo remains unknown. It
may not be possible to measure   values above 1 by quantifying reservoir size following
LRA therapy, as current co-culture assays cannot detect reservoirs smaller than about    
cells [104]. Since current approaches to LRA therapy seek to reduce reservoir size by
inducing activation of latently infected cells,   may be estimated by measuring the
dynamics of viral load during simultaneous HAART/LRA therapy (Suppl.
109Methods §6.1.5). Since the eﬀect of LRA therapy on resting CD4  T cell phenotype is not
fully characterized [315, 316], there is considerable uncertainty in this relationship;
nonetheless a sharp, transient peak viral load of at least several hundred c ml   is expected
for highly eﬀective therapy (     ) (Table ??).
5.5 Discussion
Our model is the ﬁrst to describe the action of investigational latency reversing agents and
set quantitative goals for LRA therapy, oﬀering guidance for the design and testing of
treatment protocols. There is currently little understanding of the degree of reservoir
activation required to provide meaningful beneﬁt. We analyzed experimental ﬁndings
regarding reservoir size and composition to describe three plausible settings for LRA
therapy (Fig. 5.3A). In each setting, our model translates a reactivation measure of therapy
eﬃcacy (parameter  ), which may be estimated in vitro, to a prediction of clinical beneﬁts.
For a wide range of parameters, we ﬁnd that LRAs must reduce the reservoir by at least
1.5–3 orders of magnitude to see a meaningful increase in the time to virologic rebound
after HAART interruption (upward inﬂection in Fig. 5.3C and Fig. 6.4C), and that 3–5
orders of magnitude are needed for half of patients to clear the infection (Fig. 5.4C and
Fig. 6.5). Standard deviations in rebound times of many months are expected to be the
norm for successful therapy, owing to variation in pretreatment reservoir size and roughly
exponentially-distributed reactivation times after eﬀective LRA therapy brings the infection
to an activation-limited regime. While the required LRA eﬃcacy for these beneﬁcial
outcomes is almost certainly beyond the reach of current drugs, our results do permit some
optimism: reactivation of all cells in the reservoir is unlikely to be necessary for complete
reservoir clearance and safe cessation of HAART. This is due to the reasonably high
probability that a cell in the LR will either die before reactivating or, following activation,
fail to produce a chain of infection events leading to rebound. On a more cautionary note,
the wide distribution in reactivation times implies that continual monitoring of patients is
110essential, as rebound is possible even after long periods of viral suppression.
Clinical and laboratory ﬁndings constrain the basic reproductive ratio    and active
cell death rate    in a relatively narrow range. The rebound population size, while it may
vary by over order of magnitude, has little eﬀect on model outcomes, especially in the
activation-limited regime. Remaining parameters — pretreatment reservoir size, latent cell
half-life
     
    , latent cell activation rate  , and infectivity variance   — have profound
impacts on treatment outcome, and they are not well-established to within an order of
magnitude. While LR size is generally estimated at    , recent studies have shown that
even co-culture assays — recognized as the gold standard for latency measurement — may
drastically underestimate reservoir size (Fig. 5.3(A)(ii) versus 5.3(A)(iii)). We accounted
for these studies to show that this underestimate may cause expectations of LRA therapy
outcomes to be unduly optimistic (Figs. 5.3(B,C)(ii) and 5.3(ii) versus Figs. 5.3(B,C)(iii)
and 5.3(iii)). Considering both variation in pretreatment reservoir size and latent cell
half-lives, the log-reduction needed to delay rebound for one year in half of patients is    
to       — a reduction of      - to       -fold (Fig. 6.6(C)(ii) vs. (A)(iii)). When broad
variation in   and   is also considered, the range expands to     to       (Fig. 6.8(C)(ii)
vs. (C)(iii)).
Our analysis characterizing the required eﬃcacy of LRA therapy does not rely on the
speciﬁc mechanism of action of these drugs, only the amount by which they reduce the
reservoir. We have assumed that the reservoir is a homogeneous population without
variation in activation and death rates. The presence of reservoir compartments with
diﬀerent drug penetrations does not alter our results, as they are stated in terms of total
reservoir reduction. If, however, these compartments vary in activation or death rates, or if
viral dynamics of activated cells depends on their source compartment, then our model
may need to be modiﬁed. In the absence of clear consensus on compartments constituting
the LR, we have considered the simplest scenario with fewest assumptions, which may be
able to ﬁt future LRA therapy outcomes.
111To date, laboratory and clinical studies of investigational LRAs have generally found
weak potential for reservoir reduction, with       [15, 76, 380]. We predict that much
higher eﬃcacy will be required for any hope of eradication. While we have focused on the
role of LRA therapy in reducing the reservoir size, our main ﬁndings may also serve to
interpret viral eradication or delays in rebound caused by early treatment
initiation [40, 271, 341] or stem cell transplantation [140, 152], both of which also reduce
the LR size.
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Supplementary Information: Predicting the
outcome of treatments to eradicate the HIV-1
latent reservoir
6.1 Supplementary Methods
6.1.1 Characterizing the latent reservoir
This section details the calculations summarized in Fig. 5.2.
6.1.1.1 Components of the latent reservoir
Let   be the total number of resting CD4 T cells in an individual. The fraction of these
cells containing HIV-1 DNA, written   , is measured using PCR on puriﬁed resting CD4 T
cells [104]. The total number of resting CD4 T cells with HIV-1 DNA is         .
Many of these cells may not be capable of producing infectious virions upon
reactivation. Limiting-dilution co-culture assays [325] measure the fraction     of resting
CD4 T cells that produce replication-competent virus following cellular activation. The
113total number of these cells is           .
Experiments show that    exceeds     by more than two orders of magnitude, but the
reasons for this discrepancy are unclear. Some portion of cells with HIV-1 DNA may
harbor defective provirus that cannot produce viral proteins. Others may contain intact
provirus, but evade co-culture detection for other reasons. These two scenarios can be
distinguished by full genome clonal sequencing of integrated provirus, from which defects
preventing viral replication may be identiﬁed [146]. Among those cells infected with
provirus but undetected in co-culture, let   be the fraction that nonetheless are shown by
sequencing to have all open reading frames intact. Then     , deﬁned as the frequency of
non-induced, intact provirus-containing cells, is                   .
The quantity of interest for our model is the number of resting CD4 T cells harboring
proviral DNA capable of causing infection of other cells. This latent reservoir contains    
cells, or a fraction     of  . At minimum, it includes those cells tested positive by
co-culture, and at maximum, it includes all cells containing intact proviruses. It is likely to
be less than the upper bound, since even cells with intact provirus may be incapable of
re-starting infection due to integration into a transcriptionally silent site, or due to other
defects that escaped detection.
6.1.1.2 Size of the latent resevoir and interpatient variability
The size and composition of the latent reservoir can vary signiﬁcantly between patients.
This variation is relevant to variation in rebound time. Based on results in [104, 146], we
can calculate the average parameters and estimate the population level distributions:
Table 6.1: Estimated population level distributions of measures of latent reservoir size
Quantity Average Distribution
                                 
                          
  0.14                     
114The distributions were estimated by assuming the ranges observed in these study of
approximately 30 patients represent the center 95  of the distribution (ie 2 standard
deviations). We examinine three diﬀerent cases for inter-patient variability:
Case 1: All patients have the same LR size, which equals the average value measured
in co-culture assays (         ).
Case 2: The fraction     varies among patients as in the table above, and          
for each patient.
Case 3: The fractions   ,    , and   are sampled from the above distributions,
subject to the constraint         . Then      is computed. The value          is then
sampled uniformly from the interval                     .
Inter-patient variability in outcomes is lowest for Case 1 and highest for Case 3.
Throughout this paper, we assume the only parameters that vary between patients are
those related the composition of the reservoir.
6.1.1.3 Estimating the number of virion-producing cells
The value    is deﬁned as the fraction of resting memory CD4 T cells that are capable of
producing virions that are detected in viral load assays, regardless of whether these virions
are infectious. This value is used to calibrate the reactivation rate   from observed residual
viral load values (Eq. (6.2), below). While              , we cannot establish the
relationship between    and     , as some cells in      may harbor transcriptionally
silenced provirus, and conversely some cells in    may harbor provirus with detectable
defects. As an intermediate estimate we assume                            , though we
also consider the two extreme values in the best and worst case scenarios discussed in the
main text.
1156.1.2 Estimating viral dynamics parameters
Death rate of actively infected cells   
The parameter    has been measured in many treatment initiation studies to be 1
day   [214]. In the stochastic model we constrain               day  .
6.1.2.1 Activation rate of latently infected cells  
Parameter   is estimated from observed viremia during fully supressive HAART treatment
(      ). Among patients, residual viral load is highly correlated to LR size [17]. Since
reservoir decay is slow compared to the dynamics of actively infected cells, the residual
viral load reaches a quasi-steady-state relative to the size of the latent reservoir (Section
6.1.3.2). At this level, the number of actively infected cells is
    
   
  
(6.1)
Here    is the number of cells in the LR capable of causing productive infection at the time
HAART is interrupted, which is equal to     , as described in Section 6.1.1, above.
The value    may be estimated from residual viral load measurements. Let   be the
proportionality constant such that    (residual number of infectious virions during
HAART) equals    . Since viral load measurements do not distinguish between infectious
and noninfectious particles, the only quantity that may be ascertained is the total number
of virions   , which exceeds   . Assuming that infectiousness of the released virion aﬀects
neither viral burst rate nor decay rate, the same proportionality constant   applies to the
number of cells capable of producing (infectious or noninfectious) virions, written     ,
resulting in the relationship           . Since                , the value of   equals:
   
    
    
(6.2)
116A reasonable estimate for the proportionality constant is      , as discussed in Suppl.
Materials of [296]. We use        HIV-1 RNA copies per milliliter plasma, c ml  ,
corresponding to       plasma virions for a 70 kg person with 3L plasma, and we use
        . Based on the observed averages              ,           , and         , we
estimate                 and              day  . This activation rate is below previous
estimates [311] [287], which would predict a higher residual viral load than observed for
patients on fully suppressive HAART. However, because the size and composition of the
LR are still a matter of debate, we consider a range of values. For a worst-case scenario of
high activation rate, we suppose that only cells testing positive in co-culture contribute to
residual viremia (                and             ). For a best-case scenario of low
activation rate, we suppose that residual viremia is seeded from all cells harboring HIV-1
DNA (                   and         ). Results for these scenarios are shown in
Figs. 5.4 and 6.8.
6.1.2.2 Viral rebound threshold  
A viral rebound threshold of 200 c ml   corresponds to         plasma virions (for a 70 kg
person with 3 L plasma). Using the estimate       above, the number of actively infected
cells at rebound is            . Model results are not sensitive to this value, as rebound
probability depends on the logarithm of   (Section 6.1.3, below).
6.1.2.3 Death rate of latently infected cells   
Resting memory CD4 T cells die at a rate   , which may be estimated from studies
measuring the total decay rate of the reservoir,       . Given a mean half-life of 44
117months [327], we estimate    to be
    
     
     days
   
          
  day
  
(6.3)
This parameter is varied to explore a range of half-lives in Figs. 5.3, 5.4, 6.6.
6.1.2.4 Viral fitness   
The combined viral ﬁtness parameter    can be estimated from rebound times measured in
HAART-interruption studies [88, 298]. The average rebound time in these studies is twelve
days, which consists of both the time needed for drug levels to decay such that the
infection can grow and the subsequent time needed for exponential viral growth to rebound
levels computed in Equation (6.23). For estimating the drug decay time, we used the
method of [159, 319] with a typical regimen of AZT, 3TC, and SQV. For Equation (6.23),
we used a rebound factor (described in Section 6.1.4) of          , based on residual viral
load        c ml
  , infectious residual viral load        
   
            c mL
   (using
average values of     and    in Section 6.1.1, above), and detection at 200 c ml  . We
compute a value of       , at which it takes about four days for drug levels to decay and
another eight for viral growth to rebound levels.
6.1.2.5 Infectivity variance  
Based on the rate at which patients fail therapy due to drug resistance, a previous study
estimated the rate at which cells that are fated to establish a lineage activate from the
latent reservoir to be about 4 per day, in the absence of treatment [268]. This estimate is
highly uncertain, as it is sensitive to measured mutation rates and ﬁtness costs of
resistance mutations.
Using our baseline values of              and          , the number of cells
118activating per day is 70. An extinction probability of                      (deﬁned in
Equation (6.8)) would make our baseline values consistent with the above estimate. Using
      , the implied   to obtain this lineage extinction probability is 28. To account for
uncertainty, we consider   between 2 and 50.
6.1.2.6 Birth and death parameters   and  
   and    do not uniquely determine the dynamics of the stochastic model because   and  
cannot be simultaneously identiﬁed. After choosing a value for   between 2 and 50, the
parameter   is calculated using the relationship           . The parameter   is then
obtained from the relationship           .
6.1.3 Stochastic model of viral dynamics
6.1.3.1 Stochastic process
The stochastic model of viral dynamics described in the text can be formally represented
as the reactions below:
      ... rate constant:  
     ... rate constant:   
       ... rate constant:          
     ... rate constant:  
(6.4)
In this notation   and   are individual actively or latently infected cells, respectively,
and the arrows represent events that lead one type of cell to become the other type. We
assume that an actively infected cell can either die (at rate  ) or produce a burst of virions
(at rate  ) that results in the infection of   other cells, where   is Poisson-distributed
random variable with parameter  ,        
         
   . After a burst event, the original cell
119dies. Since each birth event causes the death of the parent cell, the total death rate is
           . This model describes a two-type branching process. The reproductive ratio for
this model is        
   , where       . We do not explicitly track free virus, but assume it
is at a level proportional to the number of infected cells. This assumption is valid because
the rates governing the production of virus from infected cells and the clearance rate of free
virus are much higher than other rates, allowing a separation of time scales. Because we
are not interested in blips or other intraday viral dynamics, this assumption does not
inﬂuence our results. A method for calculating the proportionality between free virus and
infected cells is provided in Section 6.1.2, above.
6.1.3.2 Generating function analysis of the model
Let
             
[
 
     
                          
]
 
             
[
 
     
                          
] (6.5)
be the basic generating functions for the stochastic process, starting with one active cell
and starting with one latent cell, repsectively. Dummy variables   and   correspond to
active and latent cells, respectively. The backward Kolmogorov equations [169] can be
represented by the system of coupled ordinary diﬀerential equations
   
  
                                     
   
  
                           
(6.6)
with boundary conditions               and              . The birth term               
follows from the Poisson-distributed oﬀspring distribution with parameter  .
After LRA therapy, the initial reservoir size is   . The residual viremia    is determined
by activation-death equilibrium during HAART, and so it is Poisson-distributed with mean
120  0
   . The probability generating function corresponding to this initial condition is then
  0                   
 0    
[
   
  
               
]
  (6.7)
If the initial reservoir size is heterogeneous, then the relevant generating function is
given by the sum
∑
 0   0  0       , where   0 is the probability that a patient has   
latently infected cells following LRA therapy.
6.1.3.2.1 Probability that LRA therapy clears the infection The ﬁxed
points of the diﬀerential equations (6.6) give the ultimate extinction probabilities    and
  , starting with a single active cell and a single latent cell, respectively. The probability
   is the smallest root of the equation
                                     (6.8)
and the probability    of extinction starting from one latent cell follows,
    
  
      
 
 
      
    (6.9)
Using the above initial condition        , the clearance probability      is determined
by substituting these ﬁxed points into the generating function   0:
        
 0
     
[
 
   
  
        
]
  (6.10)
Deﬁne ϵ  
     1 
     , the probability that a latently infected cell is fated to activate and
establish a rebounding lineage (assuming no interference from any prior rebounding
121lineage). If this probability is small, then clearance probability is approximately
        
 
ϵ 0  +  +   
  
   
 ϵ 0 
(6.11)
where the second approximation follows from the fact that active cell dynamics are faster
than latent cell dynamics,   g      . The key parameter determining clearance probability
is therefore ϵ  , the expected number of latent cells fated to activate and establish a
rebounding lineage.
The observation in the main text that the target value of   (Fig. 5.4A) scales
logarithmically with the product of   and reservoir half-life follows from this computation,
since reservoir half-life is
     
    , and        
(
 
 0
)
.
6.1.3.2.2 Approximation of rebound probability with simplified birth
process By approximating the Poisson birth event with a simpler process where only
two new infections result per birth, closed forms for the generating functions can be
derived, allowing easier computation of rebound probabilities. In this approximation,
active cells die at “eﬀective death rate”    and give rise to two new active cells at “eﬀective
birth rate”   . Latent cell dynamics are the same as in the full model. The two parameters
are chosen to have the same extinction probability as in the original model,
  
  
      (6.12)
and the same expected growth rate (and thus the same   )
                        (6.13)
122The diﬀerential equation for active cells, analogous to the ﬁrst line of (6.6), is then
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)
             (6.14)
while the diﬀerential equation for latent cells is the same as in (6.6). The basic generating
functions for this simpliﬁed process can be solved in closed form,
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(6.15)
for the supercritical case        .
The generating function   0        for the process starting at the initial condition
described above is again deﬁned as in Eq. (6.7), now using the new functions   ,   . The
probability that there are   active cells at time  , written       , is equal to the coeﬃcient
of    in the Taylor expansion of          around      ,      . Repeated diﬀerentiation is
computationally costly and subject to compounded rounding errors, and Cauchy’s integral
formula provides an eﬀective alternative. Following [81], the probability that there are
more than   active cells at time   equals
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[
  0  
       
             
        
]
    (6.16)
Let      be the real integrand in this equation, which presents damped oscillations of
period   
   , where  
(
   
   
)
    for integers            
  . We treat each half-period
separately, deﬁning a sequence of approximations    (             ) where
    
∫        
 +1
   
 +1       . Each    (     ) is deﬁned by a trapezoidal rule, splitting the
interval
[
   
             
   
]
into 150 equal-width segments. Since a sharp peak appears at
      for certain parameter values, the value    is deﬁned using a global adaptive
123numerical integration routine (quadgk in Matlab R2012b).
Not every    must be computed to approximate the integral. In Section 6.1.3.4.1
below, we describe an eﬃcient method for selecting a small fraction of the    for
computation, yielding a several hundred-fold speedup. This method is more reliable for
this integral than the Euler summation approach presented in [1].
6.1.3.2.3 Estimating “target  ” for 50% probability of rebound A rough
estimate of the initial reservoir size    such that half of patients have rebounded at time  
can be obtained directly from the generating function   0        above. We used this rough
estimate as an initial guess for the search algorithm described in Section 6.1.3.4.4 below to
identify the target   values in Fig. 5.4B,C.
The probability that there are no actively infected cells at time   is   0       . If
suﬃcient time has passed to allow for substantial exponential growth (i.e.,          g ), then
the integral in Eq. (6.15) is dominated by values at large  , and so the fraction within the
integral may be treated as a constant,    
   . The probability is then
           0             
[
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(
     
        )
] 0
 
(6.17)
where the abbreviation             is shorthand for the expected growth rate. If,
furthermore, not so much time has passed that the reservoir may be depleted in many
patients, then
(
             )
≪   and the expression can be approximated:
            
[
             
(
   
 
  
)]
  (6.18)
Note that    has dropped out of this estimate; the rate at which active cells become
present is roughly             .
To account for growth to the rebound threshold  , we can use a point estimate for the
rebound time based on deterministic exponential growth starting at one active cell,
124 grow  
     
  . The rebound estimate then becomes
                  
[
             
(
   
     
 
 
 
  
)]
  (6.19)
The required initial reservoir size — and the corresponding target   — can then be
solved for, using                and the desired value of  . It follows from this
computation that the required    scales inversely with  . Since        
(
 
 0
)
, the target  
scales logarithmically with   and is relatively insensitive to   , as observed in the main text.
6.1.3.3 Simulation of the model
We use the Gillespie algorithm to track the number of latently and actively infected cells in
a continuous time stochastic process. We start with an intial number of latent cells
             and an initial number of actively infected cells    chosen from a Poisson
distribution with parameter            , where     is the pretreatment latent reservoir
size (described in Section 6.1.1). The simulation proceeds until the number of actively
infected cells reaches the threshold for clinical detection given by a viral load of 200 c ml  
(equivalent to             cells total). Because stochastic eﬀects are important only for
small  , we switch to a faster deterministic calculation when   reaches a level where the
probability of extinction is very low. This switch occurs when the probability that no
active cell currently alive establishes a growing infection,  
 
 , declines below     . For each
  value we perform     simulations.
6.1.3.4 Additional numerical methods
6.1.3.4.1 Approximation of the integral in Eq. (6.16) The sum
∑ 
      
described following Eq. (6.16), above, was approximated using the following algorithm:
1. Compute    for       to     InitialBlockSize    . Store the sum of these values
as  .
1252. Set NextK   InitialBlockSize. Set BlockSize   MinBlockSize. Set
NumToCompute   MinNumToCompute.
3. While NextK    , do:
(a) Initialize A    , B    .
(b) Split the block containing the values    from     NextK to
    NextK   BlockSize     into three sections:
i. FirstPart contains    for   from NextK to
NextK   NumToCompute    ;
ii. LastPart contains    for   NextK   BlockSize   NumToCompute to
NextK   BlockSize    ;
iii. MiddlePart contains all    in between. These values of    are not
computed.
(c) Compute an UpperEstimate for the sum
∑NextK BlockSize  
  NextK    by adding
together all    in FirstPart and LastPart, and then approximating the value
of each    in MiddlePart as the average of the ﬁnal two values in FirstPart.
(d) Compute a LowerEstimate for the sum similarly, except now approximating
the value of each    in MiddlePart as the average of the ﬁrst two values in
LastPart. Since the sequence    decreases in an alternating manner,
LowerEstimate   UpperEstimate.
(e) If LowerEstimate and UpperEstimate are too far apart (see Notes below),
increase NumToCompute by 2 and return to Step 3b. Otherwise, add the
average of the two estimates to   and continue.
(f) If NumToCompute   MinNumToCompute (indicating that the error
between upper and lower estimates was never so far apart as to require
increasing NumToCompute), increment A by  ; otherwise increment B by  .
126(g) Set NextK   NextK   BlockSize    . Reset NumToCompute to
MinNumToCompute.
(h) If A    B   NumRecentBlocks, then increase BlockSize by a
multiplicative factor of BlockIncreaseFactor, rounding to the nearest even
integer. Reset A    , B    .
6.1.3.4.2 Notes. LowerEstimate and UpperEstimate are required to have a
diﬀerence of less than   
         (ensuring a total error in   of under     ), and a log-ratio
of less than     . The parameter BlockIncreaseFactor is itself adaptive, increasing by
                BlockIncreaseFactor      immediately after Step 3h if B    ; but
decreasing by     (never dropping below     ) if B    .
6.1.3.4.3 Parameters used. InitialBlockSize      . MinBlockSize     .
MinNumToCompute    . BlockIncreaseFactor       . NumRecentBlocks    .
6.1.3.4.4 Binary search for   for 50% probability of rebound The estimate
in Section 6.1.3.2.3 is used as an initial guess for the post-therapy reservoir size    that
would produce a 50% chance of rebound. Survival probability  surv was computed for this
initial guess, using the method of Section 6.1.3.2.2. While  surv was not within      of    ,
a new guess for    was made using a bisection method: If  surv is too low (high), but a
previously computed value was too high (low), then linear interpolation was used between
the current and previous values to select a new    that is estimated to have  surv      . If
 surv is too low (high), but no previously computed value was too high (low), then the
guess for    was divided (multiplied) by   . For all results reported, between 3 and 8
iterations were required to obtain the desired  surv. Results were then converted to  
values for a given pre-treatment reservoir size.
1276.1.4 Deterministic model of viral dynamics
A deterministic model was used for two purposes: to provide an estimate of    (described
in Section 6.1.2, above) and to estimate the threshold   separating the growth-limited and
activation-limited regimes. The threshold value is deﬁned as that which equalizes the
deterministic rebound time and the expected waiting time until activation of the ﬁrst cell
fated to establish.
6.1.4.1 Model definition
A complete model of viral dynamics including the latent reservoir is shown in the ﬂow
diagram of Fig. 6.1. All variables respresent total amounts present in the body. State
variables  ,  ,  , and   are the number of infectable CD4 T cells, the number of
productively infected cells, the number of free virus particles, and the number of latently
infected cells, respectively. Productively infected cells produce virus at rate  , die at rate
  , and transition into latency at a rate  . Virus is cleared at rate   . The infectivity
parameter   determines the rate at which virus infects susceptible host cells. Host cell
dynamics are determined by production rate   and death rate   . Latently infected cells
reactivate at a rate   and die at a rate   . When population sizes are large, this model can
be described with a set of diﬀerential equations [181, 247, 269, 311]:
                   
                         
              
                   
(6.20)
Here we make a number of simplifying assumptions valid for understanding dynamics
leading to rebound. Because the terms   and    are an order of magnitude larger than
other rates in the system, we can apply a separation of timescales and assume that free
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a
Figure 6.1: Schematic of the deterministic viral dynamics model including the latent reservoir.
State variables  ,  ,  , and   are the number of infectable CD4 T cells, the number of produc-
tively infected cells, the number of free virus particles, and the number of latently infected cells,
respectively. Productively infected cells produce virus at rate  , die at rate   , and transition
into latency at a rate  . Virus is cleared at rate   . The infectivity parameter   determines the
rate at which virus infects susceptible host cells. Host cell dynamics are determined by produc-
tion rate   and death rate   . Latently infected cells reactivate at a rate   and die at a rate   .
virus particle levels change so quickly that they track infected cell levels. Formally, this is
accomplished by setting        , leading to           and only three diﬀerential equations.
For viral loads at or below rebound levels, uninfected CD4 T cells do not become limited
and can be assumed to remain at their pre-infection/post-long-term-HAART steady-state
level of         , and hence        . Moreover, at low viral loads, new inﬂux into the latent
reservoir can be ignored (     ).
These assumptions lead to the reduced set of equations:
                      
                 
(6.21)
where    is the combined viral ﬁtness parameter                describing the expected
number of secondary infected cells produced by a single infected cell introduced to an
uninfected host. As in the stochastic model described in Section 6.1.3, the initial conditions
129        are such that    is the reservoir size following LRA therapy, and — assuming that
latent cell dynamics are much slower than active cell dynamics (       ≪   ) — the
residual active infection is            .
6.1.4.2 Calculating rebound time from the deterministic model
Following HAART interruption (with or without LRA therapy), the number of infected
cells (and thus viral load) grows according to Equation (6.21) with latent cells at a
transiently constant value   . Let          be the infection size at which rebound is
detected (e.g.,   200 c ml  ). The parameter   is the “rebound factor”, the amount by
which the infection must grow in order for rebound to be detected.
This equation can be solved exactly:
         
       0        
      
  (6.22)
giving the time to rebound as
    
  
(
     0   
 0
)
          
  (6.23)
This equation is appropriate when cells exit the reservoir frequently (i.e. without
highly eﬀective LRA therapy). Incorporating reservoir decay negligibly changes the results
because        ≪  . In Section 6.1.2 above, this equation was used to calibrate    based
on observed rebound time   .
Following LRA therapy, the size of the reservoir is reduced to        . Let         .
Since the residual active infection    also scales by  , the rebound factor increases to    .
The time to rebound is now increased to
    
  
(
         0   
 0
)
          
(6.24)
130Eradication therapy therefore extends the rebound time by an amount ∆ :
∆           
 
 
          
  
(
                 
             
)
 
       
          
(6.25)
where the approximation is valid for               . This order relationship is very likely
to hold as the rebound factor is   100 or more. The only way for the relationship to fail
would be for    to be in a very narrow range just above 1.
6.1.4.3 Above a threshold  , the deterministic model disagrees with the
stochastic model
Under the deterministic model, rebound time increases only logarithmically with the
decrease in LR size. The stochastic model agrees with this relationship only in the
growth-limited regime, where activation of fated-to-rebound cells is common. At higher  ,
the waiting time until this activation occurs exceeds the deterministic growth time; in this
activation-limited regime, the stochastic model predicts rebound times well in excess of
those predicted by the deterministic model (Fig. 6.2). As a rough estimate, the waiting
time in the stochastic model is  
     1  0, where    is the probability that a reactivating
lineage goes extinct (deﬁned in Equation (6.8)). The threshold drug eﬃcacy    deﬁnes the
boundary between the two regimes. It can be estimated by solving numerically for the
log-eﬃcacy that sets deterministic growth time from Equation (6.24) equal to the
stochastic waiting time:
  
(
           0   
 0
)
          
 
 
                     (6.26)
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Figure 6.2: A fully deterministic model is a poor predictor of rebound times. A) Equa-
tion (6.25) was used to calculate the time to rebound for a given LRA drug eﬃcacy,  . The de-
terministic model assumes that LRA reduces the size of the reservoir and hence the residual viral
load by   orders of magnitude and then tracks the time for the viral population to grow to 200
c ml  . B) Rebound times calculated from the deterministic model for    = 2 are compared to
median rebound times calculated from the stochatic process. The models agree only for small  .
The   values where the models diverge corresponds to the transition between the growth-limited
regime and the activation limited regime.
This threshold can be observed in the upward inﬂection in the rebound time curves in
Figs. 5.3C and 6.2 occurring at     1 – 2.
Fig. 6.5 shows that    increases with pretreatment reservoir size     and decreases
with variance parameter  , since higher values of   increase the extinction probability   .
For pretreatment reservoir size          , reduction of approximately 30- to      -fold is
required to reach the activation-limited regime, in which substantial increases in rebound
time may be achieved.
6.1.5 Viremia during adminstration of LRA therapy
If LRA therapy reduces reservoir size by inducing activation of latently infected cells, then
an increase in viral load during therapy can be expected. The precise dynamics of viral
load during LRA therapy depend on the eﬃcacy and duration of therapy. To model these
dynamics, we assume LRA therapy is administered continuously for a period of time  
(ignoring pharmacokinetics) and increases the reactivation rate of latently infected cells.
During this time HAART is co-administered, and we assume no new infections can occur.
132Infected
( y’ )
Latently
Infected
( z )
d’y
dz
k’
dv
a’
Virus 
( v )
Infected
( y )
dy
a k
Natural activation:
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Figure 6.3: Schematic of viral dynamics during LRA therapy. (A) The model tracks latently
infected cells, actively infected cells, and free virus, distinguishing between cells in which HIV-1
transcription is reactivated by LRA ( ′) or naturally ( ). (B) Illustration of typical viral load dy-
namics during course of LRA therapy. LRA therapy increases the reactivation rate of cells from
the LR, causing residual viral load to increase. The timing and magnitude of this peak allow for
an estimation of the eﬃcacy  . We assume that HAART is administered for a short while be-
yond the end point of LRA therapy, preventing the reactivated cells from starting new infections.
All symbols are deﬁned in the text.
Since transcription at the HIV-1 LTR may be reactivated in resting CD4  T cells while the
cell otherwise retains a resting phenotype, cellular functions in these LRA-activated cells
may proceed at a slower rate [315]. We therefore track those cells reactivated by LRA
separately from those reactivated normally by antigenic stimulus.
The model we use to consider this scenario is shown schematically in Fig. 6.3A and
described formally in the next section. Since our goal is to track viral load during a period
when HAART is administered, we consider all cells capable of producing virions, regardless
of replication capability. As this collection of resting cells likely exceeds the LR by an order
of magnitude or more (   versus    , Fig. 5.2), and since therapy increases activation rate,
large numbers of cells can be assumed to activate daily, and a deterministic model similar
to the one presented in Section 6.1.4, above, suﬃces. Latent cells ( ) die at a rate    and
can be reactivated naturally ( ) or by LRA-induced mechanisms ( ′). Naturally reactivated
cells ( ) die at rate   , and LRA-reactivated cells ( ′) die at rate  ′
  (which may be lower
than   ) [315]. Free virus is produced at a rate   from naturally reactivated cells and a rate
 ′ from LRA-reactivated cells. Since induced cells may have smaller burst sizes [316],  ′
133may be less than  .
We use this model to relate change in residual viremia over time to the log-eﬃcacy of
LRA therapy,  . Deﬁne           ′     , the total rate at which   decays during
treatment. Assuming that this decay aﬀects latent cells regardless of whether the proviral
sequence is able to replicate, the fraction of the latent reservoir that remains after
treatment duration   is          . Log-eﬃcacy of therapy is             , resulting in the
relationship                  . Viral load approximately follows a biexponential curve,
generally reaching a peak quickly (time determined by the faster of the two rates    and
 ′
 ) and then decaying slowly (at the slower of the two rates) (Fig. 6.3B).
The height of this peak and the time after treatment initiation at which it occurs are
            
 ′
 
 ′
 
  
 ′
 
    
 ′
 
  
 ′
 
          
  
 
(6.27)
      
    ′
           
 ′
      
  (6.28)
where      2 c ml   is the residual viral load (not necessarily infectious) before LRA
therapy. This peak is reached before treatment ends if        ′
  and      
             .
Derivations for these results are provided in the next section, and examples for selected
treatment parameters are provied in Table ??. Even mildly eﬀective therapy (     ) can
result in large increases in residual viremia from the baseline level, appearing after a few
days of treatment. Viremia is lower if the same reservoir reduction   is achieved over a
longer treatment time  . Viremia is also decreased if LRA-induced cells have a lower burst
rate than normally activated cells ( ′      ). If LRA-induced cells have a longer lifespan
(    ′
     ), then peak viremia increases but is delayed.
In vivo estimates of LRA therapy eﬃcacy may be obtained from measurement of viral
load during therapy. Highly eﬀective therapy is predicted to result in large, observable
134Table 6.2: The timing and size of peak viremia, as well as viremia at treatment end, depend
on the eﬃcacy and duration of LRA therapy, the change in burst size, and the change in in-
fected cell lifespan. Therapy protocol is described in the text and illustrated in Fig. 6.3. Time
to peak viremia was calculated using Eq. 6.28. Peak viremia was calculated using Eq. 6.34, of
which Eq. 6.27 is an approximation. Symbol deﬁnitions are provided in the text. Parameters
used:   = 7   10   day  ,    = 4 6   10   day  ,    =    = 43   10  cells,    = 1 day  , and
   = 2 c ml   (implying  
   =  
     c ml   cell  ).
Log-
eﬃcacy
LRA ( )
Treatment
time ( )
(days)
Fold in-
crease in
burst size
( ′  )
Fold in-
crease in
lifespan
(    ′
 )
Time
to peak
(days)
Peak
viremia (c
ml  )
Viremia at
treatment
end (c
ml  )
1 15 1 1 2         500
1 60 1 1 3     100
1 180 1 1 4     30
1 180 0.1 1 4    4
2 15 1 1 2         100
2 16 1 1 2         100
2 180 1 1 4     7
4 15 1 1 1         5
4 15 1 10 4                
4 15 0.1 1 1        
4 15 0.1 10 4         800
4 60 1 1 2            
4 180 1 1 3        
increases in residual viremia during continuous administration (Table ??). It is important
to note that this conclusion applies only to forms of LRA that reactivate latently infected
cells without damaging viral production in these cells.
6.1.5.1 Detailed calculations
We extend Equations 6.20 and 6.21, tracking latently infected cells  , productively infected
cells reactivated naturally  , productively infected cells reactivated by LRA therapy  ′, and
135free virus  :
             
′        
              
   ′    
′     
′
  
′
            
′ 
′      
(6.29)
These equations incorporate the simplifying assumptions that fully eﬀective HAART
yields       , that uninfected CD4 T cells do not become limited and remain at their
pre-infection/post-long-term-HAART steady state level, and that new inﬂux into the LR
can be ignored.
Using the separation of timescale for virus dynamics ( ) and the initial conditions
         ,              ,  ′       , these equations can be solved:
          
    
      
   
       
  
        
       
   
  
 
    
 
′     
 ′  
 ′
      
  
        
  ′
   
      
         ′ ′   
  
 
(6.30)
where           ′     . Note that the timescale separation for      is based on the
assumption that  ,  ′, and    greatly exceed other rates, which may be violated if
LRA-reactivated cells have much smaller burst rate  ′ and/or much higher death rate  ′
 
than normally reactivated cells. In general this approximation may only slightly
overestimate viremia on the ﬁrst day after LRA is started.
The amount by which LRA therapy increases the reactivation rate ( ′) can be related
to the fraction to which the reservoir is reduced ( ), or equivalently, to the log-eﬃcacy
136            , after a treatment time  :
          
    
      
(6.31)
and so the reactivation rate is:
    
      
 
          
 
          
 
(6.32)
Note that some natural activation and cell death contribute to  , so that the absence of
treatment does not correspond to       but to                      , which is generally
small.
From these equations, we can determine the expected changes in residual viral load over
time during LRA therapy. The contribution to residual viremia from naturally activating
cells (initially        c ml  ) only decreases during treatment, as the reservoir is depleted.
If any increases in observable residual viremia occur in response to LRAs, it will come from
compartment  ′ activated by the drug. This contribution follows a biexponential curve,
increasing to peak value quickly (at roughly the smaller of the two times    ′
 ,      days),
then decaying more gradually to zero (at the smaller of the two rates  ′
 ,    per day).
We can calculate precisely the time of the peak in residual viremia due to contributions
from newly reactivated cells :
      
    ′
           
 ′
      
  (6.33)
137The viral load at this peak is:
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(6.34)
where             is the residual viral load before LRA therapy and         ′
 . The ﬁrst
approximation holds when   is small (if     is small compared to  ′
 ), and the second
holds when        ≪  ′ (    is large compared to       ). The peak viral load occurs
during treatment when         , which holds if and only if both   ′
      and
               ′
 , which places requirements on both treatment time (       ′
 ) and
treatment strength (     
              . When LRA is started, viral load approaches the
peak linearly with an initial slope of  ′  . Viremia at the end of treatment can be found by
substituting in   for   in Eq. (6.30).
1386.2 Supplementary Figures
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Figure 6.4: Clearance probabilities and rebound times following LRA therapy predicted from
model, versus infectivity variance  . A) Three cases for the population-level distribution of LR
size (see Section 6.1.1). Case i) All patients have the same latent reservoir size,     = 10 ,
estimated from the geometric mean number of cells that are capable of producing infection in
laboratory co-culture assays. Case ii) Latent reservoir size is distributed according to variation
observed in co-culture assays, with geometric mean 10 . Case iii) The latent reservoir includes
many cells that fail to be detected in co-culture but have intact viral genomes. B) Probability
that the reservoir is cleared by LRA. Clearance occurs if all cells in the reservoir die before a re-
activating lineage leads to viral rebound. C) Median viral rebound times, among patients who do
not have clearance. Each point shows the average of 10    10  simulated patients. D) Survival
curves for patients following LRA therapy. The percentage of patients who have not yet experi-
enced viral rebound is plotted as a function of the time after LRA therapy and interruption of
HAART. Curves are colored based on the eﬃcacy of LRA in reducing the size of the LR (  = 0
to 6, see legend). Results are shown for 10    10  patients, a half-life of 44 months,    = 2, and
  = 7   10   day  .
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Figure 6.5: LRA therapy eﬃcacies required for diﬀerent goals, plotted versus reservoir size
    for diﬀerent infectivity variances  . A) The threshold   that takes the patient into the
activation-limited regime, where stochastic waiting time contributes substantially to rebound
time (deﬁned in Sec. 6.1.4.3). B) The target eﬃcacy   at which at least 50% of patients still
have suppressed viral load one month after treatment interruption. C) The target eﬃcacy   at
which at least 50% of patients still have suppressed viral load one year after treatment interrup-
tion. D) The target eﬃcacy   at which at least 50% of patients have eradicated the reservoir
without experiencing viral rebound. Because some patients may go for a year without rebound
but then rebound later, the target   for one year oﬀ therapy is always less than that for a life-
time oﬀ therapy. Results are shown for 10    10  patients, a half-life of 44 months,    = 2, and
  = 7   10   day  .
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Figure 6.6: Survival curves for patients following LRA therapy depend on the size of the latent
reservoir and the reservoir half-life (varying   ).The percentage of patients who have not yet ex-
perienced viral rebound (viral load   200 c ml  ) is plotted as a function of the time after LRA
therapy and interruption of HAART. Curves are colored based on the eﬃcacy of LRA in reduc-
ing the size of the LR (  = 0 to 6, see legend). A)    = 0 day  , half-life is 330 months (27
years). B)    = 4 6   10   day  , half-life is 44 months. C)    = 4   10   day  , half-life is
6 months. Decreasing the LR half-life (increasing   ) makes survival times longer and clearance
more likely. Including interpatient variation (ii) makes the survival curves fall oﬀ more gradu-
ally, while allowing for higher reservoir sizes (iii) increases the required drug eﬃcacy. Solid lines
represent simulations, and open circles represent approximations from a branching process cal-
culation (Section 6.1.3.2.2). Results are shown for 10    10  patients,   = 20,    = 2, and
  = 7   10   day  
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Figure 6.7: Survival curves for patients following LRA therapy depend on the size of the latent
reservoir and the infectivity variance  . The percentage of patients who have not yet experienced
viral rebound (viral load   200 c ml  ) is plotted as a function of the time after LRA therapy
and interruption of HAART. Curves are colored based on the eﬃcacy of LRA in reducing the
size of the LR (  = 0 to 6, see legend). Increasing the infectivity variance   makes survival
times longer and clearance more likely. Including interpatient variation (ii) makes the survival
curves fall oﬀ more gradually, while allowing for higher reservoir sizes (iii) increases the required
drug eﬃcacy. Solid lines represent simulations, and open circles represent approximations from a
branching process calculation (Section 6.1.3.2.2). Results are shown for a half-life of 44 months,
   = 2, and   = 7   10   day  .
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Figure 6.8: Clearance probabilities and rebound times after LRA predicted from model for
alternate parameter choices. i) Best-estimate parameter values shown in the main text: reser-
voir size is predicted by the distribution of co-culture results (case ii),   = 7   10   day  ,
   = 4 3   10   day   (half-life of 44 months),    = 2. ii) Best-case-scenario, where reservoir size
is predicted by mean co-culture results (case i), half-life is short and strong stochastic eﬀects de-
crease clearance probability. Parameter values are   = 10   day  ,    = 4   10   day   (half-life
6 months),    = 2 2,   = 50, and     = 10 . This low estimate for   follows from the assump-
tion that all cells with HIV-DNA contribue to the residual viral load observed during HAART.
iii) Worst-case-scenario, when LR is large (case iii), cells reactivate frequently, are extremely long
lived, and smaller stochastic eﬀects mean most reactivating cells lead to rebound. Parameter val-
ues are   = 7   10   day  ,    = 0 day  ,    = 2,   = 2, median       7   10 . This high
estimate for   follows from the assumption that all virions in the residual viral load come from
cells with virus with intact provirus. The lower limit on    is realized if homeostatic proliferation
or other mechanisms balance reservoir decay caused by mechanisms other than reactivation.   
is always adjusted to ensure that the baseline rebound time following HAART interruption was
constant. All results are for 10    10  simulated patients.
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Infectious disease modeling of social contagion
in networks
7.1 Abstract
Many behavioral phenomena have been found to spread interpersonally through social
networks, in a manner similar to infectious diseases. An important diﬀerence between social
contagion and traditional infectious diseases, however, is that behavioral phenomena can be
acquired by non-social mechanisms as well as through social transmission. We introduce a
novel theoretical framework for studying these phenomena (the SISa model) by adapting a
classic disease model to include the possibility for ‘automatic’ (or ‘spontaneous’) non-social
infection. We provide an example of the use of this framework by examining the spread of
obesity in the Framingham Heart Study Network. The interaction assumptions of the
model are validated using longitudinal network transmission data. We ﬁnd that the current
rate of becoming obese is 2  per year and increases by 0.5 percentage points for each obese
social contact. The rate of recovering from obesity is 4  per year, and does not depend on
the number of non-obese contacts. The model predicts a long-term obesity prevalence of
145approximately 42 , and can be used to evaluate the eﬀect of diﬀerent interventions on
steady-state obesity. Model predictions quantitatively reproduce the actual historical time
course for the prevalence of obesity. We ﬁnd that since the 1970s, the rate of recovery from
obesity has remained relatively constant, while the rates of both spontaneous infection and
transmission have steadily increased over time. This suggests that the obesity epidemic
may be driven by increasing rates of becoming obese, both spontaneously and
transmissively, rather than by decreasing rates of losing weight. A key feature of the SISa
model is its ability to characterize the relative importance of social transmission by
quantitatively comparing rates of spontaneous versus contagious infection. It provides a
theoretical framework for studying the interpersonal spread of any state that may also arise
spontaneously, such as emotions, behaviors, health states, ideas or diseases with reservoirs.
7.2 Introduction
Social network eﬀects are of great importance for understanding human behavior. People
interact with a varying number of individuals and with some individuals more than others,
and this aﬀects behavior in fundamental ways. Sociologists have long studied social
inﬂuence through networks, and networks now routinely appear in investigations from
other ﬁelds, including economics[155], physics[362], public health[209] and scientiﬁc
publishing [35, 369]. Extensive reviews of social networks analysis, including investigations
of their structure and their eﬀect on social dynamics, include Mitchell[225],
Wasserman[360],Watts[362], Rogers[291], Jackson[155], and Smith[333]. Networks have also
long been known to be important in many areas of biology (reviewed by [216]), including
ecological food webs and the evolution of cooperation[202, 243, 252, 345]. Social networks
have also been studied as determinants of health (reviewed by Smith [333]), ranging from
determining the patterns of infectious disease spread [176] to the propagation of
phenomena such as emotions [55, 111, 142], smoking cessation [69] , obesity [68], suicide
[31], altruism[112], anti-social behavior [284], and online health forum participation [61].
146These studies suggest that on top of the physical environment, the social environment can
also be an important contributor to health. They have lead to suggestions that public
health interventions must be designed that work with the network structure and that the
network can be exploited to spread health related information[70, 333].
Within network studies, much work has focused on how information, trends, behaviors
and other entities spread between the individuals in social networks. These processes are
generally referred to as ‘contagion’. Such suggestions of contagious dynamics and the
possible relevance of network structure can be rigorously examined using mathematical
models of contagious processes. These can then be used to obtain accurate measures of
expected prevalences, interventional eﬃcacy, and optimized information ﬂow. Many
previous models have been proposed to study inﬂuential interactions between individuals.
Most of these have considered well-mixed populations, although more recent work has
focused on network-structured populations. The most well studied are classic
epidemiological models (like SIS and SIR) for the spread of microbial infectious diseases
[10], including spread in network-structured populations [22, 175, 219, 363], [266], [176].
Various related processes have been used to model social inﬂuence, with important
contributions including the same epidemiological models [86, 123], diﬀusion models
[29, 45, 208, 211, 224, 291], statistical mechanics type interactions [21, 58], and threshold
models[361](reviewed by Jackson [155] and Newman et al.[236]).
Each of these models, however, has one or more properties that are problematic for
studying social contagion. Many do not capture the probabilistic nature of contagion, or
the asymmetry inherent in traditional infectious disease (where the infected state spreads
through social contagion whereas the non-infected state does not). Others only consider
well-mixed populations, where everyone is inﬂuenced by everyone else, ignoring the eﬀect of
network structure. Most models inspired by epidemiology are not directly applicable to the
social spread of other phenomenon, because many phenomena that spread by social
contagion may also arise spontaneously. That is, it is possible to adopt a trend or behavior,
147or obtain information, from an outside source, without directly ‘catching’ it from a contact
in the network. In other words, on top of the probability of obtaining the infection from
each ￿infected￿ contact, there is also a non-zero probability of ‘automatically’ obtaining the
infection, independent of the local network. This ‘automatic’ non-social infection is not
included in traditional infectious disease models. Economic models for the diﬀusion of
innovations, based on early work by Bass [29], do take into account ‘automatic’ infection.
Individuals move from ‘susceptible’ (non-adopter) to an infected (adopter) state by
adopting a new product or idea, inﬂuenced by both social and non-social factors. However,
these models do not allow for recovery; because the innovation adoptions are assumed to be
permanent changes in behavior, individuals never move back to a susceptible state. This
results in the entire population becoming adopters at equilibrium. This does not reﬂect the
dynamics of many phenomena that spread socially, which may be repeatedly acquired and
lost (for example, happiness or obesity). Through a balance of infection and recovery, a
steady-state with multiple states of individuals coexisting can be reached. Finally, most
previous models make assumptions about the type of interaction between individuals, the
particulars of which are not usually validated with real data. Yet, long term behavior of a
model and the prevention strategies it suggests can depend critically on the speciﬁcs of the
interaction assumptions.
Here, we introduce a new model to study the spread of entities in a social network
which has all of the important properties listed above. We then analyze its characteristics
and show how it can be applied in diﬀerent contexts. This model is an extension of the
classical infectious disease model, combining features from other models mentioned above.
It describes infections that can be contracted both spontaneously and through social
(network-structured) transmission, and allows for recovery from infection. As an example,
we focus on the spread of obesity in the Framingham Heart Study (FHS) network. The
interaction assumptions of the model will be validated using longitudinal network
transmission data. We show how we can quantitatively assess the values for the rate of
148adopting a trend spontaneously versus by contagion to determine the extent to which
social transmission is important. We use it to predict prevalences and intervention
eﬀectiveness (i.e. get quantitative output, not just qualitative behavior). The results of this
model are very diﬀerent from models with other interaction assumptions, such as the
‘majority rules’ models. We will show that transmissive components are often small
compared to the automatic component, but may still contribute materially to prevalence
levels. Lastly, we will use pair-wise approximations to generate analytic results for
infections in network-structured populations, as well as presenting simulations using a real
social network.
7.3 Methods
7.3.1 Classic infectious disease modeling
In the simplest infectious disease models [10], individuals are classiﬁed as occupying one of
two states: ‘susceptible’, meaning they do not have the disease, and ‘infected’, meaning
they do have the disease. The disease can be transmitted to a susceptible person when
they come into contact with an infected person. The rate of this disease transmission from
infected to susceptible is deﬁned as  , the transmission rate. Once an individual is infected,
they recover from the disease at a constant rate  , regardless of their contacts with
susceptibles or infecteds. In one class of disease models (susceptible-infected-recovered, or
SIR), recovered individuals become immune to further infection and enter a ‘recovered’
state. However, behaviors, trends, health states, etc, can occur many times over an
individual’s life, and therefore we assume infected individuals return to the susceptible
state after recovering. This form of susceptible-infected-susceptible (SIS) model is used to
model infectious diseases that do not confer immunity, like many STDs.
1497.3.2 Application to social contagion
In the standard SIS model, infection can only be transmitted by having a contact between
an infected and a susceptible individual. Social ‘infections’, however, can also arise due to
spontaneous factors other than transmission. Therefore, we extend the SIS model by
adding a term whereby uninfected individuals spontaneously (or ‘automatically’) become
infected at a constant rate  , independent of infected contacts. A diagrammatic
representation of our modiﬁed SIS model, which we will call SISa, is shown in Figure 7.1.
The corresponding diﬀerential equations for a well-mixed population are described in
Eq. 7.1
                     
                      
         
(7.1)
where   is the number of infected individuals,   is the number of susceptible individuals,  
is the population size,   is the transmission rate,   is the recovery rate, and   is the rate of
spontaneous infection. This model assumes a constant population size and neglects birth
and death. The SISa model is related to infectious disease models with ‘imports’
(migration of infecteds into the population), although here the rate of spontaneous
infection is proportional to the number of susceptibles, while in import models it is a
constant or proportional to the total population size.
In the infectious disease literature, a disease is said to be ‘endemic’ if a stable, non-zero
fraction of the population is infected at steady state. If a single infected individual is
introduced to a totally susceptible population, then the average number of secondary
infections they cause before recovery is called the basic reproductive ratio,   . For the
regular SIS model in a well-mixed population of N individuals,          . An epidemic,
150Figure 7.1: The SISa model of infection. There are three processes by which an individual’s
state can change. (i) An infected individual transmits infection to a susceptible contact with rate
 . (ii) A susceptible individual spontaneously becomes infected at rate  , regardless of the state
of their contacts. (iii) An infected individual returns to being susceptible at rate  , independent
of the state of their contacts.
leading to an endemic equilibrium, only occurs for       , and hence    is a fundamental
quantity used to describe and compare infectious diseases. For the SISa model, an
epidemic occurs for all parameter values, due to the spontaneous infection term. Thus,
social behaviors that can be adopted independently of neighbors mean that there is no
longer a threshold for the behavior to become prevalent in a population, and even in the
absence of contagion there would be a non-zero steady state prevalence. Because of this,
there is not an obvious deﬁnition for    in the SISa model. The steady state fraction of
infected individuals in a well-mixed population is given by Eq. 7.2.
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7.3.3 Infectious diseases on networks
Traditional models of infection assume that the population is well-mixed. However, this
assumption is unrealistic for many diseases, and also for the social spread of trends and
behaviors. To account for the population structure, the infectious process can be
151constrained to take place on a social network. An infected individual can only pass their
infection on to the suspectibles to whom they are connected. Properties of the infectious
process thus depend on both the epidemiological parameters and the network structure,
and there are often no longer simple analytic formulas to describe the reproductive ratio or
steady state level of infection. For example, a property of disease spread on networks are
spatial correlations (in the network sense) that arise between individuals in the same state.
This correlation is deﬁned as the ratio of the observed number of connections between two
types of individuals to the number of connections expected if the positioning of individuals
in the network was random. Spatial correlations of like individuals can be caused by an
infective process spreading within a network [175], but may also be caused by confounding
environmental factors which similarly inﬂuence the behavior of connected individuals, or
the formation of contacts based on similar behavior (also called homophily). For a network
of N individuals with a total of E connections between them, the correlation between two
states X and Y is deﬁned by:
     
observed number of X-Y edges
expected number of X-Y edges
 
     
            
(7.3)
The correlation between infected individuals,    , rises above one as the epidemic
proceeds, due to cluster formation as infected individuals transmit to their contacts.
Similarly, the correlation between infected and susceptible individuals,    , drops below
one. The deviation of these correlations from 1 increases with (i) the ratio of transmissive
infection ( ) to spontaneous infection ( ) in our model (there are no correlations without a
transmissive component), and (ii) the inter-connectivity (transitivity) of the network. As a
result of these spatial correlations, diseases on networks can progress more slowly than
their well-mixed counterparts, leading to lower basic reproductive ratios. However,
heterogeneity in the number of contacts per individual acts to increase   . For two
152networks with the same average degree, if one has a larger variance in degree, then    will
be increased. Thus, it is possible for diseases on networks to have lower (or nonexistent)
thresholds for endemic epidemics.
7.3.4 Approximate pair-wise equations
There are no analytic methods to solve SIS-type dynamics on arbitrary networks without
making approximations. Thus, simulations are a more accurate tool to explore theoretical
disease dynamics in structured populations without making simplifying assumptions about
the network structure. For scaled, well-mixed populations, the formulas given in the
previous sections for    and    are good approximations if   is replaced with  , the
average contacts at a given time, while ﬁxed networks, especially if non-uniform and highly
inter-connected, can deviate from these values signiﬁcantly. We can use a pair-wise
approximation [99, 175, 283] to formulate the infectious process on a network structure in
terms of diﬀerential equations. The fundamental variables are numbers of individuals of
each type, and also the pairs of individuals, [XY] (where the edges are not directional).
Because [XY]=[YX], and the total individuals and total edges is constant, the system can
be reduced to three equations.
                           
                                           
                                                                  
(7.4)
Here [XYZ] represents the number of situations where and X individual is connected to
a Y individual who in turn is connected to a Z individual. We can approximate all these
triples in terms of pairs, using a moment closure approximation ([283], §7.6), which then
153reduces the number of variables to three also. Then these equations can be simpliﬁed to
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with
        
             
             
(7.6)
where   is the number of contacts each individual has and ϕ is the transitivity of the
network (the ratio of triangles to triples). Having a simpliﬁed set of equations is very useful
for understanding contagion dynamics in structured populations. Integrating equations is
much faster than running simulations on large networks, and from them analytic results
can be derived which allows determination of parameter dependence. These equations
assume that the local neighborhood for each individual is identical, that is, everyone has
the same number of contacts ( ) and the same ϕ. They thus take into account the eﬀects
of ﬁxed network structure but not heterogeneities between individuals. In the
Supplementary Information (§7.6) we have included the extension of these equations to
include heterogeneities. These equations can be used to easily simulate disease spread and
get expected steady state prevalences and correlations, which are very useful
approximations and give insight into parameter dependence. Later, we will compare these
equations to results from full simulations on realistic networks. When ϕ     (which is
154approximately the case for most random graphs) we can get a closed-form solution for the
prevalence at steady state:
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The result of a network structure is that the number of partnerships between
susceptible and infected individuals quickly becomes less than if random, and so        .
We can compare Eq. 7.7 to the well mixed result (Eq. 7.2), and see that the eﬀect of the
network is to lower the eﬀective transmission rate by a factor of    , and hence lower the
prevalence, due to these correlations that build up locally. The larger   is compared to  ,
the more network eﬀects are important. If infection is mostly automatic (when      0),
the network no longer matters. Equation 7.7 actually holds generally (for any homogeneous
network and any ϕ value), while Equations 7.8 and 7.9 are only applicable with ϕ=0.
Analyzing the n-regular pair-wise equations allows us to get analytic results and
determine how and under what conditions network structure aﬀects the spread of behaviors
which are both spontaneously acquired and spread interpersonally. Although simple
closed-form solutions do not exist when ϕ is non-zero, these equations can easily be
integrated or numerically solved to get solutions. These equations ignore heterogeneities in
the number of edges for diﬀerent individuals, which can facilitate spread under some
conditions (see supplement §7.6 for extension). Full stochastic simulations on large
networks can be carried out to determine how and when the results diﬀer.
1557.4 Results
7.4.1 Calibrating model with FHS Network data
The SISa model provides a formal way for assessing the social contagion of trends and
behaviors that may be repeatedly caught and recovered from. Using data from the
Framingham Heart Study (FHS)[90] we tested the validity of this model and estimated
transmission parameters for various health related behaviors, though the focus here is on
obesity as an example. To both demonstrate that obesity can display infectious-disease-like
dynamics, and to estimate values for the model parameter    , and  , we use dynamic
information about transitions between states based on our multiple time points of data.
For data points separated by time intervals (∆ ) smaller than the average time between
transitions, the transition probabilities can be linearized. The probability of a transition
from susceptible to infected after a time ∆  can be given by         ∆              ∆  ,
and the probability of transition from infected to susceptible after time ∆ , by
        ∆      ∆ . It is necessary for the time between measurements to not be
comparable to or greater than the average lifetime of a state to keep the probability of
double transitions within a time interval low.
This epidemiological approach to social contagion has important diﬀerences from other
models which look at correlations in present and past states of connected individuals. Here,
similar to others [9, 68, 69, 111] we look at how contacts inﬂuence the transitions between
states, which better captures the nature of contagion. Since we use pre-existing social ties,
we do not see eﬀects from selection bias in choosing friends with similar states.
Additionally, time invariant confounding events that lead to concurrent changes in
connected individuals will not show up as contagion eﬀects in this model.
The dataset we use is a subset of individuals from the Framingham Heart Study [90].
This study was initiated in 1948 in Framingham, Massachusetts and has continued
enrolling subjects through the present. We examined individuals in the Oﬀspring Cohort,
156enrolled starting in 1971. Subjects come to a central facility at regular intervals
(approximately every 4 years) for medical examination and collection of other survey data.
Body mass index (BMI) was measured at each exam, and obesity was deﬁned as BMI   30
[59]. All other, lower, weights, which include underweight, normal range weight and
over-weight, were classiﬁed as ’not obese’. In additional to information on mental and
physical health, subjects were asked to name at least one close friend at each exam, and
were also connected to all ﬁrst-order relatives, as well as coworkers and residential
neighbors. For each subject, the following social connection data is available: (i) each other
person to whom they were connected, (ii) the dates of initiation and termination of that
relationship, (iii) the type of relationship (neighbour, coworker, ﬁrst-degree relative, or
friend), and (v) the geographic distance between the two subjects. The social network for
each exam was constructed by creating a network matrix G, where          if subject  
nominated subject   as a connection before or during the time that subject   was
administered exam  . All relationship types are mutual except for friendships, which are
self-nominated, such that      ̸       is possible for friendships.
To study the transmission of obesity, we examine changes in BMI between sequential
exams. Seven exams were administered to the Oﬀspring Cohort between 1971 to 2001,
with network data collected for each. We examine transitions occurring between each
exam. The average fraction of the network that was classiﬁed as obese increased between
these seven exams, suggesting the transmission process is not yet at steady state (Exam 1:
14  obese; Exam 7: 29  obese). Each set of exams were closely and consistently spaced (
∆            year (exam 1),     year (exam 7)). In general when modeling an infectious
process, the rates of infection and recovery are assumed to be constant over time, with the
prevalence changing as the infectious process begins and ﬁnally reaches equilibrium or is
eliminated. When examining the spread of obesity using longitudinal data on transitions
between exams, we can actually test this assumption and detect changes in the rates
themselves.
157A given state   is considered infectious if having more contacts in state   makes you
more likely to switch to state  . That is, a positive relationship between the number of
contacts in state   and the probability to transition from state   to state   indicates that
state   is infectious with respect to state   . Therefore, to test whether a given state   is
infectious with respect to another state   , we perform an ordinary least squares (OLS)
linear regression as follows. Each subject in state   in exam N is coded as either having
transitioned to state   (transition=1) or not (transition=0) in exam N+1. We then
regress this binary transition variable for each subject against the number of contacts in
state   that subject had during exam N. A signiﬁcant positive correlation indicates that
having more friends in state   at the earlier exam makes you more likely to switch to state
  in the later exam. If state   is infectious (a signiﬁcant positive correlation exists), then
the value of   can be calculated from the slope of the regression line, and the value of   can
be calculated from the intercept. If state   is not infectious (no signiﬁcant correlation
exists), then the value of   can be calculated from the intercept. ∆  was taken as the
average time between examinations, which varied between exams from 3 to 8 years. Using
logistic regression as opposed to OLS regression gives very similar results, as the datapoint
line is within the linear range of the logistic model.
The structure of the Framingham Heart Study social network varies over the course of
time, ranging from 7500 individuals with an average of 5.3 connections each at the ﬁrst
exam, to 3500 individuals with 2.8 connections on average at the seventh exam. Summary
statistics are presented in the supplement (Table 7.2). These changes in population size
and average degree occur because individuals may die or drop out of the study but new
individuals are not added. The network is approximately Poisson distributed (see
Figure 7.2), although with some subjects having no connections. The transitivity ϕ is
consistent over time at approximately 0.64. While neighbors were included as contacts in
the study, like Fowler and Christakis[68] we ﬁnd no signiﬁcant trends when including
neighbors, and so did not include these contacts. For friendships, we only consider the
158contacts of an individual to be those other individuals whom they nominated (other
relationships are all mutual), and so the network is directional.
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Figure 7.2: The degree distribution of the Framingham Heart Study social network at the most
recent exam (7) considered in this study. Connections include friends, family and coworkers. The
average degree is around k=3 and the transitivity is ϕ=0.64 (the ratio of triangles to triples).
The results of infectiousness analysis for the spread of obesity between exams 4 and 5
are shown in Figure 7.3 as an example. Consistent with the SISa model formulation, we
ﬁnd a signiﬁcant positive correlation between the probability of transitioning from ‘not
obese’ to ‘obese’ and the number of ’obese’ contacts (Figure 7.3A, coeﬀ=0.016, p=0.0001),
and no signiﬁcant relationship between the transition from ‘obese’ to ‘not obese’ and the
number of ‘not obese’ contacts (Figure 7.3D, coeﬀ=0.006, p=0.15 ). Additionally we ﬁnd
no signiﬁcant relationship between the probability of transitioning from ‘not obese’ to
obese and the number of ‘not obese’ contacts (Figure 7.3B, coeﬀ=-0.0005, p=0.75 ) , or the
probability of transitioning from ‘obese’ to ’not obese’ and the number of obese contacts
(Figure 7.3C, coeﬀ=-0.002, p=0.85 ). The same analysis was repeated for each interval
between sequential exams and very similar results were found. The full results from the
regression analysis are presented in the supplement (Table S2). This suggests that obesity
can indeed be modeled as an infectious process in the SISa framework, with ‘not obese’
susceptibles becoming ‘obese’ infecteds, and transmitting obesity to other susceptibles.
The parameters for the SISa model can be calculated from the transition probabilities
159mentioned earlier, by dividing slope and intercept values by ∆ , the average time between
exams. These values are reported for each exam in Figure 7.4, and the values at the latest
exam intereval are summarized in Table 7.1. For most recent exam, the transmission rate,
 , is found to be        /year. The spontaneous transmission parameter   is found to be
      /year. The recovery parameter   is found to be       /year. From these SISa model
parameters, other values of interest can be calculated. The ‘average lifetime’ of a state is
the average length of time and individual spends in this state before recovering, which was
found to be 24 years for this time period. The ‘inﬂuence’ of a state is the cumulative
probability that the infection will be passed from an infected to a susceptible connection
before the infected individual recovers, and is observed here to be 13 . The ‘cycle length’
is the average length of time between spontaneous infections, and is 53 years. The basic
reproductive ratio is approximately 0.35, which implies that without spontaneous
appearance, the obesity epidemic would not be self-sustaining based on transmission alone.
However this calculation is an approximation since uses the formula for a population that
is well-mixed but only eﬀectively contacting a fraction of the total population at each time
(  contacts), so does not factor in ﬁxed network structure (there is no analytic formula for
this situation). We observed a correlation in the positioning of obese and non-obese
individuals of    =1.3 and    =0.9.
Since these rates were measured for 6 diﬀerent inter-exam transitions over 30 years, we
can look at how the value of these rates changes over time. Figure 7.4 shows the measured
automatic infection (a), transmission ( ), and recovery rates (g) for each exam interval.
Error bars are 95  conﬁdence intervals on measurements from analyses like Figure 7.3.
While the rate of recovery ( ) has remained relatively constant since the 1970s, the rate of
spontaneous infection ( ) has steadily increased over time. The transmission rate,  , also
appears to have increased over time. These trends were tested using weighted regression
(to include the diﬀerent errors for each measurement) and found to be signiﬁcant for   and
  but constant for  . For the rest of the study we used the time-averaged value of  ,
160Table 7.1: Parameter estimates for obesity between exams 6 and 7 (1995-2001) using the SISa
model framework. The ‘average lifetime’ of a state is the average length of time an individual
spends in this state before recovering. The ‘inﬂuence’ of a state is the cumulative probability
that the infection will be passed from an infected to a susceptible connection before the infected
individual recovers. The ‘cycle length’ is the average length of time between spontaneous infec-
tions. The basic reproductive ratio is calculated by setting   = 0. However this calculation is
an approximation since it does not factor in ﬁxed network structure. Since      1, the obesity
epidemic would not be self-sustaining based on transmission alone.
Parameter Description Value
a rate of spontaneous infection      /yr
g rate of recovery      /yr
  rate of transmission through contact        /yr
1/a cycle 53 years
1/g lifetime 24 years
     
   
  inﬂuence 0.13
          basic reproductive ratio 0.35
         . This suggests that the obesity epidemic may be driven by increasing rates of
becoming obese, both spontaneously and transmissively, but not by decreasing rates of
losing weight.
We also found that both happiness and depression ﬁt the SISa model, both being
contagious from a neutral emotional state[142] , that smoking cessation, though not
smoking itself, also ﬁt, and that both alcohol consumption and abstinence were contagious
from the opposite state (data not shown). For all of the above cases, we tested if the
transition probability depended instead on the fraction of contacts in a state, instead of the
number, and found no signiﬁcant dependence. We also tested for dependence on other
personal attributes such as age, sex and education, and found no dependence in most cases.
For obesity, the transition probability from not obese to obese decreased slightly with age
(coeﬀ=-0.0012, p=0.04). Our results show that many models of social inﬂuence make
assumptions about interpersonal interactions that are not supported by this longitudinal
data. One of these assumptions is the ‘majority rules’ interaction, which assumes that
people will be most likely to switch to the state most of their contacts are in[21]. Here,
transitions depend on the number of contacts, and only certain states (those we class as
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Figure 7.3: Evidence for disease-like spread of obesity. Obesity behaves like a disease agent, in-
fecting those in a susceptible ‘not obese’ state. The probability of transitioning from ‘not obese’
to ‘obese’ increases in the number of ‘obese’ contacts (A), and doesn’t depend on the number of
‘not obese’ contacts (B). Conversely, the probability of recovering to the ‘not obese’ state does
not depend on the number of ‘not obese’ contacts (D) or the ‘obese’ contacts (C)). Labels above
points on plot are the number of observations averaged into that data point, and error bars are
the standard error of the proportion.
’infectious’) actually inﬂuence transitions (in other words, contagion is only in one
direction). This has signiﬁcant eﬀects on the predictions for epidemic progression. For
example, ‘majority rules’ models predict 100   infected at steady state, and that weight
loss behavior spreads and so an eﬀective intervention is to ‘pin’ certain individuals at low
weights. Also, many models assume that the probability of transitioning to a state is zero
if no contacts are in that state, but these results show that there is a constant probability
of spontaneously becoming ’infected’. Finally, using this framework, we can get rates for
transitions, and hence have an idea for the time-course of the progression, not just the ﬁnal
outcome.
1620 1 2 3 4 5 6 7
0
0.01
0.02
0.03
0.04
0.05
A
exam
r
a
t
e
 
(
/
y
e
a
r
)
 
 
0.030
0.008
0.039
0.011
0.027
0.018
0.035
0.018
0.033
0.021
0.043
0.019
0 1 2 3 4 5 6 7
0
0.002
0.004
0.006
0.008
0.01 B
exam
r
a
t
e
 
(
/
y
e
a
r
)
 
 
0.0012
0.0021
0.0035
0.0042 0.0041
0.0050
recovery rate (g)
automatic infection rate (a)
transmission rate (  )
Figure 7.4: Change in observed parameters over time. Parameter measurements for obesity
from each set of consecutive exams. Data point at exam N represents the value for the transition
from exam N to N+1. Error bars are 95% conﬁdence intervals on measurements from regression
of transition probability versus number of contacts of a certain type. (A) Contact-independent
rates. The rate of recovery ( ) appears to be constant within the margins of error throughout the
study while the rate of automatic infection ( ) appears to increase between exams 1 and 3, then
stay constant. (B) The contact-dependent transmission rate ( ) appears to increase over time.
7.4.2 Case study: Modeling the obesity epidemic
In this section, we will use the SISa model to make predictions and evaluate interventions
for the obesity epidemic, using the parameters observed in the FHS data. For simplicity
and generality, we will keep the parameters   and   constant at the values observed for the
most recent exams, and use the time-averaged value of  . Since we are mostly interested in
predicting future trends, and the parameters seem to have relatively constant values over
the ﬁnal decade, this simpliﬁcation should not aﬀect these predictions. We also keep the
network ﬁxed at the structure observed at Exam 6, except when we compare to historic
data. While the simpliﬁed pair-wise equations we present are designed for symmetrical
networks, they can be approximately adapted to directional networks by letting   represent
the average out-degree (average number of inﬂuential contacts) instead of the total number
of contacts. In the Framingham data, greater than 90  of contacts are symmetrical, and so
there is little error in this approximation. For hypothetical networks were the contacts
formed by out-degree and in-degree are very diﬀerent sets of individuals, deviations are
expected. Figure 7.5 shows the results of both the n-regular pair-wise equations and a full
163simulation on the FHS network for the spread of the obesity epidemic. The parameters
used were those measured from FHS as discussed earlier. One of the important properties
of the SISa model is that it always leads to a stable coexistance of both infected and
susceptible individuals, with infecteds becoming 100  prevalent only in the limit as   or  
approaches inﬁnity. This is very diﬀerent from statistical-physics-based interaction models
where the population always ‘coarsens’ to everyone in a single state [21] . These results
show that for the parameters measured for obesity, the pair-wise equations are not
signiﬁcantly diﬀerent from the full simulations for predicting prevalence, and hence provide
a good substitute. The reason is that the spontaneous rate ( ) is signiﬁcantly larger than
the transmissive component ( ). For larger values of    , there is a noticeable diﬀerence (
shown in the next section).
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Figure 7.5: Simulations of obesity epidemic using SISa model. Time series of an epidemic
on the Framingham Heart Study network, using full simulations (light blue) or the n-regular
pair-wise equations (dark blue). Parameters used are those measured for the obesity epidemic:
  = 0 019   = 0 0050   = 0 035 ϕ = 0 64   = 3 0. In the SISa model there is a co-existance of
susceptible and infected individuals at steady state. For these parameters there is a good agree-
ment with simulations and the pair-wise equations for the fraction infected (A), but the equa-
tions predict less correlations (B), due to the neglect of heterogeneities in the number of con-
tacts.
This model predicts that, assuming the rates do not further change over time, the
steady state proportion of obese individuals will be 42  . While not great, this is a much
more optimistic estimate than 100   [21]. However, all of the parameters observed in this
164study have an error associated with them, and so there is some uncertainty in this
prediction. Figure 7.4 shows the ranges of the 95  conﬁdence intervals for these values.
We can estimate the uncertainty in this prediction by using ﬁrst the values of these
parameters, within the range of one standard deviation, that would give the highest
prevalence (                    ) and then those that would give the lowest
(                    ). We used  =0.05,  =0.015 and  =0.002 to get the minimum and
 =0.03,  =0.023 and  =0.008 to get the maximum. These simulations suggest the
conﬁdence interval for the expected prevalence can be approximated as 25  to 54 . This
model also allows us to estimate the time-course of the epidemic, and suggests it would
take around 40 more years for the obesity prevalence to be within 1  of this maximum
value. At the ﬁrst time point in our data (1970), we measured the rates to be  =0.008,
 =0.03 and  =0.001, and the prevalence to be 14  . These parameters would have led to a
steady state prevalence of 24  , which suggests that the rates of becoming obese must have
originally been much lower than this.
We can also compare historical data on the obesity prevalence (from both national
studies [59]and the FHS data ) to the predicted time course shown here. To generate the
model prediction, we simulated an epidemic with the pair-wise equations but allowed the
rate values and network parameters to change as measured from the data (see Figure 7.4
and Table 7.2). We kept   constant at the average value observed, 0.035, and varied   and
  as observed. The value for parameter   measured for the transition between exam   and
      (  ) was used in the simulation for times (years) between the average examination
dates of exams   and      , and then increased to      for the next time interval. The
same was done for  . For times before the earliest data points in FHS for which we have
measured rate constants(pre 1970), we assumed the epidemic was at a steady state of 14 .
This could be achieved, for example, with            and      . Figure 7.6 shows that
there is a good match in the time course of the model with reality after 1970, with similar
rates of increase in the prevalence.
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Figure 7.6: Comparing SISa model timecourse to historical data. A comparison of historical
data on the prevalence of obesity in the Framingham Heart Study (blue dots) and the National
Health and Nutrition Examination Survey (red dots) with the timeseries predicted from the SISa
model with time-varying parameters. For the simulation, we allowed the parameters   and   to
vary as observed in Figure 7.4, but kept   constant at its average value. Before 1970 (when our
measurements started), the prevalence of obesity was assumed to be stable at 14%. The model
and the data both show very similar rates of increase, with a slow post-1970 increase, followed
by a rapid increase, and then increasing more slowly. The SISa model predicts the prevalence of
obesity will increase slowly to a peak at 42%.
We can use the pair-wise equations to see how the steady state prevalence depends on
various parameters, which is especially useful to see how interventions that aim to change a
certain parameter may aﬀect the prevalence. Figure 7.7 shows these results. For the
parameter values for obesity, although   is quite large,   is still important. If   changes
from 0 to 0.005, the expected steady state changes from around 0.35 to 0.42. However,
much larger changes can be realized by decreasing   or increasing  . For the obesity
parameters, completely removing the contagious component is only expected to change the
steady state prevalence by around 7  . However, changing the spontaneous infection term
can have much larger eﬀects. While a 50  change in   will result in only a 3  decrease in
I, cutting   in half will reduce the prevalence by 15 . However, a similar absolute decrease
of 0.005 would also lead to a 7  diﬀerence. The eﬃciency of changing one parameter
166versus the other can be looked directly at       for various parameters, which will be
shown in the next section.
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Figure 7.7: Fraction infected versus SISa model parameters. Dependance of the equilibrium
fraction infected on obesity interventions which act to change the rates of infection (trans-
mission (A) and ‘automatic’ infection(B)) or recovery (C). When not varying, parameters are
  = 0 019   = 0 0050   = 0 035 ϕ = 0 64   = 3 0
7.4.3 General properties of SISa model
In this section we will examine the more general properties of ‘infections’ following SISa
model dynamics. While Figure 7.5 showed excellent agreement between the pair-wise
equations and full simulations for the time dynamics, this is not true for all parameter
regimes. When   is larger and   is smaller (as shown in Figure 7.8), and the network is
strongly heterogeneous (as the Framingham network is), the pair-wise model deviates
more. The reason is that heterogeneous network eﬀects become more important for larger
 , and the pair-wise approximations are best for homogeneous networks. The extension of
the pair-wise equations to heterogeneous networks is described in the supplement (§7.6).
We can use the pair-wise equations to see how the steady state prevalence depends on
various parameters, which is especially useful to see how interventions that aim to change a
certain parameter may aﬀect the prevalence. Figure 7.9 shows how the steady state
changes with the rate of transmission,  . The blue line (     ) shows what would happen
in a classical epidemic, with no spontaneous infection. When   is below a certain value
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Figure 7.8: Pairwise equations diverge from simulations when transmission is higher. Time se-
ries of an epidemic on the Framingham Heart Study network, using full simulations (light blue)
or the n-regular pair-wise equations (dark blue). When the ratio of     is larger than that ob-
served for the spread of obesity, the pair-wise equations diverge more from the full simulations,
both for the fraction infected (A) and the correlations (B).   = 0 005   = 0 02   = 0 0045 ϕ =
0 64   = 3 0
(      ), the infection does not spread. The fraction infected increases rapidly with   in
this regime. As soon as we add      , this thresholding behavior disappears. When      
the steady state is less sensitive to  . The red line (        ) shows the approximate
parameter values for obesity. Here although   is quite large,   is still important. As with
classical infectious disease models [175], disease spread on a network leads to decreased
   , the spatial correlation between infected and susceptible individuals, and increase    
and    , the correlation between pairs of infected individuals and pairs of susceptible
individuals, respectively. If we look at     , we can see that we expect there to be some
correlations of infected people at some     values, but not all. So while seeing spatial
correlation may hint there is a inductive process, it is deﬁnitely not necessary. You can
have an infectious process without seeing correlations, just like you can see correlations
without it being caused by the dynamics of inﬂuence. Spatial correlation is much higher
when   is small.
Figure 7.10 shows the dependence on the rate of spontaneous infection,  . The more
spontaneous infection, the more infected. When   is larger ( red line), increasing   has less
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Figure 7.9: Dependance of the equilibrium fraction infected (A) and correlations (   :(B),
   :(C),    :(D)) on the rate of transmission,  . When     0, expected in most social infec-
tions, there is no longer a threshold (     1) needed for the infection to invade the population.
The network causes infected individuals to cluster       1 away from susceptible individuals
      1, and this is more pronounced for larger     and lower fraction infected. Parameters are
  = 0 035 ϕ = 0 64   = 3 0
eﬀect. The green line is for the parameters measured for obesity. We can use these graphs
to compare the eﬀects of various interventions which may reduce the rate of infection. In
Figure 7.9 (vs  ), we can see the expected decrease in the prevalence of the infection for a
given decrease in  . Changing   has more eﬀect when   is small. The rate of recovery from
an infection is  , and in the obesity case, represents the rate at which obese people lose
weight and transition to normal BMI values, in probability per year. Higher rates of
recovery lead to lower fraction infected (Fig. 7.11). One possible intervention is to increase
the rate of recovery. For low recovery values, this has a large eﬀect on  , but for   around
0.04 (the value for obesity), only small changes in   result from changing  .
In general, the spatial correlations (   ) are negatively correlated with the fraction
infected (I); more correlations are observed when a disease is not too infectious. If the
spatial correlations were ﬁxed to be a certain value (for example obese people cluster
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Figure 7.10: Dependance of the equilibrium fraction infected (A) and correlations (   :(B),
   :(C),    :(D)) on the rate of automatic infection,  . Parameters are   = 0 035 ϕ = 0 64   =
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together due to selection bias in friendships or confounding factors), then this would
actually serve to slow infection. Since we do not observe contagion of losing weight, it does
not seem like it would be beneﬁcial to have an intervention which broke up obese clusters.
The most direct way to compare various parameters for spread, and therefore
interventions that reduce one of the parameters, is to look directly at       for various
parameters (  is the steady state fraction infected,   is the parameter of interest.
Figure 7.12 shows that for most parameter regimes, it is always best to increase the
recovery rate,  , as a method to reduce the fraction infected,  . However, for low   and low
  , it is best to decrease the spontaneous infection term  , and for a window of
intermediate  , it is best to decrease the transmissive component  . The third plot shows
the results for the   value measured for obesity, and because   is low here we are in a
regime where it decreasing   has the most eﬀect, so this is the best intervention.
Many analytic models of network phenomenon assume the transitivity, ϕ, is zero,
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Figure 7.12: Determining the best parameter to target in an intervention. This graph compares
interventions which act to change diﬀerent parameters of infection (transmission (A), ‘automatic’
infection (B), recovery (C)). Shown is the rate of change of the fraction infected at equilibrium
with respect to a change in various parameters of infection. The y axis labels represent the ab-
solute change in the percent infected for a change of 0.01 in one of the parameters. Changing  
is better for small   and changing   is best for larger  . For intermediate  , changing   is best.
Parameters are   = 0 035 ϕ = 0   = 3 0
171meaning there are no triangles in the network. This is done to get the analytic expression
presented here (Eq. 7.2), which is not necessary to numerically integrate the pair-wise
equations, as presented in the results above. In the FHS network, we observed that ϕ is
0.64, suggesting human social networks are quite transitive. We want to examine the
importance of ϕ in predicting the fraction infected. For the observed    value, the eﬀect of
ϕ is negligible, as shown in Figure 7.13. The reason is that the dominant eﬀect here is the
spontaneous infection, which does not depend on the network structure. This justiﬁes
ignoring ϕ for infections that have only low infectivity terms. However, for large    values
(the equivalent of     2 is shown in Figure 7.14) ϕ has a more pronounced eﬀect. While
for a purely infectious process (blue line), at high ϕ, a disease can die out, even for       ,
when      , this doesn’t occur, but ϕ still slightly reduces the spread. It also results in
more observed spatial correlation of infected individuals. Overall, there is very little eﬀect
of ϕ in the SISa model.
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Figure 7.13: The dependence of the equilibrium fraction infected(A) and correlations (   :(B),
   :(C),    :(D)) measured from the pair-wise equations on the network transitivity, ϕ. For the
parameters measured for the transmission of obesity, shown here, there is no strong dependence
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Figure 7.14: The dependence of the equilibrium fraction infected (A) and correlations (   :(B),
   :(C),    :(D)) measured from the pair-wise equations on the network transitivity, ϕ. For
larger    , ϕ slightly decreases the fraction infected by leading to more spatial correlation of in-
fected individuals. Parameters are   = 0 02   = 0 035   = 3 0
We’ve already discussed how changes in parameters of infection aﬀect the steady state
prevalence, and we can consider this an analysis of diﬀerent types of public health
interventions that change rates of recovery, infection or network structure. In previous
analysis of the obesity epidemic done by Bahr et al[21] they suggest a strategy of ‘pinning’
groups of people to stay in a non-obese state, similar to vaccinating against an microbial
disease, as a method to remove the ‘infection’ from the population. However, in the Bahr
model this intervention works (if enough people are ‘pinned’) because becoming non-obese
is also contagious, which we don’t ﬁnd in this analysis. In the classical infectious disease
setting, vaccinating can lower    below the threshold for disease invasion, but in the SISa
model there is no threshold, and so neither mechanism makes this an eﬀective strategy in
the SISa model. Two other possible intervention strategies come out of this model. Firstly,
from Eq. 7.7 we can see that the fraction infected decreases with    , the correlation of
suceptible and infected people. If an intervention actively reduced this number, by isolating
173or clustering infected people, this could reduce the prevalence. Secondly, the fraction
infected could be reduced if it were possible to make the ‘susceptible’ state also contagious
through contacts.
7.5 Discussion
The SISa model oﬀers a framework for quantitatively analyzing and predicting the public
health aﬀects of socially contagious phenomenon. Using a longitudinally measured health
outcome and social network data, the SISa model can be used to determine the dynamics
of a health trend in terms of rates of acquisition, recovery and inter-personal transmission.
From these rates, the relative importance of social contagion can be determined, and
changes in prevalence over time can be predicted. The framework can also be used to
examine how these rates themselves change over time, helping to understand the
mechanisms behind drastic changes in disease prevalence, such as in the obesity epidemic
current eﬀecting the United States. Finally, understanding the dynamics of a health
behavior using the SISa model allows us to evaluate the beneﬁts of various interventions,
especially those that may work within social networks.
The prevalence of obesity in the Framingham Heart Study cohort has increased from
14  in the 1970s to 30  in 2000, and continues to increase. We ﬁnd that the most recent
rate of becoming obese is 2 per year and increases by 0.5  for each obese social contact.
The rate of recovering from obesity is 4  per year, and does not depend on the number of
non-obese contacts. These results show that obesity has an infectious character: obesity
can be acquired through social contagion as well as through non-social factors. Examining
over 30 years of data, we ﬁnd that these rates have changed throughout the course of the
study, with the rate of becoming obese through mechanisms other than social contagion
increasing approximately twofold since 1970, and the rate of transmission increasing
approximately fourfold. The rate of recovery, however, has changed little. These results
suggest that social norms are changing the propensity for becoming obese by non-social
174mechanisms, and also magnifying the aﬀect that obese individuals have on their non-obese
contacts. It is possible that while causing changes in prevalence, these rates may also be
responding to changing prevalences (i.e. more obese people leads to increased social
acceptability of obesity, which leads to higher rate of becoming obese), creating a positive
feedback mechanism and a continuously increasing obese fraction of the population. It has
been suggested that changing social norms that stigmatized smoking may have lead to it￿s
decline[182], and just the opposite may be true for obesity [63].
Using the SISa model with these parameter values estimated for obesity, we can make
predictions about the future of the obesity epidemic and the important factors controlling
it. Our models suggest that if the most recent rates stay constant, the population will
stabilize at 42  obese. However, it is very likely that the rates of obesity infection may
continue to increase if successful interventions are not conducted. Our results show that
while the rate of automatic development of obesity appears to have leveled oﬀ in the past
decade, the rate of transmission has been steadily increasing.
This model allows us to can predict how much spatial correlation is expected from a
purely infectious process, and compare this to what is observed in the data, which could be
inﬂuenced by confounding factors and selection bias in choosing friends. A coeﬃcient of 1
indicates that arrangement of infected nodes is random, while higher values are indicative
of spatial correlations. We observed a correlation coeﬃcient for obese individuals of 1.30,
which was quite close to what was predicted from epidemic simulations (1.33). This
suggests that infection alone is suﬃcient for explaining the observed correlations, and there
may not be much selection bias or confounding factors in eﬀect. We also show that network
transitivity is not predicted to have a strong aﬀect on prevalences when there is an
automatic component to infection. However, our model also shows that contrary to
popular belief, a contagious process on a network does not always result in clustering of
￿infected individuals￿. This is especially true if there is a large automatic infection term,
which is likely with many trends and behaviors.
175The SISa approach allows us to compare the eﬀectiveness of diﬀerent classes of
intervention. For the parameter range observed, we ﬁnd that decreasing the rate of
transmission   is the most eﬀective intervention (largest decrease in prevalence per unit
decrease in rate), although decreasing the automatic infection   is almost as eﬀective. More
generally, while we ﬁnd that gaining weight is contagious, we do not ﬁnd that losing weight
is contagious. Thus it does not seem to be beneﬁcial to ‘break-up’ clusters of obese
individuals or ‘pin’ the weight of certain people in these clusters. Our results actually
suggest that clusters of obese people serve to slow the spread of obesity by reducing social
contagion to non-obese others outside of the clusters. Another possible intervention would
involve somehow facilitating the social spread of becoming non-obese (losing weight),
creating a bi-directional transmissive process.
One possible limitation of this study is the incompleteness of the social network dataset
used. Because the Framingham Heart Study was not designed as a study of social
networks, no attempt was made to capture all of a person’s important social contacts.
Many close friends of a person could be missing (usually only one friend per person was
recorded) and family and coworkers who play only a small part in one￿s actual social
network may have been counted. However, even if under-sampling of real-world contacts
did occur in the FHS Network, it does not change our results qualitatively: our data
clearly show that rates of becoming obese increase with the number of ‘infected’ contacts
(i.e. is contagious) while the rate of ‘recovery’ to a non-obese state does not depend on
contacts. However, under-sampling could quantitatively eﬀect our measurement of the rate
constants. If a constant number of contacts for each person were missed, our estimate of
the y intercept of the transition graphs would be shifted up from its true value, and the
actual   would be smaller than the   we measured. If a constant fraction of contacts for
each person were missed, then our estimate of the x axis would be compressed from its true
value and the slope would be increased, so then the actual value of   would be smaller
than the   we measured. While it is likely that the FHS network underestimates the total
176number of contacts, the relationship to the number of ‘inﬂuential’ contacts is unclear. In
this sense, the observed value of the transmission rates,  , are network dependent.
Additionally, network connections may be weighted diﬀerently according to their ability to
transmit behaviors. Longitudinal studies designed speciﬁcally with the intent of measuring
social networks and health, which carefully deﬁne contacts, such as by amount of time
spent together per day, inﬂuence, etc, are an important area for future research.
It has recently been suggested that certain, particular types of latent homophily, in
which an unobservable trait inﬂuences both which friends one chooses and current and
future behavior, may be impossible to distinguish from contagion in observational studies
and hence may bias estimates of contagion and homophily [314]. ￿The circumstances under
which this is likely to be a serious source of bias (e.g., whether people, empirically, behave
in these sorts of ways), and what (if anything) might be done about it (absent
experimental data of the kind that some new networks studies are providing [112]) merits
further study. ￿Observational data invariably pose problems for causal inference, and
require one set of assumptions or another to analyze; the plausibility of these assumptions
(even of standard ones that are widely used) warrants constant review.
The SISa model as presented here assumes that all individuals have the same
probability of changing state (though not everyone will actually change state within their
lifetime). It is clearly possible, however, that there is heterogeneity between individuals in
these rates. We do not have suﬃcient data on obesity in the Framingham dataset to
explore this issue, which would require observing numerous transitions between states for
each individual. Exploring individual diﬀerences in acquisition rate empirically is a very
interesting topic for future research, as is extending the theoretical framework we introduce
to take into account individual diﬀerences.
The results we have presented here reiterate an important general principle of network
processes: networks tend to magnify whatever they are seeded with, but they must be
seeded with something. The increase in obesity is not purely a network-diﬀusion
177phenomenon. Automatic infection serves to start and continuously seed the epidemic. Here
we show that the dominant process in the increasing prevalence of obesity is
contact-independent weight gain; however, the rate of interpersonal transmission contribute
signiﬁcantly to the overall prevalence and appears to be increasing steadily over time. Thus
consideration of social transmission and network eﬀects is an important issue for health
and policy professionals.
7.6 Supplementary Information
7.6.1 Deriving pairwise network equations for heterogeneous networks
In the main text, the pairwise equations were derived assuming all individuals had the
same number of contacts. This allowed us to reduce the dynamics to three diﬀerential
equations (after applying a moment closure approximation) tracking the changes in the
number of pairs of the form [AB] . Now we relax the assumption of homogeneity, and track
pairs for each class of individuals, where classes are deﬁned by the total number of contacts
an individual has. This analysis follows that presented in Eames and Keeling, 2002 [99].
Table 7.2: notation used in pairwise equations for heterogeneous networks
Term Description
a rate of spontaneous infection
g rate of recovery
  rate of transmission through contact
      of individuals with n contacts
       of pairs of individuals with n and m contacts
      of A individuals
        of A individuals with n contacts
         of edges between an    and a    individual
        
∑
 
  
  
     of B contacts of all   ’s
           of triples with    having both    and    as contacts
Table 7.2 summarizes the types of variables tracked with this approach. After
describing some variables in terms of others, only those that are starred (*) remain, for a
178total of    equations, where   is the maximum number of contacts of any individual in the
network. Whenever there is a sum, it is over all possible values for the number of contacts
an individual has, i.e
∑
 
implies
  ∑
   
. Note that while in the main text we wrote equations
for the fraction of individuals in various classes, here we have left the equations for the
absolute numbers, for simplicity of notation.
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Many variables on the right hand side of these equations can be simpliﬁed until only   
variables remain (equal to the number of equations). Firstly, triples can be reduced to
pairs using the moment closure approximation [283]:
  
  
  
    
       
 
            
    
     ϕ   ϕ       (7.11)
       
      
    
      
        
(7.12)
(7.13)
We still assume there is one ϕ that describes the whole population. We could have
ϕ   , though this would be unnecessarily complicated for most applications. Furthermore,
we can approximate pairs of the type        in terms of the smaller set of pairs of the
179type       using:
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Finally, since all individuals are either infected or susceptible, we can use:
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(7.15)
This results in    equations and variables. If we want to ﬁnd the spatial correlation
discussed in the paper, we can use:
     
    
∑
   
    
      
  
    
  
(7.16)
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Emotions as infectious diseases in a large social
network: the SISa model
8.1 Abstract
Human populations are arranged in social networks that determine interactions and
inﬂuence the spread of diseases, behaviours, and ideas. Here, we evaluate the spread of
long-term emotional states across a social network. We introduce a novel form of the
classical SIS disease model which includes the possibility for ‘automatic’ or ‘spontaneous’
infection, in addition to disease transmission (the SISa model). Using this framework and
data from the Framingham Heart Study, we provide formal evidence that positive and
negative emotional states behave like infectious diseases spreading across social networks
over long periods of time. The probability of becoming content is increased by 0.02 per
year for each content contact, and the probability of becoming discontent is increased by
0.04 per year per discontent contact. Our mathematical formalism allows us to derive
various quantities from the data, such as the average lifetime of a contentment ‘infection’
(10 years) or discontentment ‘infection’ (5 years). Our results give insight into the
182transmissive nature of positive and negative emotional states. Determining to what extent
particular emotions or behaviours are infectious is a promising direction for further
research with important implications for social science, epidemiology, and health policy.
Our model provides a theoretical framework for studying the interpersonal spread of any
state that may also arise spontaneously, such as emotions, behaviours, health states, ideas
or diseases with reservoirs.
8.2 Introduction
Social network eﬀects are of great importance for understanding human behaviour. People
interact with diﬀerent numbers of individuals and with some individuals more than others,
and this aﬀects behaviour in fundamental ways. Investigations from diverse ﬁelds,
including sociology, economics, physics, mathematics, and public health, have studied
social networks, both to understand their structure and their aﬀect on social dynamics.
Economic behaviour, such as purchasing decisions [194], employment prospects [56, 215],
bankruptcy [351], investment [77] and productivity[258] have been shown to be inﬂuenced
by network contacts (reviewed in Jackson [156]). Other behaviours such as college GPA
[301] and crime [122, 138] have been related to peer eﬀects. Recently, social networks have
been studied as determinants of health (reviewed by Smith [333]), ranging from
determining the patterns of infectious disease spread [176] to the propogation of behaviours
such as smoking cessation [69] , obesity [68] and suicidal ideation [31]. Networks also play
an important role in evolutionary biology, where population structure determining
interactions can facilitate the evolution of cooperative behaviour [115, 245, 252, 344, 345].
Human emotions are strongly inﬂuenced by social contacts. ‘Emotional contagion’
[136] is known to occur over short times scales between people in frequent close contact,
such as families [192], roommates [151] and teammates [27], and even occurs in
experimental situations [112]. Positive and negative moods also spread during workplace
interactions such as cooperation [27], negotiation[183] and successful leadership [48]. The
183spread of positive mood is a common technique in interpersonal relations, and the ‘service
with a smile’ technique is a well-known example [277]. Depressive moods and symptoms
have been found to be contagious both by media and by personal contact with strangers or
acquaintances [161]. Over longer time scales, clinically relevant depressive states can also
spread between social contacts [349]. Unlike most of these previous studies, in the present
work we demonstrate the interpersonal spread of long-lasting emotional states over
protracted time-scales.
Recently, Fowler and Christakis [111] have studied the properties of happiness in
relation to a network of social contacts, extracted from the Framingham Heart Study [90].
They observe correlations in happiness between individuals that are connected in a social
network. If your friends are happy, then you are more likely to be happy in the future.
This correlation, they suggest, is caused in part by an inductive eﬀect of happiness
spreading from person to person. Thus, happiness could be thought of as a form of social
infection. Here, we evaluate this conceptual approach to emotional transmission in a
mathematically rigourous way, by formally modelling the spread of positive and negative
emotions using theoretical tools from epidemiology.
Mathematical models for the spread of microbial infections help us to understand and
predict the spread of disease [10]. Such models have also been used to explore the spread of
non-microbial infections, such as rumors [86] or computer viruses [266]. Studying the
dynamics of epidemiological models on social networks is currently an active area of
research. Many models have been developed to study how the structure of networks aﬀects
disease spread [176]. These models have been used to understand contagious diseases where
the network describes contacts in geographical proximity (for example SARS [222],
Foot-and-mouth disease [109]), or for studying sexually transmitted diseases where the
network consists of sexual partnerships [99].
Here we introduce a novel approach for studying the spread of emotions in a social
network. We can think of emotions at three levels: ‘moods’,‘states’ or ‘traits’. These levels
184have increasing duration and permanence, and diﬀer in terms of the extent to which they
are deeply characteristic of the individual, and therefore the extent to which they are
mutable or immutable. We will use the word ‘long-term emotional states’ to describe the
phenomena of interest to us here, lying in between ﬂeeting moods and permanent traits
(like personality traits). We use the terms content and discontent for these phenomena
that have been characterized, in prior work, as akin to happiness and depression, with
validated scales. We modify a classical infectious disease model to represent the spread of
emotions, to account for the fact that emotions can by contracted both spontaneously and
through transmission. We then use this model to ask whether emotional states in the
Framingham Heart Study dataset [90] do indeed act like infectious diseases. For an
emotional state such as content to ﬁt the classical deﬁnition of an infectious disease, (i) the
probability of becoming content must depend on the number of content contacts (and not
on the number of non-content contacts), and (ii) the probability of switching from content
back to neutral (‘recovering’ from content) should be independent of any properties of
social contacts. The particular structure of the Framingham Heart Study dataset, with a
social network, reliable emotional evaluation, and longitudinal follow-up, allows application
of our model to the spread of content and discontent over long time scales. We ﬁnd that
both content and discontent behave like infectious diseases. The data allow us to then
estimate values for model parameters, and to calculate derived quantities which give
insight into the dynamics of emotional contagion.
8.3 Methods
8.3.1 Basic infectious disease model
In the simplest infectious disease models [10], individuals are classiﬁed as occupying one of
two states: ‘susceptible’, meaning they do not have the disease, and ‘infected’, meaning
they do have the disease. The disease can be transmitted to a susceptible person when
185they come into contact with an infected person. The rate of this disease transmission from
infected to susceptible is deﬁned as  , the transmission rate. Once an individual is infected,
she recovers from the disease at a constant rate g, regardless of her contact with susceptible
or infected others. In one class of disease models (susceptible-infected-recovered, or SIR),
recovered individuals become immune to further infection and enter a ‘recovered’ state.
However, an emotion can occur many times over an individual’s life, and therefore we use
assume infected individuals return to the susceptible state after recovering. This form of
susceptible-infected-susceptible (SIS) model is used to model infectious diseases that do not
confer immunity, such as many sexually transmitted diseases.
In the standard SIS model, infection can only be transmitted by having a contact
between an infected and a susceptible individual. Emotional ‘infections’, however, can also
arise due to spontaneous factors other than transmission. Therefore, we extend the SIS
model by adding a term whereby uninfected individuals spontaneously (or ‘automatically’)
become infected at a constant rate a, independent of infected contacts. A diagrammatic
representation of our modiﬁed SIS model, which we will call SISa, is shown in Figure 8.1.
The corresponding diﬀerential equations for a well-mixed population are described in
Eq. 8.1. When the population is not well-mixed but instead constrained on a social
network, the transmission rate for each individual depends on the number of infected
contacts (  ) instead of the total number of infected individuals ( ).
                      
                     
         
(8.1)
where   is the number of susceptible individuals,   is the number of infected individuals  
is the transmission rate,   is the recovery rate, and   is the rate of spontaneous infection.
This model assumes a constant population size, neglecting birth and death.
186Figure 8.1: The SISa model of infection. A) There are three processes by which an individual’s
state can change. (i) An infected individual transmits infection to a susceptible contact with rate
 . (ii) A susceptible individual spontaneously (‘automatically’) becomes infected at rate  , re-
gardless of the state of her contacts. (iii) An infected individual returns to being susceptible at
rate  , independent of the state of her contacts. B) The rates of movement for an individual be-
tween the susceptible and infected states.    is the number of infected contacts.
8.3.2 Parameter estimation
The classical deﬁnition of an infectious disease in the SIS/SIR context is that (i) the
probability of an individual transitioning from susceptible to infected is an increasing
function of the number of infected contacts, while (ii) the probability of a transition from
infected to susceptible (i.e. recovery) is independent of the number or state of contacts.
Exposure to infected individuals makes you more likely to become sick, but once you are
infected you recover at a constant rate regardless of contacts. In addition to infectious
contagion, the SISa model has an additional spontaneous mode of acquiring disease. To
both test that a behavior displays infectious-disease-like dynamics, and to estimate values
for the model parameters a  , and g, we can use dynamic information about transitions
187between states based on multiple time points in longitudinal data. For data points
separated by time intervals (∆ ) smaller than the average time between transitions, the
transition probabilities can be linearized. The probability of a transition from susceptible
to infected after a time ∆  can be given by         ∆              ∆  , and the
probability of transition from infected to susceptible after time ∆ , by
        ∆      ∆ . It is necessary for the time between measurements to not be
comparable to or greater than the average lifetime of a state to keep the probability of
double transitions within a time interval low.
8.3.3 Dataset
In this study, we evaluate the assumption that emotions behave like infectious agents. We
use data from the Framingham Heart Study [90] and the framework discussed above to test
whether content and discontent ﬁt the dynamics of infectious diseases. The Framingham
study was initiated in 1948 in Framingham, Massachusetts and has continued enrolling
subjects through the present. Subjects were examined at regular intervals of approximately
three years. They were administered a psycho-social exam called the CES-D, which allowed
us to classify each individual as content, discontent or neutral. We used the well-deﬁned
cut-oﬀ of a score of 16 on the full CES-D scale to classify subjects as discontent. This
measure has previously been called ‘depression’, though it is not speciﬁc to clinical
depression and represents general distress or depressive symptoms [299]. Content was
deﬁned as a score of 12 on the positively worded questions of the CES-D, and is the same
subscale used by others and called ‘positive aﬀect’, ‘well-being’ or ‘happiness’
[111, 229, 256, 276]. The terms ‘content’, ‘discontent’ and ‘emotional state’ as used in this
paper represent long-term states reﬂecting general life satisfaction, as opposed to
short-lived moods evinced in response to stimuli. Additionally, social networks were
constructed for each subject based on recorded information on friends, family, coworkers
and residential neighbours. For details, see the Electronic Supplementary Material (ESM).
188We hypothesize that a neutral emotional state may act like a susceptible state, and
that content and discontent act like ‘infected’ states (Fig. 8.1). We validate this
classiﬁcation using the data analysis presented below. Note that we exclude the possibility
of coinfection by both content and discontent simultaneously, as this doubly infected state
very rarely appears in the data (ESM Fig. S1). However, superinfection may be possible:
individuals could potentially move directly between being content and discontent without
passing through neutral. The data is used to validate the model assumptions and estimate
values for the parameters   a and g. These parameters are then used to calculate derived
quantities of interest, such as the average lifetime of an emotional infection, the probability
an infected person passes the infection to a given contact sometime during the course of
her infection, and the average frequency with which infections arise spontaneously.
Additionally, agent based simulations are used to compare model dynamics and clustering
with the observational data.
8.3.4 Measuring transmission of emotions
To study the transmission of emotions, we examine changes in emotional state between the
two sequential exams of the Framingham Heart Study in which the CES-D was
administered (Exams 6 and 7). The average fraction of the network that was classiﬁed as
content or discontent was very similar between the two exams, suggesting the transmission
process is at steady state (Exam 6: 65% content, 9% discontent; Exam 7: 62% content, 9%
discontent). Additionally, these exams were closely and consistently spaced (
∆         year). We include only subjects who answered all questions on the CES-D in
both exams.
Subjects were initially classiﬁed as ﬁrst as either ‘content’ or ‘not content’, and then
separately as ‘discontent’ or ‘not discontent’. Individuals who are neither ‘content’ nor
‘discontent’ are classiﬁed as ‘neutral’. As expected, very few people who are classiﬁed as
‘content’ are also classiﬁed as ‘discontent’ (less than 1/1000). Thus we have three possible
189emotional states. A diagram of the distribution of subjects between emotional states in
included in the Electronic Supplementary Material (Fig. S1).
A given state   is considered infectious if having more contacts in state   makes you
more likely to switch to state  . That is, a positive relationship between the number of
contacts in state   and the probability to transition from state   to state   indicates that
state   is infectious with respect to state  . Therefore, to test whether a given state   is
infectious with respect to another state  , we perform an ordinary least squares (OLS)
linear regression as follows. Each subject in state   in exam 6 is coded as either having
transitioned to state   (transition=1) or not (transition=0) in exam 7. We then regress
this binary transition variable for each subject against that subject’s number of contacts in
state   during exam 6. A signiﬁcant positive correlation indicates that having more friends
in state   at the earlier exam makes you more likely to switch to state   in the later exam.
If state   is infectious (a signiﬁcant positive correlation exists), then the value of   can be
calculated from the slope of the regression line, and the value of a can be calculated from
the intercept. If state   is not infectious (no signiﬁcant correlation exists), then the value
of g can be calculated from the intercept. ∆  was taken as the average time between
examinations, which was 2.5 years. Using logistic regression as opposed to OLS regression
gives very similar results, as the datapoint line is within the linear range of the logistic
model.
It is important for our analysis that subjects do not change emotional states rapidly
(days or weeks), but instead on the timescale of years or longer. While the CES-D asks
subjects to evaluate feelings in the last week, it is known to be a reliable measure of
long-term emotions, as opposed to short-lived moods evinced in response to stimuli.
Several studies have shown CES-D scale scores to be stable for up to 12 months, with high
intra-individual test-retest correlations [281, 290]. Furthermore, we ﬁnd a strong positive
correlation between each subject’s emotional state in the two measurement periods
(r=0.47). This suggests that emotional states are not ﬂuctuating on the timescale of weeks
190or months, but rather on the timescale at which we are measuring: if they were changing
faster than 3-5 years, then a subject￿s state in Exam 6 would not be strongly predictive of
her state in Exam 7. Note that this correlation is also conﬁrmed by a more detailed
analysis [111]. Thus, there is strong evidence that the emotions we are measuring change
only on the time scale we are measuring, as opposed to ﬂuctuating much more rapidly.
Our epidemiological approach to social contagion has important diﬀerences from other
models which look at correlations in present and past states of connected individuals
[68, 69, 111]. Here, we look at how contacts inﬂuence the transitions between states, which
better captures the nature of contagion. Since we use pre-existing social ties, we do not see
eﬀects from selection bias in choosing friends with similar emotional states. Additionally,
confounding events that lead to concurrent changes in connected individuals will not show
up as contagion eﬀects in this model.
8.4 Results
In the Framingham Heart Study network, individuals may be connected to neighbours,
coworkers, ﬁrst-degree relatives and self-nominated friends. An individual￿s degree is the
number of contacts that individual has to other people in the network. Restricting to only
individuals who had been administered the CES-D at both exam 6 and 7, and their
connections that existing at exam 6, gives a population of size N=1880, with average
degree 3.1. The network is approximately Poisson distributed, with a long tail, although
with some subjects having no connections. It has been previously shown found that family
and friends living more than 2 miles away are not signiﬁcantly associated with emotional
inﬂuence [111], suggesting that face-to-face contact is important for transmission. Thus we
restrict our analysis to connections involving only friends and relatives living closer than 2
miles away, next-door or same address neighbours and coworkers. With these further
constraints, the degree of the network was reduced to            .
The results of the infectiousness analysis for the spread of content and discontent
191between exams 6 and 7 are shown in Figure 8.2. Consistent with the SISa model
formulation, we ﬁnd a signiﬁcant positive correlation between the probability of
transitioning from neutral to content and the number of content contacts (Figure 8.2A,
coeﬀ=0.052, p=0.024), and no signiﬁcant relationship between the transition from content
to neutral and the number of neutral contacts (Figure 8.2B, coeﬀ=-0.011, p=0.59).
Additionally we ﬁnd no signiﬁcant relationship between the probability of transitioning
from neutral to content and the number of neutral contacts (coeﬀ=0.48, p=0.10), or the
probability of transitioning from content to neutral and the number of content contacts
(coeﬀ=0.22, p=0.98). This suggests that content can indeed be modelled as an infectious
process in the SISa framework, with neutral susceptibles more likely to become content
infecteds with each content contact they have. The parameters for the SISa model can be
calculated from the transition probabilities using equations mentioned previously, by
dividing slope and intercept values by ∆ , the average time between exams. The
transmission rate,  , is found to be      /year. The spontaneous infection parameter a is
found to be      /year. The recovery parameter g is found to be       /year. These results
are dependent on restricting analysis to contacts who had exams separated by less that
three and a half years (   ). For longer times it becomes increasingly likely that more
than one transition has been made between exams.
We now repeat this analysis for discontent. We ﬁnd that discontent can be also
described in the SISa framework as a contagious emotion with neutral as the susceptible
state. The probability of transitioning from neutral to discontent is positively correlated
with the number of discontent contacts (Figure 8.2C, coeﬀ=0.097, p=0.027), and the
probability of transitioning from discontent back to neutral is independent of the number
of neutral contacts (Figure 8.2D, coeﬀ=0.032, p=0.56). Additionally we ﬁnd no signiﬁcant
relationship between the probability of transitioning from neutral to discontent and the
number of neutral contacts (coeﬀ=0.11, p=0.75), or the probability of transitioning from
discontent to neutral and the number of discontent contacts (coeﬀ=0.002, p=0.99). The
192Figure 8.2: Both content and discontent behave like disease agents, infecting those in a suscep-
tible neutral emotional state. The probability of transitioning from neutral to content increases
in the number of content contacts (A), and the probability of transitioning from neutral to dis-
content increases in the number of discontent contacts (C). Conversely, the probability of re-
covering to the neutral state does not depend on the number of neutral contacts for either emo-
tion (B,D). Error bars represent the standard error of the mean, and labels are the number of
individuals averaged for each data point. We also ﬁnd no signiﬁcant dependence of these tran-
sitions on age, sex or education (A: age, coeﬀ=0.0014, p=0.52; education, coeﬀ=0.0024, p=0.81;
sex, coeﬀ=-0.0074, p=0.87. B: age, coeﬀ=0.0016, p=0.21; education, coeﬀ=-0.0095, p=0.08; sex,
coeﬀ=0.0109, p=0.64. C: age, coeﬀ=0.0001, p=0.93; education, coeﬀ=0.0008, p=0.90; sex, co-
eﬀ=0.0485, p=0.08. D: age, coeﬀ=-0.0006, p=0.88; education, coeﬀ=-0.0165, p=0.35; sex, coeﬀ=-
0.024, p=0.77).
model parameters are          /year, a         /year, g        /year . Interestingly, the
rate of transmission though a contact is similar for both content and discontent, while the
rate of spontaneous infection is much larger for content and the rate of recovery is larger
for discontent.
We also include for the possibility of direct transitions between content and discontent
(‘superinfection’), which are sometimes observed. We calculate the rate of direct
transitions from content to discontent to be                       /year and the rate from
discontent to content to be                     /year. See ESM for details. The estimated
rates of all transitions are visualized in Figure 8.3.
193Figure 8.3: Parameter estimates for content and discontent using the SISa model framework.
From these results, derived from Figure 8.2, we show that content and discontent are infectious
emotions that can be ‘caught’ by neutral (susceptible) individuals from content or discontent (in-
fected) contacts. There is also some ‘superinfection’ present: direct transitions between content
and discontent.   (  )=rate of spontaneously becoming content (discontent),   (  )=rate of re-
covery from content (discontent),   (  )=transmission rate of content (discontent),    (   )=rate
of spontaneous superinfection from content to discontent (discontent to content)
From the SISa model parameter estimates, various quantities of interest can be
calculated. The average lifetime of an emotional state is the average length of time an
individual spends in this state before recovering. For both content and discontent,
’recovering’ usually means going to the neutral state (   or   ), but also includes the
possibility of transitioning directly to the other ’infected state’ (    or    ). The total
recovery rate (  ) is the sum of both these rates. The average lifetime of a contentment
infection is 10.1 years, and for discontentment it is 5.0 years. Thus the average
contentment infection appears to last twice as long as the average discontentment episode.
The ‘inﬂuence’ of an emotion is the cumulative probability that the infection will be passed
from an infected to a susceptible connection before the infected individual recovers. This is
calculated as            ≃     . For both content and discontent, this value is 0.18. The
‘cycle length’ is the average length of time between spontaneous infections, and is 5.6 years
for content and 25 years for discontent. This suggests that that an individual may
spontaneously become content many times throughout life.
194In the regular SIS or SIR models, the average number of secondary infections caused
before recovery is called the basic reproductive ratio,   . An epidemic only occurs for
      . In the SISa model, there is no thresholding behavior as seen in traditional models,
because of the spontaneous infection term. Even if there are no individuals initially
infected and no contagion ( =0), spontaneous infection will nonetheless lead to a non-zero
steady state level of infected. In the absence of spontaneous infection, the eﬀective    can
be estimated as     , where n is the average degree. For content,    is 0.28 and for
discontent it is 0.39. Since for both    is less than one, self-sustained epidemics of either
emotion could not be sustained if people did not become spontaneously infected.
We also perform further analysis to examine diﬀerences in local network structure for
individuals in diﬀerent emotional states. Content individuals have on average 1.26
connections to other people in the data, neutral individuals 1.37 connections, and
discontent individuals 0.97 connections. The smaller number of connections among
discontent individuals suggests isolation, which could be contributing to or secondary to
depressive symptoms. We can also ask whether people in a given state tend to cluster.
Clustering is a measure of the spatial correlation (in the network sense) between
individuals in the same emotional state. Clustering is deﬁned as the ratio of the observed
number of connections between two types of individuals to the number of connections
expected if the positioning of individuals in the network was random. Clustering of like
individuals can be caused by an infective process spreading within a network [175], but
may also be caused by confounding environmental factors inﬂuencing behaviour, or
selection of contacts based on similar behaviour. In a purely infectious process on a
network, the average correlation between two infected individuals will be greater than one,
and the average correlation between an infected and a susceptible individual will be less
than one. To compare observed clustering to that expected from a pure infection, we
perform agent based simulations of SISa epidemics on networks with the FHS network
topology and calculate the predicted clustering (Table 8.1). For content, there is good
195agreement between observed and predicted clustering, suggesting that the inductive spread
of content can explain the observed clustering of content individuals. For discontent,
however, there is less clustering in the data then predicted by the infectious disease
simulations. Thus discontent people are more isolated in the network then predicted by the
infectious model, which is consistent with the reduced average degree observed above. This
could be explained by a tendency for depression to cause people to interact less with
others, or for social isolation to lead to depression [32].
Table 8.1: Network structure dependance on emotional states, and comparison with epidemic
simulations. Discontent individuals have a signiﬁcantly lower number of contacts (degree) than
others.     is the clustering between individuals of type x and y. c=content, d=discontent,
n=neutral. The clustering of like individuals that arises from an infectious process can explain
the clustering of content individuals, but discontent individuals are less clustered than expected
for the transmission rate.
Content Discontent Neutral
average degree 1.26 0.97 1.37
observed clustering
   =1.04    = 1.07 -
   =0.91    =0.77 -
simulated clustering
   =1.09    =1.92 -
   =0.95    = 1.0 -
8.5 Discussion
Here we have shown that long-term emotional states can spread between socially connected
individuals. The transmission rate for content is found to be          /year, and the
spontaneous infection parameter is found to be          /year, thus each content contact
increases the probability of becoming content by 11 /year. For discontent, the rate of
spontaneous infection is a         and the rate of transmission is         , so each
discontent contact makes an individual 100 /year more likely to become discontent. The
average lifetime of a contentment ‘infection’ is measured to be 10 years, and a
discontentment ‘infection’, 5 years. We have introduced a novel framework for formalising
social contagion derived from the study of infectious diseases, which can be used to study
196the spread of emotions or other social phenomena. This infectious disease approach has
several advantages over methods which examine correlations in behaviours of connected
individuals. Our method controls for selection bias in choosing contacts with similar
behaviour, as well as confounding environmental factors synchronously aﬀecting contacts.
Moreover, we ﬁnd no dependence of the probability of changing emotional state on age,
sex, or education, which have been found in previous studies of content and discontent to
aﬀect the propensity for emotions and confound the correlations between contacts [11, 111].
This lack of dependence when we focus on transitions suggests that our approach is more
robust to variation across individuals than previous methods.
Much of the appeal of our approach is the signiﬁcance of our results despite the great
simplicity of the model used, and the assumptions made about the dataset. Determining
the various transition rates for the model requires the implicit assumption that all
individuals are identical in their susceptibility to various emotional states. These rates
therefore represent ensemble averages over the population. In reality, individuals are likely
to diﬀer in their predispositions to various emotional states.
The ability to observe transmission of emotional states over long time frames requires
some particular properties of the Framingham Heart Study. These include large sample
sizes, longitudinal follow-up, extensive information on social contacts and various
relationships, closely and consistently spaces exams, and reliable measures of emotions and
behavioural states. This study was not designed to study social networks or mental health,
and so there are some drawbacks that could be improved upon in more speciﬁcally
designed projects. For example, we only examine changes between two time points, which
give us stationary values for the rates of transmission, although it is plausible that these
rates themselves change over time. Future work exploring the dynamic spread of emotions
with higher resolution data collection is called for. This may also allow for more complex
and perhaps realistic models, such as modeling emotions as continuous variables rather
than discrete states, with transmission depending on the severity of infection.
197One possible limitation of this study is the social network dataset used. We have also
assumed that the social network collected through the Framingham Heart Study is the
same as the contact network for the spread of emotions, which is almost certainly not true
given the sparseness of the Framingham network. Because the Framingham Heart Study
was not designed as a study of social networks, no attempt was made to capture all of a
persons important contacts. Many close friends of a person could be missing (usually only
one was recorded) and family and coworkers who aren’t part of ones actual social network
may have been counted. Even if undersampling of real-world contacts did occur, it does
not change our results qualitatively: our data clearly show that rates of becoming
“content“ or “discontent“ increase with the number of “infected“ contacts (i.e. are
contagious) while the rates of “recovery“ to a “neutral“ state do not depend on contacts.
However, it could change the measured rate constants. If we missed a constant number of
contacts for each person, the intercept of the transition graphs would be shifted to the
right, then the actual   would be smaller than the   we measured. If we missed a constant
fraction of contacts for each person, then the x axis would be compressed and the slope
would be increased, so then the actual value of   would be smaller than the   we
measured. However, while it is likely that the Framingham network underestimates the
total number of contacts, the relationship to the number of ‘inﬂuential’ contacts is unclear.
In this sense, the observed value of the transmission rates,  , are network dependent.
Additionally, network connections may be weighted diﬀerently according to their ability to
transmit emotions. It would be ideal to design longitudinal study with the intent of
measuring social networks and health and carefully deﬁne contacts, such as by amount of
time spent together per day, inﬂuence, etc.
A CES-D score of greater than 16 (which we deﬁned as ‘discontent’) can occur with
major depression (94  speciﬁc) as well as alcohol or drug dependence, anxiety, dysthymia,
or bipolar disorder. Thus it is a measure of depressive symptoms or general distress and
not necessarily clinical depression [281, 299]. The 10-year prevalence of all aﬀective
198disorders is close to 30  [11] which suggests that a large portion of the population is
susceptible to depressive symptoms. This fact is consistent with our ensemble treatment,
and with the observed cycle length for discontent of 25 years. Treating discontent as a
spontaneously acquired or transmitted infection has one major drawback: it assumes that
the probability of becoming discontent is independent of an individual’s history of
depressive episodes. In reality, depression is known to be a recurrent condition, with
relative risk increasing with history of illness [12]. It has been found that 72   of people
with major or minor depression experience recurrent episodes [179]. No comparable data
exists for the CES-D measurement of content, which is less routinely used. Relevant data
for comparison will likely become available as the study of ‘positive psychology’, and
especially its relation to health [276], becomes more widespread. There have been no
studies to our knowledge which examine the lifetime or cycle of discontent or content in the
general population, as deﬁned by the CES-D.
Our study provides evidence for a transmissive component to the dynamics of the
emotions of content and discontent. However, this dataset does not give insight into the
mechanism of infection. It is possible that displayed emotions are directly contagious (via
mimicry, pheromones, etc), or that emotions spread indirectly, for example by sharing some
type of good fortune. While short-term emotional states have been suggested as a
mechanism for systemically coordinating body functions to react in the most favourable
way to an environmental stimulus, and as a means of ‘quick-and-dirty’ communication of
this stimulus to others [201], it is not obvious how this argument extends to the contagion
of long-term emotional states. The observed fact that ‘catching’ content and discontent
depends on social contacts, while ‘recovering’ to a neutral state does not, suggests that
infection involves a process similar to teaching a life skill that can then persist without a
constant stimulus. The mechanisms behind the transmission of long-term emotional states
merit further study.
We have formally demonstrated that emotions can be thought of as infectious diseases
199spreading across social networks. We have introduced a novel form of mathematical
infectious disease model for describing the spread of emotions which has advantages over
previous methods. We have validated this model by studying content and discontent
propagating across a large social network. Our results give insight into the transmissive
nature of positive and negative emotions, and our model provides a theoretical framework
for studying the spread of other emotions, as well as a wide range of other social
phenomena. Determining to what extent particular emotions or behaviours are infectious is
a promising direction for further research with important implications for social science,
epidemiology, and health policy.
8.6 Supplemental Information
8.6.1 Framingham Heart Study Dataset
In this study, we evaluate the assumption that emotions behave like infectious agents. We
use data from the Framingham Heart Study [90] and the framework discussed above to test
whether positive and negative emotions ﬁt the dynamics of an infectious disease. The
Framingham study was initiated in 1948 in Framingham, Massachusetts and has continued
enrolling subjects through the present. We examined individuals in the Oﬀspring Cohort,
enrolled starting in 1971. Subjects come to a central facility at regular intervals
(approximately every 3 years) for medical examination and collection of other survey data.
In additional to information on mental and physical health, subjects were asked to name at
least one close friend at each exam, and were also connected to all ﬁrst-order relatives,
coworkers, and residential neighbours.
For each subject, the following social connection data is available: (i) each other person
to whom they were connected, (ii) the dates of initiation and termination of that
relationship, (iii) the type of relationship (neighbour, coworker, ﬁrst-degree relative, or
friend), and (v) the geographic distance between the two subjects. The social network for
200each exam was constructed by creating a network matrix G, where          if subject  
nominated subject   as a connection before or during the time that subject   was
administered exam  . All relationship types are mutual except for friendships, which are
self-nominated, such that      ̸       is possible for friendships.
Individuals in the Framingham Heart Study were administered a widely validated
psycho-social exam called the CES-D (The Center for Epidemiologic Studies Depression
Scale, [281]) at exams 6 and 7 (administered on average in 1997 and 2000). The full version
of this survey style exam is commonly used to classify depressive symptoms [281, 299, 309]
and a subscale which comprises a distinct factor [164, 276, 282, 318, 347] has also been
validated as a measure of positive aﬀect [229, 256, 276]. Similar measures of positive aﬀect
using subjective surveys have been shown to be highly correlated with objective measures
of well-being [257]. We have chosen to call this positive state measured by the CES-D
content, though it has been called ‘happiness’ by others. It is also related to optimism and
self-esteem. The negative emotion measured by the full CES-D scale is generally called
‘depression’, though as described in [299], this measure is generally agreed to represent a
long-term emotional state of depressive symptomology that is distinct from (and less severe
than) the mental illness state of clinical depression. To prevent confusion, we have called
this measure discontent throughout the paper.
A content score and a discontent score were calculated for each subject from the raw
responses to 20 multiple choice questions from the CES-D. The questions asked subjects to
judge the frequency with which they experienced a particular feeling or behaviour, with
available answers being 0=(rarely or none of the time,  1 day per week), 1=(some or a
little of the time, 1-2 days per week), 2=(occasionally or a moderate amount of the time,
3-4 days per week) and 3=(most of the time, 5-7 days per week). Subjects are classiﬁed as
content if they scored the maximum value of 3 on each of four particular questions related
to positive feelings. Summing the answers to the 16 CES-D questions related to negative
feelings and adding inverted answers to the 4 positive questions, subjects are classiﬁed as
201discontent if they have a total score greater than 16 (out of a possible 60). Individuals who
are neither content nor discontent are classiﬁed as neutral. The distribution of emotional
states among our subjects is shown in Figure S1A. We ﬁnd that less than 1 out of every
1000 subjects are both content and discontent, validating our classiﬁcation of emotions into
the three states content, discontent and neutral. Figure S2B shows the number of people
who made each transition between the two examinations.
Discontent
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Figure 8.4: Figure S1. A) The distribution of subjects between four emotional states measured
by the CES-D. Subjects were classiﬁed as ﬁrst as either ‘content’ or ‘not content’, and then sep-
arately as ‘discontent’ or ‘not discontent’. Individuals who are neither ‘content’ nor ‘discontent’
are classiﬁed as ‘neutral’. As expected, very few people who are classiﬁed as ‘content’ are also
classiﬁed as ‘discontent’, while those that are ‘not content’ may be ‘discontent’ or ‘not discon-
tent’. Fraction content=0.63, discontent=0.09, neutral=0.28. B) Each circle represents an emo-
tional state, and the arrows and numbers display the number of transitions that occurred be-
tween each state.
8.6.2 Super-infection: Direct transitions between content and discontent
infected states
Figure S1B shows that direct transitions between the content and discontent states are
sometimes observed. There are two possibles explanations for these transitions. Firstly,
because exams are only every 3 years, it is possible that some of these individuals actually
moved through the neutral state, and thus made two transitions between observations (ie
content to neutral to discontent). The second explanation is that these individuals actually
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Figure S2. Observed rates of direct transitions between content and discontent and vice
versa. We see no signiﬁcant dependance on the number of infected contacts for these direct
transitions.
moved directly between these states via ‘super-infection’. We can predict how often we
would expect double transitions to occur within the 3 year window, based on the estimates
for each individual transition. These predictions are lower than the observed number of
direct transitions. Thus the diﬀerence between the observed and expected can be
interpreted as the rate of actual direct transitions. This is explained in detail below. The
estimated rates of all transitions are visualized in Figure 3 in the main text.
For a Markov process, if an event occurs at a rate  , then the probability that this event
has occurred after a time ∆  is        ∆ . If two events occur at rates    and   , and must
occur in that sequential order, then in a time period ∆  the probability that both occur is :
∫ ∆ 
 
        
  2 ∆            ∆   
  
  
      
  2∆   (8.2)
From this expression we can calculate the expected rate of double transitions between
content and discontent (going through the neutral state) in a single time period between
exams.
For content   discontent, the two transitions that must occur are : content to neutral
(       ) and neutral to discontent (              ). There values are:
203•                    /year
•                    /year
•                  /year
For discontent   content, the two transitions that must occur are : discontent to
neutral (       ) and neutral to content (              ). There values are:
•                  /year
•                  /year
•                  /year
Using Equation 8.2, the expected rate of double transitions are (with standard
deviations included):
• content to discontent:                                                    /year
• discontent to content:                                                    /year
Observed double transition, from Figure S2:
• content to discontent:                                                    /year
• discontent to content:                                                      /year
Note that the contact dependent terms for the double transition are observed to be
non-signiﬁcant, and also expected to be overlapping with zero due to the margins of error
on the calculated rates. We hence ignore them for the reported rates of double transitions.
The rate of direct bypass transitions is the extra number of transitions that cannot be
accounted for by double transitions. This is found by subtracting the expected rates
(         ) from the observed rates (         )
Rate of direct bypass transition:
204• content to discontent:                       /year
• discontent to content:                     /year
It is interesting to note that in Figure S1B, the number of individuals transitioning
directly from content to discontent is very similar to number transitioning from discontent
to content. The same is true of the transitions between content and neutral, and between
discontent and neutral. Thus the system is in detailed balance, suggesting a unique subset
of the population may be responsible for the direct transitions between content and
discontent. For example, it could be those suﬀering from bipolar disease, who represent
about 1  of the population and switch between manic and discontent episodes on the
order of months.
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